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Abstract 
Background: The Quality and Outcome Framework (QOF) is a major pay for 
performance scheme that was introduced in 2004 in the UK. The introduction of 
QOF is a unique opportunity to evaluate the impact of pay for performance on 
inequalities and in particular on ethnic inequalities. This thesis examines the 
impact of QOF on ethnic inequalities and on patients with and without 
comorbidities in diabetes management. 
 
Methods: (1) Interrupted time series analysis of electronic medical record data of 
diabetes patients registered with 29 family practices in South West London for 
the years 2000 to 2007. (2) Cross-sectional study to examine the association 
between ethnicity, concordant and discordant comorbidity status and 
intermediate outcomes (HbA1c, blood pressure, total cholesterol).  
 
Results: The quality of diabetes care, as measured by the QOF indicators, has 
improved substantially throughout the study period, especially for the process 
aspect of care. The introduction of QOF was associated with initial additional 
improvements in systolic blood pressure in white and black patients but this was 
only sustained in black patients. Initial improvements in diastolic blood pressure 
in white and in cholesterol in black and white patients were not sustained in the 
post-QOF period. There was no beneficial impact of QOF on HbA1c in any 
ethnic group. The presence of !2 cardiovascular comorbidities was associated 
with similar blood pressure control among white and South Asian patients when 
compared with whites without comorbidity but with worse blood pressure 
control among black patients. 
 
Conclusion: The QOF scheme did not appear to address important inequalities 
in diabetes management over time. Targeted quality improvement strategies 
may be required to improve health care in vulnerable populations. 
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1.0 Introduction 
 
1.1 Definition of diabetes !
Diabetes mellitus is a chronic disease characterized by hyperglycemia because 
of insulin deficiency, or insulin resistance. It is one of the leading causes of death 
in many developed and developing countries. Diabetes is an expensive chronic 
disease and, if not managed correctly, it can lead to long-term complications 
such as cardiovascular diseases, lower limb amputation, kidney failure, 
blindness and may lead to death. 
The World Health Organization (WHO) criteria for the diagnosis of diabetes 
mellitus is a fasting blood glucose of !7.0 mmol/l or a 2-hour glucose level of 
!11.1 mmol/l following an oral glucose tolerance test.  Recently glycated 
hemoglobin (HbA1c) is being advocated as a measure for the diagnosis of 
diabetes. The American Diabetes Association published a position statement to 
recommend a cut-off value of 6.5% for the diagnosis of diabetes. This should be 
confirmed with a repeat test of HbA1c (1). Similarly, the WHO recently 
recommended the use of HbA1c as a diagnostic measure for diabetes (2). 
Diabetes is divided into three main types: Type-1 diabetes (formally known as 
insulin-dependent diabetes), which results from the destruction of beta cells in 
the islet cells of Langerhans in the pancreas. This results in insulin deficiency and 
patients need daily insulin administration. Type-2 diabetes (formally known as 
non-insulin dependent diabetes) mainly affects adults and account for ~90% of 
the diagnosed cases. It is characterized by ineffective action of insulin. 
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Gestational diabetes is glucose intolerance first identified during pregnancy, and 
may or may not require insulin treatment (3). 
The rising prevalence of diabetes, its long-term complication, its economic cost 
and inequalities in the quality of diabetes care make it a priority for governments 
to improve the performance of their health system and invest in preventing and 
improving the quality of diabetes care as effective treatment and coordination 
between health professionals leads to reductions in fatal complications (4). The 
following section discusses these issues including the secondary prevention 
efforts. However, primary prevention of diabetes is beyond the scope of this 
thesis. !
1.2 Incidence, prevalence, consequences, and cost of diabetes 
1.2.1 Incidence and prevalence of diabetes 
 
The prevalence of diabetes is increasing globally and is a major challenge in 
both developed and developing countries. Wild et al., estimated that the 
worldwide prevalence of diabetes will increase from 2.8% in 2000 to 4.4% in 
2030 among all age groups (171 million in 2000 to 366 million in 2030) (5).  
Show et al., provided an updated estimate using a larger number of studies than 
that previously used. They estimated that worldwide prevalence of diabetes is 
set to increase to 7.7% (439 million adults) in 2030 from 6.4% in 2010 (285 
million adults) (6). This is lower than estimate by Danaei et al, of 347million adults 
in 2008 (7). In the United States 28.6 million (7.8% of the population) were 
estimated to have diabetes in 2007 (8). Similar increases are evident in Europe. 
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The International Diabetes Federation (IDF) has estimated the prevalence of 
diabetes in Europe in 2010 to be 8.5% and to increase to 10.0% in 2030 (9). 
Similar to the United States and other European countries, the United Kingdom 
(UK) has experienced a marked rise in the incidence and prevalence of diabetes 
over the past two decades. Using data from 208 practices in England and 
Wales, which contributed to the General Practice Research Database (GPRD), 
Ryan et al., estimated the incidence of diabetes over a period of five years from 
1994 to 1998. The age standardised incidence rate increased from 17.6 per 
10,000 person-years in 1994 to 22.1 per 10,000 person-years in 1998.  The 
largest absolute increases in the rate of new cases were observed among 
individuals aged between 65 and 74 years, but the authors did not distinguish 
between type-1 and type-2 diabetes (10). A more recent study that used data 
from the Health Improvement Network Database and covered 300 practices 
found an overall increase in diabetes incidence of 63% from 1996 to 2005. 
Throughout the study period, the incidence of type-1 diabetes was 0.13 (95% 
Confidence Interval (CI): 0.12#0.14) per 1000 person-years and the incidence of 
type-2 diabetes increased from 2.60 (95% CI: 2.47#2.74) per 1000 person-
years in 1996 to 4.31 (95% CI: 4.21#4.42) per 1000 person-years in 2005. 
These increased with age and were similar for both sexes. However, this 
changed for adults aged more than 40 years, where men had a higher incidence 
than women. The prevalence of diabetes increased from 2.8% in 1996 to 4.3% 
in 2005, an overall increase of 54% across the study period. The prevalence 
increased by 0.4% in individuals aged 10-19 years and 17% in individuals aged 
70-79 years (11). Data from 240 practices covering 4 million patients found an 
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increase in the age-standardised incidence from 1.82 per 1000 person-years in 
1994 to 3.31 per 1000 person-years in 2003. The trend in incidence was similar 
in both sexes but the absolute age-standardised rate was higher in men then 
women in all years. Similarly, the age-standardised prevalence rate increased 
from 16.2 per 1000 person-years in 1994 to 28.7 per 1000 person-years in 
2003. This was higher in men than women in every year (12). Recent data from 
the Health Survey of England (HSE) showed a similar picture of increases in 
prevalence. The prevalence rose from 2.9% to 6.5% among men and 1.9% to 
4.5% among women between 1994 and 2009, respectively. This picture was 
similar among younger adults but there were larger increases among older 
adults. The prevalence increased between 1994 and 2009 from 7.5% to 19.5% 
and 5.2% to 12.7% among men and women aged 75 and older, respectivley 
(13). These estimates are lower than estimates by the APHO (Association of 
Public Health Observatory), which applied age-sex-ethnic specific reference 
prevalence rate to local population in a prevalence model to estimate the 
prevalence of diagnosed and undiagnosed diabetes in England. Estimates of 
total diabetes in 2010 were 7.4% with an expected increase to 9.5% in 2030. 
These were adjusted for age, sex, ethnicity, and deprivation (14). These figures 
were also higher than figures derived from the Quality and Outcome Framework 
(QOF). Estimates of prevalence in England were 3.3%, 3.6%, 3.7%, 3.9%, 
5.1%, and 5.4% in 2004, 2005, 2006, 2007, 2008 and 2009 respectively. All 
ages were used until 2007, followed by adults only from 2008, hence, the 
increased prevalence in 2008. 
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1.2.2 Consequences of diabetes !
Diabetes is a major cause of premature mortality around the world. Roglic et al., 
found that almost four million deaths in 2010 are attributable to diabetes (6.8% 
of all-cause mortality) (15). In Europe more than 630,000 individuals are 
expected to die from diabetes in 2010. Figure 1 shows the percentage of 
mortality in 2010 broken by age and sex.  
 
 
!
Figure 1 Percentages of all-cause mortality attributable to diabetes by age and sex in 2010 in Europe 
Source: International Diabetes Federation 
 
Using data from GPRD in 2006, Mulnier et al., found the hazard ratio (HR) for all-
cause mortality in type-2 diabetes patients was 1.93 (95% CI: 1.89#1.97) when 
compared with individuals without diabetes (16). Likewise, using the same 
database, Soedamah-Muthu et al., found that the hazard ratio of all-cause 
mortality in type-1 diabetes was 3.7 (95% CI: 3.2#4.3), when compared to those 
without it (17). 
 
Cardiovascular disease: 
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People with diabetes have a substantially elevated risk of cardiovascular disease 
morbidity and mortality (18). Life expectancy in diabetes is substantially lower (by 
5 to 10 years) when compared to those without (19), and though the overall 
cardiovascular mortality is declining, a similar picture is not evident in patients 
with diabetes (18). A 3.5-year follow-up of 1,298 subjects selected from a Finish 
population found that 14.8% of type-2 diabetes patients and 3.4% non-diabetic 
subjects suffered myocardial infarction or died from coronary heart disease (20). 
A follow-up of the Framingham heart study participants from 1950 to 2005 
found that all-cause mortality rates have declined throughout the period for 
patients with and without diabetes but patients with diabetes had a 2 fold higher 
mortality rate than individuals without diabetes (21). Diabetic patients who 
develop a cardiovascular disease have a worse prognosis of survival when 
compared to non-diabetics with cardiovascular disease. A 19 months follow-up 
found a mortality rate of 25% in diabetic patients who survived an acute 
myocardial infarction, compared to 8% in non-diabetic patients (22). 
In the Multiple Risk Factor Intervention Trial, men with diabetes had a 2 to 3 fold 
higher risk of cardiovascular disease than men without diabetes (23). 
In the United States the prevalence of ischemic heart disease was higher in 
persons aged 18 to 44 years with diabetes, when compared with those without 
it (2.7% vs. 0.2%) (24). Individuals with diabetes may have a risk of heart attack 
similar to non-diabetic individuals with previous heart attack. Patients with 
diabetes and no history of myocardial infarction have a high risk of dying from 
coronary heart disease similar to patients without diabetes and with a history of 
myocardial infarction (HR: 1.4; 95% CI: 0.7#2.6). This findings did not change 
! *(!
even after further adjustment to smoking status, hypertension, and levels of 
cholesterol and triglycerides (HR: 1.2; 95% CI: 0.6-2.4) (25). This is in contrast to 
a study carried out in Tayside, Scotland, patients who had myocardial infarction 
were at higher risk of dying (HR: 1.33; 95% CI: 1.14#1.55), when compared to 
patient with diabetes (26). This finding is in keeping with a recent prospective 
study carried out in south Europe. The hazard ratio for the 10-year follow-up for 
all-cause mortality was lower for the diabetic group than the non-diabetic group 
with myocardial infarction: 0.39 (95% CI: 0.32#0.46) (27). This is also in keeping 
with a recent meta-analysis of 13 studies which found an overall odds ratio of 
0.56 (95% CI: 0.53#0.63) for patients with diabetes when compared to patients 
without diabetes with prior myocardial infarction (28). 
 
Retinopathy: 
Damage to the small blood vessels in the eye is another complication of 
diabetes. This can lead to visual impairment and blindness. A survey conducted 
between 2005 and 2008 in the United States found a prevalence of 28.5% (95% 
CI: 24.9%#32.5%) and 4.4% (95% CI: 3.5%#5.7%) for diabetic retinopathy and 
vision-threatening diabetic retinopathy, respectively (29). The WHO estimated 
that diabetic retinopathy accounts for 4.8% of blindness worldwide (30). In 
2007-08, diabetic retinopathy was the second commonest cause of blindness 
and accounted for 6.3% of blindness in England and Wales (31). 
 
Nephropathy: 
Diabetes is a major risk factor of kidney disease and if damage to the kidneys 
occurs, it might lead to kidney failure. Individuals with diabetes are more than 
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twice as likely to have persistent microalbuminuria (32). The United Kingdom 
Prospective Diabetes Study (UKPDS) found an annual progression rate of 2%, 
2.8%, and 2.3% from the time of type-2 diagnosis to microalbuminuria, from 
microalbuminuria to macroalbuminuria, and from macroalbuminuria to renal 
replacement therapy, respectively (33). In the UK, diabetic nephropathy 
accounted for 24% of kidney failure in 2008 making it by far the most common 
cause for kidney failure (34). 
 
Neuropathy: 
Diabetic neuropathy is another complication of diabetes and can affect 30#50% 
of patients with diabetes (35). It can lead to functional impairment, and 
subsequently, to foot ulceration and lower-limp amputation (36). It leads to 
increased number of visits to health care providers and increased morbidity. For 
example, in the United States patients with diabetic neuropathy were more likely 
to be unable to work due to physical limitation (Odds Ratio (OR): 3.23; 95% CI: 
1.60#6.52), or had four or more health care visits in the previous year (OR: 2.25; 
95% CI: 1.32#3.83) than patients with diabetes alone (37). 
 
Lower extremity amputation: 
Non-traumatic lower extremity amputations are a serious complication of 
diabetes. In 2004-05, an analysis in England, using HSE, found a relative risk of 
lower extremity amputation of 20.5 (95% CI: 19.7#21.3) in patients with 
diabetes, when compared with those without diabetes. This was not significantly 
different from the 2007-08 relative risk of 21.2 (95% CI: 20.4#22.1) (38). 
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1.2.3 Cost of diabetes !
Diabetes accounts for a large proportion of healthcare expenditure in the world. 
The IDF has estimated the global healthcare expenditure on diabetes prevention 
and management to be $376 billion in 2010, and is projected to reach $490 
billion in 2030. Estimates from the UK showed that the cost of hospital care 
attributable to diabetes was 8.7% of the National Health Service (NHS) budget 
(39). These estimates were updated again in 2004 to 12.1% of acute hospital 
care (40). Analysis of the treatment cost for type-1 and type-2 diabetes in 
primary care setting showed a rise in trend between 1997 and 2007. For 
example, the overall prescribing cost for type-1 diabetes rose from £573 to 
£1014 per person per year (pppy), and increased from £391 to £740 pppy for 
type-2 diabetes (41). 
 
1.3 Comorbidity !
The presence of more than one clinical condition is a common feature in 
patients with diabetes. For example, Analysis of 422 practices from the GPRD in 
2005 found that 17.3% of patients had no comorbidity, 32.4% had at least one 
comorbid condition and 21.9% had two co-morbid conditions (42). However, 
there has been limited research examining association between diabetes 
management and comorbidity (43). This can be explained by the lack of 
agreement on how to define and measure comorbidity (44). Valderas et al (45), 
identified four major distinctions that affect the definition of a comorbidity:  
• The nature of the health condition. For instance, in the case of 
depression and anxiety and if they are considered as a separate entity. 
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• The relative importance of the condition. Which condition will be the index 
condition can be affected by factors such as the specialty of the 
attending physician, the condition that resulted on the patient seeking 
care and the research question. 
• Chronology. Considering whether the comorbid conditions occurred at 
the same time or across a period of time can also be a factor. In addition, 
the sequence of the appearance of the comorbid conditions can have 
significant affect on treatment. 
• Burden of illness. Comorbidity has been used to measure the burden of 
illness, this lead to the use of scales for the measurement of the 
combined burden of specified disease such as the Charlson index and 
the Cumulative Illness Rating Scale. 
Furthermore, different classification systems are used to which can have an 
effect on clinical care and research (45). For example, in the past, studies that 
examined the effect of comorbidity have focused on one specific disease while 
others have used simple counts of disease without any kind of classification. 
Piette and Kerr (46), proposed classifying comorbid conditions into concordant 
and discordant conditions. Concordant condition was defined as “a condition 
that represent parts of the same overall pathophysiologic risk profile and are 
more likely to be the focus of the same disease and self management plan” (e.g. 
diabetes and hypertension), whereas discordant conditions are “conditions that 
are not directly related in either their pathogenesis or management” (e.g. 
diabetes and asthma). Other studies have used an index to measure 
comorbidity, however there is no single index agreed upon as a universal 
measure for comorbidity. For example, a review of methods to measure 
comorbidity found 12 different indexes used to measure comorbidity (47). 
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These complexities in the definition and measurement of comorbidities make it 
difficult to reach a conclusion on the association between diabetes care and 
comorbidity. For instance, Hudon et al, found no association between 
comorbidity, measured using the cumulative illness rating scale, and glycaemic 
control in a sample of diabetes patients in Canada (48). In a study conducted in 
the United States, Bae et al, found that diabetes patients with comorbidities 
were more likely to have HbA1c test and eye examination (49).  Similarly, HbA1c 
and lipid testing differed only slightly according to comorbidity status for 
diabetes patients enrolled in a Medicare managed care health insurance plan 
(50). However, Greenfield et al. (51), used the Total Illness Burden Index and 
found that patients with a high level of comorbidity may not benefit from intense 
glycaemic control compared to patients with a lower level of comorbidity. 
Analysis of data from GPRD found that patients with comorbidity were more 
likely to reach the treatment target of HbA1c and cholesterol, but less likely to 
reach the blood pressure target, when compared to patients without 
comorbidity (42). 
Furthermore, patients with comorbid conditions are increasingly becoming the 
rule; not the exception (52-54); such patients can be complex to manage, have 
a higher risk of additional morbidity and mortality and represent a growing cost 
for health systems (46). A follow-up of 741,847 patients between 1999 and 
2004 in United Stated found the risk of death for patients with one condition to 
be 1.45 (95% CI: 1.41#1.49), when compared to patients with four or more 
conditions: 4.07 (95% CI: 3.95#4.19) (55). Patients with comorbidity also receive 
several medications to manage their conditions, which put them at risk of 
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adverse drug events. A survey conducted in the United States found that for 
each additional medication, the number of adverse events per patient increased 
by 10% (95% CI: 6#15) (56). Analysis of data from the United States Medicare 
Chronic Condition Data Warehouse found nearly 30% of people with diabetes 
suffer from at least one co-morbid chronic condition and the average payment 
per beneficiary increased from $2,820 for patients with no co-morbid condition 
to $7,172 and $14,931 for patients with one or two co-morbid conditions 
respectively (57). In the UK, the mean cost for a patient with diabetes only was 
£434 per year, £999 per year for one co-morbidity, £1,641 per year for two co-
morbidities, and £2,462 for three co-morbidities per year (58). 
 
1.4 Secondary prevention !
Prevention of diabetes complication includes the control of potentially modifiable 
risk factors. These include control of blood glucose levels, blood pressure and 
lipid levels. Further screening for retinopathy, nephropathy, and neuropathy is 
essential for the early identification and management of diabetic complications. 
 
Glucose control: 
Tight glucose control is effective in reducing microvascular and, to some extent 
macrovascular complications. HbA1c is a useful marker of glucose control over 
prolonged periods of time (59). Several clinical trials have showed that reduction 
in HbA1c levels corresponds to reductions in retinopathy, nephropathy, 
neuropathy and cardiovascular end-points. The UKPDS showed that intensive 
therapy for type-2 diabetes with sulphonylureas or insulin achieved a median 
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HbA1c of 7.0% compared to median HbA1c of 7.9% in the conventional 
treatment group at a 10-year follow-up. Patients in the intensive treatment group 
had an overall microvascular complication rate reduction of 25% (p=0.009).  
Glycaemic control had a less substantial impact on macrovascular 
complications. When compared with the conventional group, the intensive 
treatment group had a 16% (p=0.052) risk reduction in myocardial infarction and 
6% (p=0.44) in all-cause mortality (60). A prospective observational study by the 
UKPDS group, found a reduction of 37% (95% CI: 33#41) in the risk of 
microvascular complication and a reduction of 14% (95% CI: 8#21) in the risk of 
myocardial infarction for each 1% reduction in HbA1c (61). A meta-analysis of 
10 prospective cohort studies found a relative risk of 1.18 (95% CI: 1.10#1.26) 
for total cardiovascular disease with each one-percentage point increase in 
HbA1c (62).  
A 10-year post trial monitoring of the UKPDS participants found significant 
relative reductions in the sulphonylurea#insulin group of 24% (p=0.001) for 
microvascular disease when compared with conventional therapy. Furthermore, 
a significant risk reduction emerged in the sulphonylurea-insulin group of 15% 
(p=0.014) for myocardial infarction and 13% (p=0.007) for all-cause mortality 
(63).  
 
Recently, a debate was triggered with regard to pursuing glycaemic control 
below 7% as measured by HbA1c, when compared with adequate glycaemic 
control in type-2 diabetes (64). This was raised as a result of the Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) trial in 2008, which found an 
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association between tight glucose control (HbA1c achieved was 6.4%) and 
higher all-cause mortality, when compared with the conventionally treated group 
(HbA1c achieved was 7.5%) (65). Conversely, two other major trails (Action in 
Diabetes and Vascular Disease: Preterax and Diamicron Modified Release 
Controlled Evaluation Trial and the Veterans Affairs Diabetes Trial) found no 
significant increase in mortality in the intensive control group (66, 67). A meta-
analysis of these trials and others including UKPDS found lower rate of 
cardiovascular events but no effect on the mortality in the intensive group, when 
compared with the standard group (68). Finally, analysis using the General 
Practice Research Database (GPRD) found a U-shaped association between 
levels of HbA1c and all-cause mortality, a finding that supports that of the 
ACCORD study (69).  
 
 
Blood pressure: 
Follow-up of a median of 8.4 years in the UKPDS showed a significant reduction 
in blood pressure in patients assigned to the tight blood pressure control group 
(mean blood pressure: 144/82 mm Hg), when compared with those with less 
tight control (mean blood pressure: 154/87 mm Hg). This difference was 
associated with a reduction in risk of diabetes-related end points by 24% (95% 
CI: 8#38), death related to diabetes by 32% (95% CI: 6#51), stroke by 44% 
(95% CI: 11#65) and microvascular end points by 37% (95% CI: 11#56). 
However, there was no significant reduction in all-cause mortality or myocardial 
infarction (70). Unlike glucose control, no legacy effect was found for blood 
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pressure control after a median follow-up of eight years post-trial monitoring 
(71). 
The Appropriate Blood Pressure Control in Diabetes trial was established to 
assess whether the effect of lowering the blood pressure in normotensive 
patients is associated with lower cardiovascular incidence. At a mean follow-up 
of 5.3 years, normotensive patients in the intensive group had lower incidence of 
stroke, when compared with the moderate therapy group (1.7% vs. 5.4%, 
p=0.03) (72). Analysis from the Irbesartan Diabetic Nephropathy Trial found a 
decreased risk in cardiovascular mortality of 39% with a 20 mm Hg reduction in 
systolic blood pressure (73). 
A 10 mm Hg increase in systolic blood pressure increases the risk for end stage 
renal disease or death by 6.7% (p=0.007) (74), and the UKPDS illustrated better 
retinopathy outcomes in the tight blood pressure control group (mean blood 
pressure: <150/85 mm Hg) when compared with less tight control (mean blood 
pressure: <180/95 mm Hg) (75). 
 
Lipid control: 
Lipid lowering is essential in the prevention of cardiovascular disease in patients 
with diabetes. The UKPDS found an association between coronary disease risk 
and LDL-cholesterol or total cholesterol levels (76). The Collaborative 
Atorvastatin Diabetes Study found a 37% (p=0.001) reduction rate in any major 
cardiovascular end point, and 27% (p=0.059) in all-cause mortality in diabetes 
patients without high concentration of LDL-cholesterol assigned to lipid lowering 
treatment (77). 
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The latest evidence comes from the Cholesterol Treatment Trialists’ 
Collaboration. A meta-analysis of 14 randomized trials identified a linear 
relationship between the absolute reductions in LDL-cholesterol and reductions 
in the incidence of coronary and other major vascular events irrespective of their 
lipid profile. For example, a reduction of 1 mmol/l of LDL-cholesterol was 
associated with 9% reduction in all-cause mortality. This was similar to the 
reductions seen in patients without diabetes (78). 
 
Smoking cessation: 
Smoking is a modifiable risk factor that can increase the already raised risk of 
macro and micro-vascular complications in diabetes patients. For instance, 
findings from UKPDS demonstrate that patients who smoke have a higher risk 
of developing coronary heart disease (HR: 1.41; 95% CI: 1.06#1.88) (76). A 
meta-analysis of 17 trials of offering brief smoking cessation advice to patients 
compared to no advice found a significant increase in the rate of smoking 
cessation (RR: 1.66; 95% CI: 1.42#1.94) among the advice group (79). 
 
1.5 Prevalence, incidence and health outcomes of diabetes in ethnic minority 
patients !
Before discussing the prevalence, incidence and health outcomes of diabetes in 
ethnic minorities, it is essential to review the concept of ethnicity and policies 
that have been undertaken to reduce health inequalities in the UK. 
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1.5.1 Definition of ethnicity !
Ethnicity is a complex concept that arises from differences such as race, culture 
and religion and has been used commonly in research (80). Definitions of 
ethnicity groups include one or more of the following (81): 
• “Share a common origin or social background; 
• Share a cultural and traditions that are distinctive, maintained between 
generations, and lead to a sense of identity and group; 
• Have a common language or religious tradition.” 
There are several methods to allocate individuals into ethnic groups. For 
instance, the 1991 UK Census included a self-determined ethnic question. 
Coding of ethnic groups in the 1991 census included ‘black other’ and ‘any 
other ethnic group’ in case individuals did not feel they fit in the pre-coded 
options. However, due to several limitations, such as the lack of recognition of 
the Irish group, the coding of ethnicity in the 2001 census has been expanded 
(Box 1 and 2) (82). According to the 2001 census, 4% of the population is Asian 
or Asian British, 2% are black or black British. 
 
Box 1 The 1991 census ethnic categories 
Ethnic groups: 
1. White 
2. Black-Caribbean 
3. Black-African 
4. Black Other              please describe 
5. Indian 
6. Pakistani 
7. Bangladeshi 
8. Chinese 
9. Any other ethnic group           please describe 
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Box 2 The 2001 census ethnic categories 
Ethnic groups: 
A. White 
• British 
• Irish 
• Any other white background, please write in 
B. Mixed 
• White and black Caribbean 
• White and black African 
• White and Asian 
• Any other mixed background, please write in 
C. Asian or Asian Brit ish 
• Indian 
• Pakistani 
• Bangladeshi 
• Any other Asian background, please write in 
D. Black or Black Brit ish 
• Caribbean 
• African 
• Any other black background, please write in 
E. Chinese and other ethnic group 
• Chinese 
• Any other, please write in 
 
Ethnic minorities have disproportionate burden of chronic diseases. For 
example, in England men and women born in East Africa, West/South Africa, 
Scotland and Ireland have the highest all-cause mortality rate. Ischemic heart 
disease rates are higher in people born in the Indian subcontinent (83). 
 
Strategies to reduce health inequalities in the United Kingdom: 
Reducing health inequalities has been on the agenda of many developed 
countries (84). The Black report (85), commissioned in 1977 by the then Labour 
government, was an influential report that put inequalities on the political agenda 
in the UK (86). The report found that inequalities have persisted despite the 
introduction of the NHS in 1948. However, the Conservative government largely 
! #+!
ignored the recommendations of the report when it was published in 1980. In 
1998, the government published the Acheson report (87). The report is 
considered a “fundamental source document for the United Kingdom 
government thinking on the causes of health inequalities and how to tackle 
them” (86). The report found widening gap between social classes despite an 
improvement in health measures such as life expectancy. The committee made 
a number of recommendations including the following key ones: 
• All policies likely to have an impact on health should be evaluated in 
terms of their impact on health inequalities; 
• A high priority should be given to the health of families with children; 
• Further should be taken to reduce income inequalities and improve the 
living standards of poor households. 
The report also stated that targeting prevalent health conditions will result in 
most gains in reducing inequalities and improving average health may not 
benefit those in most need without any targeted efforts. The widening gap in 
inequalities found in the report might be because improvements reach more 
affluent groups faster than deprived groups. Such explanations, have been 
illustrated by Victoria et al, who developed the “inverse equity hypothesis” which 
states that “new interventions will initially reach those of higher socioeconomic 
status and only later affect the poor” (88). However, such a hypothesis has not 
been tested to a great extent in chronically ill patients in the UK. 
The government responded to the Acheson report by producing two key 
documents. The white paper “Our Healthier Nation” (89), which produced a 
programme to promote healthier living and reduce inequalities. The NHS plan 
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document (90), set a map for the reform of the NHS.  It stressed out the need to 
reduce inequalities in access to health services and to improve child health. In 
addition, it targeted prevalent conditions through improved prevention and 
control. Finally, the government established national health inequalities targets to 
narrow the gap in infant mortality and life expectancy at birth. 
 
1.5.2 Prevalence, incidence and outcome of diabetes in ethnic minorities !
Incidence of diabetes is higher in ethnic minorities when compared to the white 
group. For example, using data from a large database (551 practices) in the UK, 
the age standardised incidence of type-2 diabetes was 7.90 (95% CI: 
6.73#9.08) per 1000 person years for Indian women and 9.60 (95% CI: 
8.35#10.8) per 1000 person years for Indian men, compared to 4.13 (95% CI: 
4.08#4.17) per 1000 person years for white women and 5.31 (95% CI: 
5.26#5.36) per 1000 person years for white men (91). 
Analysis of the same database suggests that, when compared to the white 
group, the hazard ratio for risk of type-2 diabetes was 1.71 (95% CI: 1.48#1.96) 
for Indian women, 1.92 (95% CI: 1.70#2.18) for Indian men, 2.15 (95% CI: 
1.83#2.51) for Pakistani women, 2.53 (95% CI: 2.20#2.92) for Pakistani men, 
4.07 (95% CI: 3.24#5.11) for Bangladeshi women, 4.53 (95% CI: 3.67#5.59) for 
Bangladeshi men, 0.79 (95% CI: 0.69#0.91) for Black Caribbean women, 0.95 
(95% CI: 0.82#1.10) for Black Caribbean men, 0.80 (95% CI: 0.66#0.97) for 
Black African women, 1.69 (95% CI: 1.42#2.02) for Black African men. These 
values were adjusted for age, BMI, family history and smoking status (91). 
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People from an ethnic minority background have higher diabetes prevalence 
rates. For example, in the Unites States (92), the 2010 prevalence of diabetes in 
non-Hispanic white, Asian Americans, Hispanic/Latinos, non-Hispanic blacks 
was 7.1%, 8.4%, 11.8%, 12.6%, respectively. Further, Asian Americans, 
Hispanic/Latinos, non-Hispanic blacks have a higher risk of being diagnosed 
with diabetes of 18%, 66%, 77%, respectively, when compared to non-Hispanic 
white. 
The Coventry diabetes study, in the UK, found the age adjusted prevalence of 
non-insulin dependent diabetes to be 3.2% (95% CI: 2.6#4.0) and 4.7% (95% 
CI: 4.0#5.5) for Europeans males and females, compared to 12.4% (95% CI: 
11.0#13.8) and 11.2% (95% CI: 10.0#12.5) in South Asian males and females 
(93). The Southall survey in the UK found an age-adjusted prevalence of 
diabetes in South Asians almost four times higher than that in Europeans (94). 
The 2004 HSE showed a higher prevalence of diabetes among black 
Caribbeans, Indians, Pakistanis, and Bangladeshis than in the general 
population. This was true for men (ranging from 7.3% to 10.1%) and women 
(ranging from 5.2% to 8.6%) (95).  
Furthermore, ethnic minorities with diabetes have worse outcomes. Swerdlow et 
al., conducted a prospective cohort study in the UK on 828 South Asians with 
type-1 diabetes. The standardized mortality ratio (SMR) was 3.9 (95% CI: 
2.0#6.9) in men and 10.1 (95% CI: 5.6#16.6) in women among the South Asian 
group, when compared with 2.7 (95% CI: 2.6#2.9) in men and 4.0 (95% CI: 
3.6#4.3) in women for the non-South Asian group (96). An 11-year follow-up of 
the Southall diabetes survey in the UK found a mortality rate ratio of 1.80 (95% 
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CI: 1.03#3.16) for circularity disease (South Asian vs. European) and 2.02 (95% 
CI: 1.04#3.92) for ischemic heart disease. Furthermore, South Asians were more 
likely than Europeans to report a history of myocardial infarction (OR: 3.8; 95% 
CI: 1.8#8.0) and have laser treatment for retinopathy (OR: 1.7; 95% CI: 1.1#2.8) 
(97). Gill and colleagues reported that black Caribbean patients have higher 
SMR compared to the rest of the population and individuals born in China have 
comparable SMR to the general population (98). A similar study was undertaken 
to compare African Caribbean’s and Europeans. The risk ratio for all-cause 
mortality was 0.41 (95% CI: 0.23#0.73) for African Caribbean’s vs. Europeans. 
However, this was no longer significant after further adjustment for sex, body 
mass index, and smoking (99). 
 
Complications such as the risk of lower-extremity amputation were found to be 
lower in some ethnic minorities group. For example, between 1992 and 1997 no 
ethnic differences were found between African Caribbeans and Europeans 
(relative risk: 0.67 (95% CI: 0.32#1.40)) (100). South Asians had a higher 
incidence rate of end stage renal failure (486.6; 95% CI: 185.1#788.1 per million 
person-years per year) than white patients (35.6; 95% CI: 17.0#54.2) in 
Leicestershire (101). Finally a cross-sectional study conducted in central 
England by the United Kingdom Asian Diabetes Study found that South Asian 
patients have a higher prevalence of diabetic retinopathy than white Europeans 
(45 vs. 37%, p<0.05) (102).  
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1.6 Quality of health care in the UK !
This section discusses the quality of diabetes care delivered to ethnic minorities 
in the UK. However, it is essential to have an overview of the quality of care, 
including definitions, dimensions, levels, and assessment of quality of care. 
1.6.1 Definition of quality of care !
The concept of quality has been discussed in the literature to a considerable 
extent and many definition of quality of care exist (Table 1) and the choice 
depends on the level of analysis or perspective of the stakeholder (103, 104). 
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Table 1 Definitions of Quality 
Author Definition 
Donabedian (1980) Quality of care is the kind of care, which is expected to maximize 
an inclusive measure of patient welfare, after one has taken 
account of the balance of expected gains and losses that attend 
the process of care in all its parts. 
Institute of Medicine 
(1990) 
The degree to which health services for individuals and population 
increase the likelihood of desired health outcomes and are 
consistent with current professional knowledge. 
Department of Health 
(1997) 
Doing the right thing, to the right people, at the right time, and 
doing things right first time. 
Council of Europe (1997) The degree to which the treatment dispensed increases the 
patient’s chances of achieving the desired results and diminishes 
the chances of undesirable results, having regard to the current 
state of knowledge. 
 
One of the most commonly cited definitions of quality of care is the one put 
forward by the Institute of Medicine (IOM), which has been adopted by many 
organisations in the United States. In 1990, the IOM reviewed over 100 
definitions and parameters of quality of care. Accordingly, quality of care was 
defined as “the degree to which health services for individuals and population 
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increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge” (105). The definition includes a “measure of 
scale, wide range of elements of care, and individuals and populations as 
targets. It is goal-oriented, links process with the outcome, highlights the 
importance of differing perspectives, and finally highlights the importance of 
evidence-based medicine” (105). 
1.6.2 Dimensions of quality of care !
The definition of quality of care consists of different dimensions or themes that 
can be used to judge the delivered quality. For instance, in their influential report, 
“Crossing the Quality Chasm”, IOM defined quality along seven themes: 
effectiveness, efficiency, safety, equity, patient centeredness, timeliness and 
satisfaction (106). Others have included dimensions such as access and 
appropriateness (107-109). Table 2 presents examples of quality of care 
dimensions. 
Even though definitions of quality of care vary depending on the setting, some 
themes are common between them. Effectiveness questions whether the 
intervention in a place produced the intended effects. However, efficiency 
questions whether the intended effects were achieved by the least amount of 
resources used.  Access is another theme present in quality definitions, except 
the one put forward by IOM. Access can be seen as the percentage of 
population in need of health care, whom could actually can get them (110). 
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Table 2 Dimensions of Quality of Care 
 Donabedian IOM Department 
of health 
Leatherman 
(Quest for 
quality) 
Council of 
Europe 
Effectiveness X X X X X 
Efficiency X X X  X 
Access X  X X X 
Safety X X   X 
Equity X X X X  
Appropriateness X    X 
Timeliness  X X X  
Acceptability     X 
Satisfaction  X X  X 
Responsiveness  X  X  
 
IOM defines patient safety as “freedom from accidental injury due to medical 
care, or medical errors.” (111). It is seen as an important component of quality of 
care dimensions; however, sometimes, quality and safety are used 
synonymously because some view it as a pre-requisite to quality (106), while 
others believe the two are indistinguishable (112). 
Equity of care is the absence of variations in the quality of care between groups 
with different personal characteristics such as sex, ethnicity, geographic 
location, and socioeconomic status (106). Whitehead, in her widely cited 1992 
paper, defined health inequity as “differences in health that are not only 
unnecessary and avoidable but in addition unfair and unjust.” (113). She further 
defined equity in health care “as equal access to available care for equal need, 
equal utilization for equal need, equal quality of care for all.” (113).  
Equity is different, but frequently confused with, equality. Health equity 
concentrates on the process that drives a specific kind of health inequality, a 
kind that has systematic differences in health between the groups that are 
considered to be unjust or unfair, i.e., not all health inequalities are unfair or 
unjust (114). Important distinct aspects of equity are noted in the literature: 
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vertical equity, which is different treatments for different need, and horizontal 
equity, which is equal care for equal need, which is the one commonly used in 
practice (115). However, difficulties in defining the need for care can make this 
problematic (116). 
 
1.6.3 Levels of quality of care !
Similar to the diversity in the definition of quality, assessment of quality of care 
can take place at different levels. One concept, proposed by the Council of 
Europe, assesses quality at central (country or district), local (hospital or 
practices), and individual level (117). Donabedian proposed a more 
comprehensive model. He presented measurement of quality of care at four 
levels. At the core, care that is delivered by providers can be assessed by the 
technical aspect of it and by the management of interpersonal relationship. The 
second level includes the characteristics of the care setting. The third level, 
focuses on the implementation of care and the final level focuses on the care 
received by the community (108). 
 
1.6.4 Measurement of quality of care !
Donabedian’s framework for the measurement of quality of care has been the 
basis for much of the work in this field. Donabedian proposed a 
structure#process#outcome model, and argued that “good structure increases 
the likelihood of good process, and good process increases the likelihood of 
good outcome.” (108). Structure is the characteristic of the setting where 
delivery of care takes place (e.g., facilities, equipment, information system, 
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human resources). Process refers to the transaction in giving and receiving care 
either related to the patient (e.g., checking the blood pressure of a patient, 
checking the smoking of status of patient), or to the organization (e.g., managing 
waiting list). Outcome is the results of health care on the health of the patients 
and population, such as mortality and morbidity (108).  
Shaw and Kalo matched the different dimensions of quality with Donabedian’s 
structure#process#outcome model. Table 3 presents some of the examples 
proposed by them (118). 
Table 3 Dimensions in the assessment of quality of care 
 Dimension of quality of care 
Fairness in sharing costs and benefits (Equity) 
Structure 
Responsiveness to the needs of populations (access) 
Reduction of risk (Safety) 
Process 
Use of time and resources (efficiency) 
Clinical outcome (Effectiveness) 
Outcome 
Meeting expectations of patients (satisfaction) 
 
Even though Donabedian’s model is commonly referred to, there is a debate on 
the relative merit of the process and outcome measures. For example, some 
commentators believe that process measures are more sensitive than outcome 
measures as a poor outcome does not necessarily mean poor provision of care 
(119). Giuffrida et al., noted that outcome measures can be influenced by factors 
that are outside the control of the health care providers such as socio-economic 
status (120). Although, in theory, these can be adjusted for, such information is 
not always available in the medical record (121). In addition, outcome measures 
usually take time to show a difference in the quality of care, e.g. myocardial 
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infarction, while process of care is immediate (122) and it is difficult to assess 
outcome measures in small practices. Nevertheless, outcome measures are 
more focused on the patient, when compared with process measures that focus 
on the service (123). Outcome measures are more meaningful to the patients 
and encourages a longer term view by the providers (124). In primary care, it is 
recognized that the use of process measures that are linked to effective 
outcome (also referred to as intermediate outcomes) are the most useful 
measures available (125). 
 
1.6.5 Quality improvement in the UK !
Since the late 1990s, the UK government has embarked on an ambitious quality 
improvement agenda within the NHS. A key objective of this agenda is to 
improve the management of common chronic diseases, such as diabetes, in 
primary care. Standards setting and monitoring, target setting, regulation and 
payment reform were some of the key functions introduced over the years to 
improve the quality of health care in the NHS.  
The National Service Frameworks (NSFs) were launched in the late 1990s to 
define and set national standards for a number of common conditions. On an 
average, two NSFs were introduced per year. For example, NSFs for cancer and 
coronary heart disease were introduced in 2000 and NSFs for older people and 
diabetes were introduced in 2001. The NSF for diabetes includes a set of 
standards and key interventions. For instance, standard four refers to clinical 
care of adult patients and states that “All adults with diabetes will receive high-
quality care throughout their lifetime, including support to optimize the control of 
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their blood glucose, blood pressure and other risk factors for developing the 
complications of diabetes”. In addition, it includes a strategy to enhance disease 
registers in primary care, a prerequisite to the delivery of systematic, high-quality 
care (126).  
The National Institute for Clinical Excellence (NICE) was set up to produce 
evidence-based guidelines and health technology assessment. It was merged 
with the Health Development Agency and was consequently renamed National 
Institute for Health and Clinical Excellence (still abbreviated as NICE) in 2005. 
NICE publishes detailed guidelines that inform the development of NSFs and 
diabetes management. For example, NICE recommends that “Simvastatin 40 
mg or equivalent for all patients with type-2 diabetes aged over 40 irrespective 
of experience of cardiovascular disease” (127).  
Furthermore, the United Kingdom has well-developed systems for auditing 
performance and regulation of healthcare locally through local commissioning 
organisations (Primary Care Trusts), and nationally through the Healthcare 
Commission (now replaced by the Care Quality Commission) that monitors the 
quality of healthcare organization against specific standards in key areas, such 
as cost effectiveness, safety, public health, patient focus, and accessible and 
responsive care (128). Another relevant organisation is the National Patient 
Safety Agency (NPSA) that leads on initiatives to improve patient safety, 
investigates the performance of individual clinical practitioners, and ensures that 
research is carried out safely. 
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1.7 Ethnic inequalities in diabetes care !
In developed countries, there are signs of improvements in the quality of care 
being delivered for individuals with diabetes (129-131). However, the gap 
between ethnic groups in diabetes care is a continuing challenge. In the United 
States, improvements seen between 1999#2003 in Medicare managed care 
enrollees with diabetes failed to close the differences between white and black 
patients and in some quality measures it increased. For example, differences 
between white and black patients in the control of HbA1c increased from 4% in 
1999 to 7% in 2003 (132). 
Similarly, in the UK, the quality of diabetes care has improved substantially. For 
example, a study of 42 general practices in England between 1998 and 2003 
found considerable improvements in three chronic conditions including diabetes. 
These include significant improvement in cholesterol control (!5 mmol/l) from 
21.5% in 1998 to 52% in 2003 and control of blood pressure (!145/85 mm Hg) 
from 21.8% in 1998 to 35.8% in 2003. However, there was no significant 
improvement in HbA1c control (133). These findings are similar to those of 
another study of 74 general practices in England and Wales, which examined 
the intermediate outcome measures between 1994 and 2001. Achievement of 
national targets for cholesterol and blood pressure increased significantly over 
this period (p<0.001), with no significant improvement in glycaemic control 
(134). 
These improvements were not uniform across all groups and evidence of 
persisting inequalities exists. For example, patients from deprived areas were 
less likely to have a recording of HbA1c or achieve HbA1c target levels, when 
! $"!
compared with those from affluent areas (135). In a secondary analysis of the 
HSE 2004, Nazroo and colleagues found no evidence of ethnic inequalities in 
glycaemic control, except for the Pakistani group (Relative Risk Ratio 1.95; 95% 
CI: 1.03#3.68). However, the small sample size may explain the non-significant 
findings in the other ethnic groups (136). Furthermore, Millett and colleagues 
carried out an analysis of time trend using the HSE between 1999 and 2004 and 
found that South Asian group had lower improvement in cholesterol control 
(2.7%; 95% CI: 1.9#3.5), when compared with the white group, while the black 
and Irish group had greater improvements. With regard to blood pressure 
control, improvements were lower in the black group (13.9%; 95% CI: 13#14.8) 
but higher in the Irish and south Asian groups, when compared with the white 
group (137). In addition, Mukhopadhyay et al., found higher levels of HbA1c and 
smaller improvements in the south Asian group, when compared with European 
patients between 1991 and 2003 (138). 
McElduff and colleagues, examined the trend in changes in the intermediate 
outcome indicators between 1995 and 2001 to compare the care delivered to 
Europeans and south Asians in primary and secondary care setting in North-
West England. They found that both the groups had significant increases in the 
measurement of intermediate targets, but the Europeans had greater 
improvement, when compared with the south Asian group, with respect to 
cholesterol and blood pressure measurements. In addition, they observed higher 
levels of HbA1c in the south Asian group, when compared with the European 
group (139).  
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2.0 Financial Incentives and quality improvement !
Many countries have sought to use provider payments as a policy lever to bring 
about improvements in the delivery of care. Each payment method sends an 
economic signal to the provider, potentially shaping their behaviour. This 
relationship between the provider and the purchaser has been explained 
through the principal-agent theory. As Robinson puts it “the essence of incentive 
contracting is the effort by one individual or organization (the principal) to induce 
and reward certain behaviors by another (the agent)” (140). There have been, 
traditionally, four main ways for paying providers in primary care settings, with 
each having its advantages and drawbacks: Line item budget, salary, fee-for-
service and capitation. Additionally, other payment methods used in hospital 
settings are also discussed here.  
Payments can be categorized into a time based, service based, or population 
based. Time based include payments that reward providers regardless of time 
spent in delivering the service, e.g. budget and salary. With service-based 
payments, the provider is remunerated according to the number of services 
provided, e.g. fee for service. Lastly, population based payments are payments 
that depends on the size of the population served by the provider, e.g. 
capitation (141). Another way to examine provider payments is whether the 
payment is retrospective or prospective. Retrospective payments are made after 
the service has been provided (e.g. fee for service), while prospective payments 
are made or agreed upon before the services are provided (e.g. capitation) 
(142). 
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2.1 Provider payment methods !
Line item budget 
Providers are paid an amount of money for a period of time, usually a year. The 
total budget is broken down into different items such as salaries, equipments, 
and medicines. Usually providers cannot transfer funds across lines, thus limiting 
the incentive for the provider to be efficient but it is preferred with government-
run facilities, such as Egypt, Bahrain, Saudi Arabia, as it offers the strong 
administrative control. Providers usually have the incentive to spend all funds by 
the end of the financial year (143). 
 
Salary 
In this method, providers are paid an income for specific hours irrespective of 
the number of patients they treat. As such there is no incentive to over or under 
provide services. It is one of the most neutral forms of payment. There may be a 
need to use rules and regulation and other quality improvement strategies that 
enhances the delivery of high quality of care. However, this may lead to 
improvement in quality of care or result in lower quality of care (144). 
 
Fee-for-service 
In this method, the provider is reimbursed for every service provided. Such 
services include doctor consultation, lab test, x-ray test and other medical 
products. So there is an incentive for the provider to provide more care. It can 
be further broken down to two types. If there is no fixed-fee schedule and 
services are not bundled, the providers can bill the purchaser for all costs. If 
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there is a fixed-fee and services are bundled the provider is paid per encounter 
which provides an incentive to limit services provided in each encounter. 
Although fee-for-service encourages the overprovision of services regardless of 
their effectiveness, it has its advantages. First, it can easily be implemented. 
Second, it reflects the services performed more accurately. Third, it can improve 
access to underserved population since providers do not have incentive to 
under provide services (143). 
 
Capitation 
The provider receives a fixed amount of money for each patient for a particular 
time (e.g. one year) to provide a specific service. It was introduced in the 1990s 
to address the cost escalation issue associated with fee for service.  Thus it 
generates an incentive for the provider to provide as little as possible, an 
opposite effect to fee for services. The provider may also try and shift the 
financial risk to someone else by referring the patient to a hospital or a specialist 
care (143). If capitation is not risk adjusted (i.e. payments takes into account 
factors such as age and socioeconomic status) it may encourage providers to 
avoid high-risk patients such as patients with multiple comorbid conditions, a 
process known as “cherry picking” (145). 
Institutions higher-up in the health system are paid using similar methods to 
those seen in the primary care setting but in addition include other payment 
methods, such as per diem payment and case fees. In the per diem method, 
the provider is paid according to the number of in-patient days. Consequently, 
there is an incentive to increase the number of hospital days but there is an 
incentive to reduce resources used per day. In the case fees payment, the 
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provider is paid a fixed amount per case, based on Diagnostic Related 
Groupings, and as such it creates an incentive to minimize the input for each 
case and encourages early discharge (142). For example, introduction of the 
case fees payment system in the United Stated was associated with reduction in 
hospital stays (146). However, it may encourage admission and unnecessary 
readmissions. Additionally, providers may code patients in more expensive 
groups.  
Langenbrunner et al., noted that the impact of the different payment approaches 
highly depends on other factors such as the context where the policy is being 
used (e.g. level of resources available, extent of competition), the presence of 
any information constraints (e.g. technical resources, baseline information on 
cost and needed care), and the management capacity of the providers (e.g. 
autonomy of providers) (147). All of the payment methods discussed above have 
an implicit effect on quality of care and do not fully align with the optimal care of 
patients, especially those with chronic conditions. As such, new payment 
methods have been proposed. However, many governments are moving toward 
the use of blended payment to counterbalance the disadvantages of each. For 
example, there has been a shift from service-based payment (e.g. fee for 
service) approaches in tax-financed health system to a combination of payment 
methods. Although, in social health insurance and mixed funded health systems 
service based payment is still dominant (e.g. United States) (148). The following 
table presents some examples of payment approaches to providers in Western 
Europe. 
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Table 4 Examples of provider payment methods in Western Europe 
Country Salary Capitation Fee for service Combination 
Tax-based health system 
Denmark    X (capitation + FFS) 
England X X (public) X (private)  
Finland X    
Ireland  X (public) X (private)  
Norway   X  
Sweden X (public)  X (private)  
Italy  X   
Portugal X    
Spain    X (salary + capitation) 
Social Health Insurance based system 
Germany   X (private)  
Belgium   X  
France   X  
Source: Langenbrunner et al. (141). 
 
2.2 Pay for performance as a quality improvement lever !
Many countries recognized the need to develop more innovative ways to pay 
providers. The use of explicit financial incentives to improve the quality of health 
care is increasing in many countries, through “pay for performance” schemes. In 
the literature, there are many terms used for pay for performance, such as 
results-based financing, performance-based financing, and conditional cash 
transfers. Pay for performance is one of the approaches of value based 
purchasing. Other approaches include selective contracting and public reporting 
of provider performance (149). 
Various factors contributed to the increase use of pay for performance schemes 
in different health systems and specifically in the United States and UK. First, 
evidence from sectors that resembles health care sector, such as education, 
showed that employees do respond to explicit incentives (150). Second, there is 
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a sponsorship from high-profile organisations for the use of explicit financial 
incentives. For example, in 2000, the WHO encouraged purchasers of health 
care services to move from passive purchasing of health care services to more 
strategic purchasing (151). In their report “Crossing the Quality Chasm”, the IOM 
recommended the alignment of financial incentives with quality improvement 
(106), and recently the Institute explicitly stated that monetary incentives can be 
a powerful stimulus to derive change in the health care provider behavior (152). 
Third, there is a shift in cultural beliefs where in the past providers faced limited 
accountability; however, with the advances in evidence based medicine and 
performance measurement (153), coupled with growing recognition that the 
views of patients, the public, and other key players are relevant (118, 154), 
resulted in a greater pressure on providers to deliver better care. Fourth, a 
number of research findings suggest that patients are not receiving optimal care. 
For instance, McGlynn et al., found that adult patients in the United States 
received evidence based care only 54.9% of the time (95% CI: 54.3#55.5) (155). 
Similarly, a systematic review of studies evaluating the quality of care delivered in 
primary care from 1995-99 concluded that care did not reach acceptable 
standards in the UK, Australia, and New Zealand (156). Five, paying for 
performance is seen as a way to overcome the barriers to tailor care to 
individual patients brought by the current reimbursement strategies (157). 
Finally, policy commentators have argued that provider payment methods, such 
as fee-for-service and capitation, are limited in their impact on quality 
improvement (140, 158). 
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The instinctive appeal of pay for performance, along with the factors mentioned 
above, prompted many countries to use pay for performance schemes in their 
providers’ contract including the United States (159), UK (160), Australia (161), 
New Zealand  (162), Canada (163), Germany (164), the Netherlands (165), and 
in developing countries (166).  
 
2.3 Description of selected pay for performance programmes !!
United States: 
The first generation of pay for performance schemes in the United States were 
small in scale and mainly focused on preventive measures such as 
immunizations and were mainly implemented by private health plans. Many of 
the systematic reviews that examined the impact of financial incentives on 
quality of care (167-170) drew much of their conclusions using similar studies 
(171-174). However, this has changed in recent years with several private and 
public payers engaging in pay for performance schemes in the United States. 
For example, in a survey of commercial Health Maintenance Organizations 
(HMO) published in 2006, Rosenthal et al., found that 53% use pay for 
performance schemes (175) and a recent survey found an overall increase of 
pay for performance schemes from 11% in 2008 to 55% in 2010 (176). 
Medicare has several pay for performance demonstration projects. The most 
important is the Premier Hospital Quality Incentive Demonstration, which covers 
about 250 hospitals. The scheme collects data on 34 measures relating to five 
clinical conditions: acute myocardial infarction, heart failure, community-acquired 
pneumonia, coronary-artery bypass graft, and hip and knee replacement. 
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Hospitals in the top 10 percent were given a 2% bonus payment and those in 
the next decile were given 1% bonus payment (177). Evaluation of the first two 
years of the programme found an improvement in the composite process 
measures ranging from 2.6% to 4.1% compared to the control group (178). 
Conversely, Glickman et al., found smaller improvements in process measures 
for acute myocardial of 1.6% over 3 years and no association were found 
between pay for performance and mortality (179). 
Another demonstration is the Physician Group Practice demonstration, which 
was initiated in 2005 and directed towards physicians groups. The scheme uses 
32 performance measures covering diabetes, heart failure, coronary artery 
disease and preventive care. Physicians may earn up to 80% of the savings 
generated (180). No empirical evaluation of the program is yet available; 
however, a case study reported encouraging efforts in identifying high-cost 
patients and improving the care delivered to them, hence avoiding hospital stays 
(181). 
 
Australia: 
The Australian government introduced the Enhanced Primary Care Practice 
incentive in 1998 to increase the engagement of general practitioners in 
structured and coordinated care. Measures identified include: information 
systems; after-hours care; teaching of medical students; participation in national 
prescribing service; care for patients with diabetes, asthma, cervical screening 
or mental health; and rural location. Practices receive various payment 
structures according to the service provided (182). For example, in the case of 
the diabetes incentive programme, the practice will receive a sign on payment in 
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the amount of AUD $1.00 (£0.64) per Standard Whole Patients Equivalent (a 
measure of practice size and adjusted for the age and gender of patients), when 
the practice register for the programme and uses a register and a recall system 
for patients with diabetes. Further, a payment of AUD $20 (£12.8) per Standard 
Whole Patients Equivalent if 2% of the practice patients are diagnosed with 
diabetes and have a completed a set of clinical activity (183). 
A study published in 2008, assessed if this scheme had positive effect on the 
proportion of consultation in which HbA1c been measured. Data were collected 
from 2001-2006 from 1,000 general practitioners. Practices that joined the 
scheme were 15% more likely to order HbA1c than practices that did not join 
(184). 
 
Taiwan: 
The Taiwanese government implemented a pay for performance scheme in late 
2001. Initially the program covered four diseases: diabetes, tuberculosis, breast 
cancer, and asthma. In 2006, hypertension and depression were added. The 
scheme is voluntary and any provider can participate given they meet specific 
quality measures, such as having the required certification for participating 
providers and follow established treatment guidelines. Payment structure varies 
according to the disease. For instance, in the case of breast cancer, providers 
are paid 1% of regular case payment at 1st year survival and 2% at 2nd year 
survival. For diabetes, a more complex process-based bonus scheme that 
includes a number of points for every process with each point translates to TWD 
$1.00 (£0.02) (185). For example, a provider would receive 1845 points for initial 
visit for new patient. Of note, the scheme does not incorporate any risk 
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adjustment method in providers’ payment. Evaluation of the diabetes scheme 
found an increase in diabetes-specific test post-intervention (3.8% vs. 6.4%, 
p<0.001) compared to the control group who did not enroll in the scheme (3.5% 
vs. 3.6, p<0.001) (186). 
 
2.4 Pay for performance in the UK !
The Quality and Outcomes Framework (QOF) was introduced as part of a new 
General Practitioner contract in April 2004 (Table 5). The scheme is unique in its 
size and scope. It has been described as “the boldest quality improvement 
initiative ever attempted anywhere in the world” (187). The scheme links up to 
25% of provider income to their performance. This is considerably higher than 
the percentage of income incentivised in schemes in the United States, which 
typically range from 2#10% (188). The framework covered eleven conditions 
when it was introduced. However, this was not the first time the UK tried to 
introduce financial incentives. In 1986, the government attempted to introduce a 
“Good Practice Allowance” to reward practices that provided high-quality care 
but the British Medical Association (BMA), which negotiates on behalf of general 
practices, dismissed it (189). The first experience of pay for performance was in 
1990 when the government introduced incentives to achieve targets for cervical 
cytology and childhood immunization, which lead to improvement in coverage in 
these areas. This also resulted in many general practices to invest in information 
technology in order to achieve these targets effectively (160). !
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Table 5 Component of the general practitioner contract 
Services Funding 
Essential Services: Treatment of any registered 
patient who is ill or thinks he is ill 
Global sum: practices received an average 
payment of £56 per patient per annum 
 
Enhanced services: Services that are not 
included in the essential or additional services 
and are optional. They can be Directed, or 
Local 
 
Payment rate is set national for the Directed 
services and negotiated locally for local 
services. 
 
QOF: pre-specified quality and activity targets Payment according to total points achieved 
 
Source: http://www.bma.org.uk/images/FundingGeneralPractice_tcm41-179188.pdf !
The aim of QOF is to financially reward practices for the delivery of evidence-
based standards of care. Up to one quarter of general practice income is 
dependent on achieving a detailed set of quality indicator targets. Practices can 
earn up to 1000 points across clinical (655 points), organizational (167.5 points), 
patient experience (146.5 points) and additional services (36 points) domains 
where each point triggers an average payment of £124 (revised to £130 in 
2011-12) (190) (Table 6). 
Table 6 QOF domains 
Clinical 
2004/05 Added in 2006/07 
Organisational Additional services Patient 
experience 
Holistic 
care 
Coronary Heart 
Disease* 
Heart failure* 
Education and 
training 
Cervical screening 
Length of 
consultation 
Holistic care 
Stroke/transient 
ischemic attack 
Palliative care 
Medicines 
Management 
Child health 
surveillance 
Patient 
survey 
 
Hypertension Dementia 
Patient 
communication 
Contraceptive 
services* 
  
Diabetes* Depression* 
Practice 
management 
Maternity services   
Chronic 
obstruct ive 
pulmonary 
disease 
Chronic kidney 
Disease* 
Records and 
information about 
patients 
   
Epi lepsy Atrial fibrillation     
Hypothyroidism Obesity     
Cancer 
Learning 
disabilities 
    
Mental health 
Cardiovascular 
disease*‡ 
    
Asthma      
Smoking      
*Points and indicators changed in 2008/09. 
‡Added in 2008/09 revision. !
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Diabetes is one of the twenty conditions included in the clinical domain of QOF 
and accounts for nearly 15% of QOF clinical domain points. Quality indicators 
cover structural, process and outcome dimensions of care. The majority of 
points (more than 50%) are directed to intermediate outcome measures. The 
total!points assigned for intermediate outcome measures for HbA1c, blood 
pressure and cholesterol are 35, 18 and 6 points respectively. One criticism is 
that the treatment targets set within QOF are less stringent than those set out in 
national clinical guidelines (Table 7).!
Points are awarded to a practice according to their measured achievement on a 
sliding scale with a minimum and maximum threshold. For example, the mini-
mum and maximum threshold for the cholesterol target is 40% to 70%. If 55% 
of patients reached the desired target the practice will earn 3 points out of the 
possible 6 points. Beyond the 70% threshold the practice will not be rewarded 
more than 6 points. 
Table 7 Examples of the indicators used in QOF for diabetes care 
Quality domain Indicator Points Threshold 
Structural 
The practice can produce a register of all patients 
aged 17 years and over with diabetes mellitus, which 
specifies whether the patient has type 1 or type 2 
diabetes 
6 NA 
Process 
The percentage of patients with diabetes who have a 
record of HbA1c or equivalent in the previous 15 
months 
3 40-90% 
Process 
The percentage of patients with diabetes whose notes 
record BMI in the previous 15 months 
3 40-90% 
Process 
The percentage of patients with diabetes who have a 
record of the blood pressure in the previous 15 
months 
3 40-90% 
Outcome 
 
The percentage of patients with diabetes in whom the 
last HbA1c is 7 or less in the previous 15 months 
17 40-90% 
Outcome 
 
The percentage of patients with diabetes in whom the 
last blood pressure is 145/85 mm Hg or less 
18 40-60% 
Outcome 
 
The percentage of patients with diabetes whose last 
measured total cholesterol within the previous 15 
months is 5 mmol/l or less 
6 40-70% 
Source: http://www.nhsemployers.org 
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Quality indicators can be revised in QOF but any changes require agreement 
between the government and the British Medical Association. Since its 
introduction, QOF has undergone two revisions. In 2006, new clinical conditions 
were added to the clinical domain (atrial fibrillation, depression, chronic kidney 
disease, obesity, palliative care, dementia, and palliative care) and the clinical 
domain points were increased to 655 from 550. In addition, the overall 
maximum points to be reached were slightly reduced to 1000. In 2009, more 
points were added for a new area of primary prevention of heart disease, which 
brought the clinical indicators to 697 points (nearly 70% of the framework).  
Revisions can include the removal or addition of indicators. For example, the 
2009/10 revision of QOF included additional points for HbA1c control. For 
example, practices achieve 17 points if 50% of their diabetes patients achieve 
HbA1c level of !7% (191). This has now been removed in the latest revision of 
QOF. The QOF is a voluntary scheme, yet more than 99% of practices 
participate in this scheme and achievement in the first year exceeded the 
expectation of the government making it a very expensive scheme (192).  
 
Exception reporting in QOF: 
An important concept in the QOF is exception reporting which allows practices 
to remove patients from the denominator calculations in order not to penalize!
practices for underachieving for reasons outside their control, such as a patient 
not attending a review, and ensure that they are not incentivised to deliver 
clinically inappropriate care (Box 3). A disadvantage of allowing for exception 
reporting is that providers might exclude patients solely to boost their 
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performance; at its most severe, simply excluding patients not meeting the 
targets. For example, qualitative work in 27 practices found that practitioners 
considered exception reporting as a gaming tool (193). Regardless of whether 
exception reporting is being willfully misused it will mean information about the 
quality of health care delivered to these patients is left unknown. Furthermore, 
levels of exception reporting might be used to judge if an indicator in the 
scheme should be removed (194). 
  
Box 3 Reasons of exception reporting under QOF 
Family practitioners are able to exception report patients if a patient: 
• Refuses to attend review having been invited on at least three occasions 
during the preceding twelve months  
• Is inappropriate for review of the chronic disease parameters due to 
particular circumstances e.g. terminal illness, extreme frailty 
• Is on maximum tolerated doses of medication and whose levels remain 
sub-optimal  
• Is not clinically appropriate to prescribe a medication e.g. those who have 
an allergy, another contraindication or have experienced an adverse 
reaction 
• Has not tolerated medication 
• Does not agree to investigation or treatment (informed dissent), and this 
has been recorded in their medical records 
• Has a supervening condition which makes treatment of their condition 
inappropriate e.g. cholesterol reduction where the patient has liver 
disease  
 
According to the Department of Health Information Centre, exception-reporting 
rates for England in 2008/09 for HbA1c (!7.5%), total cholesterol (!5mmol/l), 
and blood pressure target (!145/85 mm Hg) were 10%, 9% and 6%, 
respectively with considerable variation between practices. Little is known about 
the characteristics of diabetes patients who are exception reported or the 
reasons for this. Ecological analysis of the exception rate during the second year 
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of the QOF found an overall median rate of exception reporting in intermediate 
outcomes of 7.1 and more specifically a median of 8.4 for diabetes intermediate 
outcomes (195). Obtaining further information about exception reporting is 
important because there is the potential for practices to game the system to 
maximize income from QOF and because patients who are exception reporting 
may receive poorer quality care. 
In a serial cross sectional analysis, using individual level data from 23 practices 
in North London, of exception reporting that I was involved in, older patients 
(blood pressure control, AOR: 2.52, p<0.01; cholesterol control, AOR: 2.79, 
P<0.01), black and south Asian groups (HbA1c control, AOR: 1.55 and AOR: 
1.64, p<0.01, respectively), and patient with co-morbid conditions (blood 
pressure control, AOR: 1.68, p<0.01; cholesterol control, AOR: 1.59, p<0.01) 
were more likely to be exception reported. Those patients were less likely to 
achieve the intermediate treatment target. However, we did not have reasons for 
exception reporting (196). 
2.5 Has QOF improved the management of diabetes in the UK? !
Studies seeking to evaluate the impact of QOF on patient care face a number of 
methodological challenges. Firstly, the General Practitioner contract was 
implemented nationally. This means that there is no comparison group that can 
be used as a concurrent control. Secondly, as mentioned earlier, quality was 
already improving before the introduction of QOF. Finally, the Quality 
Management and Analysis System (QMAS), the main reporting tool for QOF and 
most commonly used dataset for!QOF evaluation research, contains no pre-
QOF data or patient level information, such as age, gender and ethnicity. This 
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has meant that few studies evaluating the impact of QOF have taken into 
account underlying trends in quality improvement or undertaken subgroup 
analyses.!!
2.5.1 Studies examining trends after the introduction of QOF !
A recent study of QMAS data obtained from the 98% of general practices 
participated in England illustrates overall improvements in intermediate outcome 
targets for diabetes patients over the first 4 years of QOF. The median practice 
proportion for the HbA1c target of !7.5% increased from 59.1% in the first year 
to 66.7% (IQR: 60.6#72.7) in the fourth year. The median achievements for the 
blood pressure target of !145/85 mmHg increased from 70.9% in the first year 
to 80.2% in the fourth year. Achievements were also apparent for the cholesterol 
target of !5.0mmol/l reaching 83.6% in the fourth year compared to 72.6% in 
the first year. Further, the percentage of low-performing practices, measured as 
practices that achieved less than the 25th centile for HbA1c target, dropped from 
57% to 26% (197). 
2.5.2 Studies examining quality before and after the introduction of QOF 
 
Achievements of diabetes clinical indicators were collected before and after the 
introduction of QOF from 66 practices in Shropshire, England. Significant 
improvement on process and intermediate outcome were noted between April 
2004 and March 2006. For example the percentage of patients achieving blood 
pressure control targets was 47% in 2004 compared to 65% in 2006 (198). 
Another study found similar improvements in south London, where clinical data 
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were extracted from 26 practices. Median practice achievement increased from 
2003 to 2005: for recording of HbA1c from 78% to 95%; for a target of HbA1c 
!7.4% from 38% to 57%; for a target of HbA1c !10% from 72% to 89%; for 
recording of blood pressure from 89% to 98%; for a target of blood pressure 
!145/85 mmHg from 50% to 70%; for recording of cholesterol from 77% to 
93%; and for a target of cholesterol !5.0 mmol/l from 47% to 72% (199). A 
longitudinal study involving 32 practices in southwest London examined the 
impact of QOF on smoking cessation support among 4284 patients with 
diabetes. The proportion of patients whose smoking status recorded was 
greater in 2005 than 2003 (86.7% vs. 67.6%, P<0.001); the proportion of 
patients with a documented smoking cessation advice was also greater in 2005 
than 2003 (83.5% vs. 48.0%, P<0.001) (200). Further, the prevalence of 
smoking decreased from 20% to 16% (P<0.001) over this period. These findings 
are consistent with those from a systematic review of studies published between 
1999 and 2006, which compared achievement of process and outcome 
indicators for diabetes before QOF to those reported nationally in the first year of 
QOF. The study found that achievement of quality indicators for diabetes was 
considerably higher after QOF than that seen in prior published studies (201). 
Although these studies identified improvements in quality associated with the 
introduction of QOF, none adjusted for underlying trends. 
 
2.5.3 Studies adjusting for underlying trends !
A longitudinal study of 42 volunteer general practices in England, comparing 
actual quality of diabetes care in 2005 with that predicted by the underlying 
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trend (between 1998 and 2003), found that the introduction of QOF was 
associated with accelerated improvements in care (P=0.002) (202). The authors 
updated their analysis in 2009 by collecting performance measures for the same 
practices in 2007. They then employed a segmented time series analysis to 
examine the impact of QOF on diabetes care and if this effect was maintained. 
There was a significant change in the level of improvement in diabetes care 
(7.5%; 95% CI: 4.1#11.0), but these improvement were not maintained after 
2005 (-0.6%; 95% CI: -1.4#0.1) (203). However, both of these analyses used 
only two pre-QOF measurement points and hence there is some uncertainty 
about the robustness of the projections made in the two studies. 
Using data from the doctors’ independent network database, Calvert et al., 
examined data from 147 general practices from 2002 to 2007 to evaluate if QOF 
had an effect on HbA1c control. Introduction of QOF was associated with small 
improvements in the HbA1c target level of !7.5% (AOR: 1.05; 95% CI: 
1.01#1.09) for patients with type 2 diabetes, but similar associations were not 
seen for HbA1c level of !10% in patients with type 2 diabetes and HbA1c levels 
of !7.5% or !10% for patients with type 1 diabetes (204). However, the effect of 
QOF on blood pressure and cholesterol was not modeled in this study. Further, 
the authors did not use a segmented time series analysis instead of estimating 
an overall effect of QOF. 
 
Studies that have examined the relationship between practice characteristics, 
such as list size; diabetes case volume; and number of practitioners, have 
identified little variation in the quality of diabetes management after the 
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introduction of QOF. For example, a study of 9,411 practices in England and 
Scotland in the first year of QOF found broadly similar achievements on 
intermediate outcome indicators in small and large practices (205). Smaller 
practices had lower achievement on process quality indicators than larger 
practices, but the differences tended to be small (<5%). These findings were 
confirmed by a more recent longitudinal study, which found that achievements 
on the majority of diabetes indicators were similar before and after QOF. The 
only exception was glycaemic control, where there were significant differences in 
the mean proportion of patients achieving HbA1c !7.4% and HbA1c !10% 
between large and small practices before the introduction of QOF (64% vs. 
36%, P=0.02 and 73% vs. 64%, P=0.003 for HbA1c !7.4% and !10%, 
respectively). Nevertheless, these differences were attenuated in 2005 (49% vs. 
47%, P=0.39 and 85% vs. 84%, P=0.48 for HbA1c !7.4% and !10%, 
respectively) and 2006 (62% vs. 61%, P=0.67 and 88% vs. 88%, P=0.72 for 
HbA1c !7.4% and !10%, respectively) (206). 
 
Research into whether the improved QOF scores will translate into measurable 
improvement in population health, such as unplanned admission to hospitals 
because of complications, is limited. In an ecological cross-sectional study 
conducted during the first year of QOF, Bottle et al examined associations 
between the achievement of QOF targets, for 303 primary care trusts in 
England, and hospital admissions. After allowing for area deprivation and 
diabetes prevalence, the study found a significant negative association between 
glycaemic control and hospital admissions among patients aged 65 and older, 
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but there was no significant association for younger patients (207). In contrast, 
Downing et al., did not find significant association between increases in the 
clinical domain scores for diabetes and hospital admission in 94 practices 
across two primary care trusts (208). Dusheiko et al., expanded these findings 
by using a longitudinal analysis and accounting for more covariates in the first 
three years after QOF introduction. Improvements in HbA1c control were 
associated with lower hospital admission (209). 
Srirangalingam et al., used cross sectional study conducted to assess the 
impact of QOF on referral patterns for diabetes care before and after six months 
of implementation. The authors did not find any significant increase in the total 
number of referral to specialty clinic, however increases were evident for poor 
glycemic control (210). 
 
2.6 Does QOF provide value for money? !
Despite increases in the number of pay for performance schemes, the evidence 
on the efficiency of these schemes is scarce. For example, the 2006 systematic 
review by Peterson et al (167), found only one study (211) that assessed the 
cost effectiveness of pay for performance in the United States. The study 
examined the impact of pay for performance on access and Medicaid 
expenditure in nursing homes. Cost in the intervention group was 20% lower 
than that of the control group over a period of 12 months. Furthermore, a recent 
systematic review on the economic evaluation of pay for performance schemes 
found only nine studies, all from the United States except one, with mixed 
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results. The authors concluded that the evidence is “scarce and inconclusive” 
(212).  
A recent report by the Health Foundation assessed whether better management 
in primary care reduces hospital cost.  None of the QOF clinical areas were 
statistically associated with hospital cost except Stroke. One-point increase in 
stroke QOF rate was associated with a decrease of £0.44 per person (213). 
 
2.7 Potential unintended consequences of pay for performance !
Several authors have raised concerns about the perverse consequences of 
using financial incentives to improve quality. For example, Salisbury et al., found 
that the incentive introduced by the UK government to reduce waiting times to 
see general practitioners made it difficult for people to book appointments in 
advance (214). Financial incentives could lead the provider to be concerned with 
those clinical measures that are incentivised only. Evidence from the QOF 
reveals that care for non-incentivized indicators for conditions in the QOF 
improved at a lower rate (11%; 95% CI: 6#15%) compared to incentivized 
indicators (16%; 95% CI: 10#22%) (215). Pay for performance might affect the 
internal motivation of providers and crowd-out some of the caring aspects of 
consultation. However, analysis from two general practices in England suggest 
that QOF did not have any effect on internal motivation but some concerns were 
raised by the nurses (216). Analysis from 12 practices in east of England found 
that some doctors and nurses raised their concern with loss of holistic care and 
continuity of care (217). 
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Structured, systematic interventions to improve quality in chronic disease 
management, such as the use of financial incentives, can lead to reductions in 
inequalities if they improve the monitoring of risk factors which might benefit 
minorities the most (218). However, it may also have a potential negative 
consequence on its impact on inequalities. Concerns that pay for performance 
might erode equity in the provision of health care have been raised in the United 
States. For example, Casliano et al., noted that providers serving minorities may 
receive less income, pay for performance schemes might provoke providers to 
introduce interventions to improve quality and minority patient may not benefit 
from them, such as using patient leaflet in a specific language and providers 
may engage in “cherry picking” to avoid costly patients (219). For example, in 
the United States, based on 9 Heath Plan Employer and Data Information Data 
Set found that patients who received care from providers in the top performance 
tertile had fewer minority patients, and non-English speaking patients, when 
compared to patients of providers in the bottom performance tertile (220). One 
example of “cherry picking” is illustrated in the Taiwanese experiment of pay for 
performance to improve diabetes care. Providers in this scheme are allowed to 
choose which patient to be included in the scheme. Not surprisingly, patients 
with comorbidity and older patients were more likely to be excluded from the 
scheme (221). Another example, is the adverse selection of most severe 
substance abuse patients in the United States between 1991 and 1995 (222). 
Similar concerns have been raised with the introduction of QOF (160, 223). For 
instance, a number of studies suggest that QOF may not address inequalities in 
diabetes management previously evident between age, gender and ethnic 
! &%!
groups (135, 224). However, the government and the BMA have stated that the 
scheme is likely to reduce inequalities in health care (225, 226). Others have 
stated that “QOF is a truly equitable public health intervention” (227). 
Furthermore, indicators used in pay for performance schemes are designed 
using evidence from clinical trials (228). These trials may exclude older patients 
and patients with comorbidities. Hence, they tend to focus on patients with only 
a single condition (44). 
 
2.8 Contribution to the literature !
In recent years, financial incentives have gained momentum and were seen as a 
way to change providers’ behaviour towards the delivery of better care (as 
discussed in the start of this section). The impact of pay for performance on 
diabetes care and on care delivered to ethnic minorities is still unclear and how 
such impact is disseminated to minorities. In addition, the important primary 
care role in reducing inequalities has been reaffirmed by the WHO and the 
recent Marmot review (229, 230). Furthermore, the WHO has recently 
recommended that all government policies and programmes be assessed for 
their impact on health and health equity (231). Despite this recommendation, 
research into the impact of pay for performance programmes on health care 
inequalities is limited. For example, a recent systematic review did not identify 
any study evaluating the impact of pay for performance on inequalities in health 
care (232). However, the review was confined to United States studies that 
examined impacts on ethnic and racial inequalities only. Assessing the impact of 
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pay for performance on other known inequalities in health care, including those 
related to age, sex and socioeconomic status is important. 
My work contributes to the literature in three ways. First, synthesis of the 
available evidence on the impact of pay for performance on health care 
inequalities is lacking. Second, studies that assessed the impact of QOF on 
ethnic inequalities in diabetes management have mainly used a pre-post design 
(200, 233), which meant underlying trends in improvement where not adjusted 
for. Further, one study that adjusted for underlying trend (234), used one 
measurement point after QOF had been implemented and examined only 
HbA1c and blood pressure only, in addition the authors did not adjust for other 
patients’ covariates such as, the number of comorbidities and duration of 
diabetes. I extend on this work by conducting a longitudinal analysis by using 
multiple measurement points before and after QOF introduction. This should 
allow me to examine the “inverse equity hypothesis” (88), which is based on 
findings from child health inequities studies in Brazil and remains largely 
untested in populations with chronic illnesses in developed countries. The 
authors explored this by examining trends for inequality ratio for morbidity and 
mortality within Brazil. Examining whether universal quality improvement 
programs, such as the QOF, address inequalities in health care over time has 
important implications for policy makers and health planners. This is because it 
will inform decisions about whether additional resources are required for 
targeted interventions to improve care in vulnerable populations.!While the QOF 
was not explicitly designed to narrow inequalities, associated systematic 
improvement and standardization in the quality of care maybe expected to lead 
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to reductions in inequalities (235), and the UK department of health has stated 
that the QOF is likely to reduce inequalities (226). Third, ethnic minorities with 
diabetes are more likely to have comorbid conditions and clinical guidelines are 
geared to the management of single medical condition (236, 237). Previous 
studies suggest that patients with multiple conditions may receive similar or 
higher quality of care than those with a single condition and may have benefited 
more from quality improvement strategies (238). The impact of QOF on diabetes 
management among patients with diabetes from different ethnic groups with 
and without comorbid medical conditions is limited. For example, Previous 
research has found white-black group disparities in blood pressure control were 
greater among hypertensive patients with multiple cardiovascular conditions 
(239). 
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3.0 Aims and Objectives !
Research question: 
What is the impact of the quality and outcomes framework on ethnic 
inequalities in diabetes management? 
Aim: 
To assess the impact of QOF on ethnic inequalities in delivered quality of 
diabetes care. 
 
Objectives: 
1. To carry out a systematic review on the impact of pay for performance on 
inequalities in health care quality. 
2. To examine longer-term impact of the quality and outcome framework on 
ethnic inequalities in diabetes management. 
3. To examine the impact of the quality and outcome framework on ethnic 
inequalities in patients with and without comorbidities in diabetes 
management. !
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4.0 Impact of pay for performance on inequalities in health 
care: a systematic review !
The evidence on the use of explicit financial incentives to improve quality, albeit 
mixed, prompted wide implementations of pay for performance schemes. 
Despite this, there remains limited evaluation of their impact, particularly in 
relation to possible unintended consequences, such as their impact on 
inequalities. Reducing health inequalities, is a key policy objective in many 
countries (240, 241), which requires a multifaceted approach including achieving 
greater equity in health care delivery (230). In this chapter I aim to undertake a 
systematic review of published articles that assessed the impact of pay for 
performance programmes on the quality of health care in relation to age, sex, 
ethnicity and socioeconomic status (SES). 
4.1 Methods 
4.1.1 Search strategy !
Papers published between 1 January 1980 and 1 November 2008, were 
identified through a systematic search of published English language literature in 
MEDLINE, EMBASE, PsycINFO and the Cochrane Library. The search was 
periodically updated to include the most recent publications with the last update 
ended on February 2011. I examined papers that assessed quantitatively the 
impact of pay for performance on health care inequalities. In MEDLINE, my 
search included Medical Subject Heading (MeSH) terms and text words. MeSH 
terms used were: physician incentive plans; reimbursement, incentive; 
reimbursement mechanisms; insurance, health, reimbursement; quality 
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indicators, health care; ethnic groups; minority groups; minority health; 
healthcare disparities; health care inequalities, health status disparities; and 
socioeconomic factors. Text words used were: pay for performance and P4P. In 
EMBASE I used the following EMTREE heading terms: reimbursement, health 
care quality, prospective payment, performance measurement system, minority 
group, ethnic group, ethnic difference, race difference, and social status. Text 
word included pay for performance, P4P, pay for quality, physician incentive and 
deprivation. In PsycINFO terms used includes: incentive, monetary incentive, 
quality of care, racial and ethnic groups, minority groups, racial and ethnic 
differences, social deprivation, social justice, socioeconomic status, and health 
disparities. The following text words were also used: pay for performance, 
physician incentive, incentive payment, and performance measurement. Where 
the title or abstract of the paper were not clear, the full text of the article was 
retrieved and reviewed. In addition, the grey literature was consulted. 
4.1.2 Study selection !
Pay for performance incentives were defined as the use of monetary incentives 
to reward health care providers’ achievements in predetermined quality 
standards. Quantitative studies were included if they examined the relationship 
between the use of an explicit financial incentive and healthcare inequalities. 
Dimensions of health care inequality examined included: age, sex, ethnicity, and 
SES status. I included both experimental and observational studies. I excluded 
papers that examined the use of non-monetary rewards, such as public report 
cards. Along with a colleague we independently used the Downs and Black 
critical appraisal tool to assess the methodological quality of the retrieved 
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studies (242). I used a similar approach used by Peterson et al. (167) to assign 
studies into a quality scale from 1 to 4. Studies considered to be of poor 
methodological quality were scored as ‘1+’ and studies considered to be of 
excellent methodological quality were scored as ‘4+’. Whenever there was 
conflict in the score of the retrieved articles, a third scorer was consulted. 
4.2 Results !
Our search yielded 4396 articles (Figure 2). Based on the title of the articles, I 
identified 85 papers for further review; out of which, 23 relevant articles were 
identified. One additional article was retrieved through the reference list search 
of the retrieved articles. A summary of the retrieved studies is in Appendix 2. 
Most of the studies retrieved were observational studies conducted in the UK 
assessing the impact of the introduction of the QOF in April 2004. Some studies 
examined more than one aspect of inequality. 
 
4396 Articles identified from search 
85 articles for full review  
Excluded by title or 
abstract: 
4311 Articles 
One from 
reference list 
24 articles met inclusion 
criteria 
64 Studies excluded on full review 
Financial incentives not examined: 37 
 
Inequalities not examined: 22 
 
Review articles: 5 
 
 
 
 
 
Figure 2 Flow chart of study selection 
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4.2.1 Socioeconomic inequality !
SES was the most frequently examined variable (199, 200, 205, 243-259). Most 
studies used a cross-sectional design and examined associations between 
quality of care and an area deprivation score after the implementation of the 
QOF. Only one study, which was conducted in a largely rural and relatively 
deprived part of Scotland, found that deprivation was positively associated with 
higher quality in the first year of the QOF (254). The remaining studies identified 
significantly lower quality of care in deprived areas compared with affluent areas. 
However, the magnitudes of the differences were generally small and appear to 
have been attenuated in the second and third year of this pay for performance 
programme. For example, Ashworth et al. (243) found a difference in the 
achievements between least and most deprived practices of 64.5 QOF points (a 
difference of 6.1%) in the first year of the QOF, but this figure decreased to 30.4 
QOF points (a difference of 2.9%) in the second year. Doran and colleagues 
(249), undertook a similar analysis and found a further narrowing of quality 
during the third year of QOF. Median achievement increased by 4.4% in the 
least deprived quintile of practices and by 7.6% in the most deprived quintile of 
practices. Consequently, the gap in median achievement narrowed from 4.0% 
to 0.8% during this period and was no longer associated with deprivation 
(P=0.062). Furthermore, the authors found a significant association between 
scores in the previous year and increases in achievement. The lower the score in 
the previous year, the better were the achievements in the following year 
(p<0.01). 
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In a methodologically similar paper (244), data were collected from over 97% of 
practices in England to examine the values of blood pressure monitoring and 
control in five chronic diseases in relation to deprivation over a period of three 
years after QOF introduction. Differences between affluent and deprived areas 
seen in the first year after the QOF had almost disappeared by the third year. For 
example, 79.2% of diabetes patients attending practices in affluent areas 
achieved the desired blood pressure targets compared to 78.6% of diabetes 
patients attending practices in deprived areas. By the third year deprivation had 
a weak positive effect on blood pressure monitoring (P<0.001). 
A study by Ashworth et al. (246), found higher levels of statin prescribing in 
deprived areas when compared to affluent areas in the first year of the QOF after 
adjusting for differences in cardiovascular disease prevalence. Saxena et al. 
(251), examined associations between deprivation and quality of care for 
coronary heart disease, hypertension and stroke in the first year of this pay for 
performance programme. Achievements were very similar in practices working 
in deprived and affluent areas. However, affluent practices achieved better 
scores for some indicators associated with initial diagnosis and management, 
such as referral for exercise testing (p<0.001). Using a comparable study 
design, Millett et al. (205), found broadly similar achievement of quality indicators 
for diabetes in practices working in deprived and affluent areas. Sigfrid and 
colleagues (252), examined associations between deprivation and ‘exception 
reporting’ for 15 diabetes indicators in the QOF, whereby patients can be 
excluded from the data used to calculate the achievement of a target. They 
found that practices working in deprived areas were more likely to report 
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‘exceptions’ for process of care indicators (p<0.05), although the relationship 
appeared to be reversed for intermediate clinical outcome indicators, which 
raised the concern that reported achievements in the QOF could mask wider 
inequalities. 
Three studies evaluated the impact of this pay for performance programme 
using a before and after study design. McGovern et al. (256), found that patients 
with coronary heart disease living in deprived areas were less likely than patients 
living in affluent areas to have their smoking status recorded (Pre-QOF: Adjusted 
Odds Ratio [AOR] 1.04; 95% CI: 0.86#1.26, Post-QOF: AOR 0.78; 95% CI: 
0.62 – 0.99), blood pressure recorded (Pre-QOF: AOR 0.95; 95% CI: 
0.74#1.20, Post-QOF: AOR 0.59; 95% CI: 0.45#0.78), or have beta blocker 
therapy (Pre-QOF: AOR 0.87; 95% CI: 0.77#0.97, Post-QOF: AOR 0.84; 95% 
CI: 0.76#0.92) after the implementation of the QOF. These differences were not 
evident before the introduction of the QOF. However, deprived Coronary Heart 
Disease (CHD) patients were more likely than affluent CHD patients to have 
antiplatelet or anticoagulant therapy (Pre-QOF: AOR 1.11; 95% CI: 0.95#1.28, 
Post-QOF: AOR 1.14; 95% CI: 1.00#1.22). Using a similar study design, 
Simpson and colleagues (257), found significant difference between stroke 
patients living in most and least deprived areas after QOF introduction. Stroke 
patients in the highest deprivation group were less likely to have a recording of 
blood pressure (Pre-QOF: AOR 0.98; 95% CI: 0.88#1.09, Post-QOF: AOR 0.66; 
95% CI: 0.54#0.80) and a record of smoking status (Pre-QOF: AOR 1.16; 95% 
CI: 1.05#1.29, Post-QOF: AOR 0.81; 95% CI: 0.71#0.94) after the 
implementation of the QOF. Millett et al (200), found no significant variation in 
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ascertainment of smoking status and provision of smoking cessation advice in 
patients with diabetes living in deprived and affluent areas before and after the 
introduction of QOF. Using data from the GPRD Hamilton et al. (259), found no 
differences between patients living in affluent and deprived areas in the 
achievement of intermediate outcomes.  
4.2.2 Age and sex inequalities !
Four studies explored the impact of the QOF on age and sex inequalities. In 
Scotland, a serial cross sectional study found large improvements in quality 
indicators for stroke patients. However, inequalities present before the 
introduction of QOF did not narrow. For instance, stroke patients aged more 
than 75 years were less likely than young stroke patients to have their smoking 
status recorded (AOR: 0.69; 95%CI: 0.62#0.76), have a smoking advice given 
(Pre-QOF: AOR 0.92; 95% CI: 0.76#1.12, Post-QOF: AOR 0.75; 95% CI: 0.60 
#0.93) and have their cholesterol level recorded (Pre-QOF: AOR 0.35; 95% CI: 
0.32#0.38, Post-QOF: AOR 0.71; 95% CI: 0.66#0.77). Older stroke patients 
were more likely to receive antiplatelet or anticoagulant therapy after the QOF 
introduction (Pre-QOF: AOR 0.68; 95% CI: 0.64#0.74, Post-QOF: AOR 1.75; 
95% CI: 1.60#1.91). Women who had a stroke were less likely than men to be 
current smokers (Pre-QOF: AOR 0.92; 95% CI: 0.76#0.98, Post-QOF: AOR 
0.87; 95% CI: 0.81–0.95), or receive antiplatelet or anticoagulant therapy (Pre-
QOF: AOR 0.95; 95% CI: 0.89#1.00, Post-QOF: AOR 0.93; 95% CI: 
0.86#0.99). Further, women with stroke were less likely to have a controlled 
blood pressure (Pre-QOF: AOR 0.90; 95% CI: 0.84#0.98, Post-QOF: AOR 0.86; 
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95% CI: 0.81#0.91) or controlled cholesterol levels (Pre-QOF: AOR 0.59; 95% 
CI: 0.51#0.68, Post-QOF: AOR 0.56; 95% CI: 0.52–0.60) after QOF compared 
to men (257). In a similar study, pay for performance did not improve the age 
and sex inequalities for CHD patients seen before introduction of the QOF. For 
example, women were less likely than men to have a recording of blood 
pressure (Pre-QOF: AOR 0.92; 95% CI: 0.87–0.97, Post-QOF: AOR 0.89; 95% 
CI: 0.82–0.97) or having their blood pressure controlled (Pre-QOF: AOR 0.84; 
95% CI: 0.79#0.89, Post-QOF: AOR 0.84; 95% CI: 0.80#0.87), or have a 
recording of beta blocker therapy (Pre-QOF: AOR 0.85; 95% CI: 0.81 #0.88, 
Post-QOF: AOR 0.81; 95% CI: 0.79#0.84). Older patients were less likely than 
younger patients to have a recording of beta-blocker therapy (Pre-QOF: AOR 
0.39; 95% CI: 0.36#0.42, Post-QOF: AOR 0.53; 95% CI: 0.51#0.56) (256). 
Using a serial cross sectional study, Millett et al. found that the introduction of 
QOF was associated with an attenuation of differences in ascertainment of 
smoking status and provision of cessation advice in people with diabetes from 
different age groups. For instance, patients aged 75 years had an AOR of 0.92 
(95% CI: 0.26#3.31). Ascertainment of smoking status remained significantly 
higher in women with diabetes than in men (AOR: 2.01; 95% CI: 1.59–2.54) 
after introduction of the QOF, however reduction in smoking prevalence was 
lower in women than men (AOR: 0.71; 95% CI: 0.53#0.95) (200). Using data 
from GPRD, differences in diabetes care seen between men and women before 
the QOF narrowed after QOF introduction. Further, older patients (>45 years) 
appear to have benefited more than younger patients after QOF have been 
introduced (259).  
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4.2.3 Ethnic inequalities !
In an analysis undertaken during the first year of pay for performance, Ashworth 
et al. found lower statin prescribing in areas with high proportions of residents 
with African-Caribbean or South Asian ethnicity (246). A cross-sectional survey 
of 32 general practices in London, identified significant ethnic group inequalities 
in diabetes management, with black and South Asian patients less likely to 
achieve all three intermediate clinical outcome targets when compared to the 
white group (258). Using a serial cross sectional design, Millett et al. (233), 
examined inequalities in prescribing and intermediate outcomes for diabetes 
management before and after the introduction of the QOF. The study found that 
percentage achievement of treatment targets for blood pressure, HbA1c and 
total cholesterol increased in all ethnic groups after the implementation of pay for 
performance. However, the magnitude of the improvement in HbA1c control 
(AOR: 0.75; 95% CI: 0.57–0.97) and blood pressure control (AOR: 0.65; 95% 
CI: 0.53 – 0.81) was lower in the black Caribbean group than the White British 
group which meant that inequalities in HbA1c and blood pressure control 
persisted. Variations in prescribing were also documented in the study, with 
lower prescribing of insulin in the Black African group (AOR: 0.69; 95% CI: 
0.51#0.93), Indian group (AOR: 0.51; 95% CI: 0.38–0.70), Pakistani group 
(AOR: 0.56; 95% CI: 0.40–0.78) and Bangladeshi group (AOR: 0.49; 95% CI: 
0.25–0.98) relative to the white British group, differences which persisted after 
introduction of the QOF. Furthermore, prescribing of oral hypoglycaemic agents 
increased significantly after QOF introduction, however these changes were 
largely seen in the black African and South Asian groups rather than the white 
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British (P<0.001). A more recent longitudinal study assessed the impact of QOF 
on mean blood pressure and HbA1c values among white, black and South 
Asian patients with diabetes living in South-West London. The introduction of 
QOF was associated with reduction in mean values for systolic and diastolic 
blood pressures and HbA1c; these reductions were significantly greater than the 
predicted values using the underlying trends in all ethnic groups. However, the 
magnitude of improvement varied between ethnic groups. For example, 
reduction in mean HbA1c was significantly greater than the predicted trend in 
the white group (-0.5%, P<0.05) but similar significant reductions were not seen 
in the black (-0.3%) or the south Asians (-0.4%) groups (234). 
In another study Millett et al., found no variations between different ethnic 
groups in the recording of smoking status and smoking cessation advice (200). 
In a study evaluating QOF, (260) achievements of incentivised quality indicators 
were evaluated before and after the QOF introduction. Overall attainment of 
CHD management and intermediate clinical outcome improved significantly after 
the QOF introduction and were similar across ethnic groups. 
4.2.4 Longer term impact of pay for performance on inequalities !
I identified an additional UK study which examined the impact of a more limited 
pay for performance scheme introduced as part of the 1990 General Practitioner 
contract (247). This scheme provided financial incentives for reaching fixed 
targets for cervical cancer screening coverage. The study findings suggest that 
while these incentives were initially associated with widening of inequalities in 
cervical screening coverage between deprived and affluent areas, these were 
largely attenuated at five years follow up. The inequality ratio (equality 
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represented as a ratio of 1) in 1991 was 0.46 however it increased towards 
equality when the affluent areas maintained maximum levels and by 1999 the 
inequality ratio was 0.77. 
4.2.5 Pay for performance impact on inequalities in the United States !
Karve et al. (261), used data from 3449 hospitals to examine the impact of pay 
for performance on process measures for acute myocardial infarction, 
community acquired pneumonia and heart failure. The study shows that 
hospitals with more than 20% of African American patients were less likely to 
improve on the scores for acute myocardial infarction and pneumonia compared 
to hospitals that served a lower proportion of non-minority patients. In contrast, 
Jha et al. (262), found that hospitals with more poor patients had greater 
improvements in performance for acute myocardial infarction and pneumonia 
when compared to hospitals that did not participate in the Medicare 
demonstration project. However, these improvements were not evident for 
congestive heart failure. 
4.3 Comment !
The introduction of QOF was associated with reductions in inequalities in 
chronic disease management between affluent and deprived areas. However, it 
is unclear if these reductions are attributable to QOF or part of underlying trend 
that pre-dates QOF such as the NSFs. Other Important inequalities in quality of 
care between age, sex and ethnic groups present before the introduction of this 
programme appear to have persisted. Specifically women, older patients and 
those from some minority ethnic groups continued to receive lower quality of 
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care after the introduction of QOF. The studies included in this review have a 
number of important limitations. This partly reflects the way that pay for 
performance programmes have been introduced into health care systems, 
generally precluding evaluation using an experimental design or a non-
intervention comparison group. The data for most studies included in this review 
was derived from the financial administration system for QOF, the QMAS, and its 
usefulness for evaluating impacts on inequalities in health care is limited for a 
number of reasons. Firstly, the system does not hold patient level information on 
characteristics such as age, sex, ethnicity and SES. Hence, most of the QOF 
evaluations reported here used practice level data and may underestimate the 
relationship between deprivation and quality of care. This has been further 
compounded by poor recording of patient based measures of ethnicity and of 
SES within primary care information systems in the UK. Secondly, the ability of 
practices to exclude patients from performance reporting for the contract means 
that this data may underestimate the extent of inequalities in care. Finally, 
studies that use data from the system are unable to examine underlying trends 
in quality, making it difficult to attribute reductions in socioeconomic inequalities 
to QOF. This is an important limitation given that the UK government has 
instituted a policy agenda to reduce health inequalities since the late 1990s (240) 
and the important role primary care plays in achieving such objectives (229). 
Most of the studies identified in this review examined the impact of the QOF on 
health care inequalities. Conclusions drawn from these studies may not be 
applicable to other settings, particularly to low and middle-income countries, or 
to market-based health care systems in countries without universal access to 
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healthcare, such as the United States. Pay for performance programmes vary 
considerably within the United States, in terms of the type of incentives being 
offered (bonuses, penalties), the type of achievement being rewarded 
(percentage achievement or improvement), the recipient of incentives (provider 
organizations or individual physicians) and their overall financial cost, and as 
such may have differential impacts on health care inequalities (144). In contrast, 
the UK system is much more standardised and is applied uniformly across the 
country. This may change if purchasers are given more local flexibility in the 
implementation of pay for performance schemes. The lack of studies undertaken 
in the United States may be due to a number of factors, including lack of funding 
from payers to evaluate pay for performance programmes and the low adoption 
of electronic medical records (263, 264). This also likely reflects the fact that the 
impact of pay for performance programmes on health care inequalities is a 
relatively new area of research enquiry.  
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5.0 Pay for performance and ethnic disparities: an interrupted 
time series analysis 
 
5.1 Methods !
5.1.1 Study setting !
The study was conducted in Wandsworth in South West London (Figure 3), 
where the population is younger than that of England as a whole, with 74% 
aged less than 45 years (compared with a national average of 60%); and with a 
high proportion of residents from ethnic minorities groups. According to the 
2001 census, the proportion of Wandsworth population who refer to 
themselves, as white is 65% and 22% consider themselves as non-white. The 
proportion of residents who describe themselves as black Caribbean, black 
African, Indian, Pakistani, Bangladeshi, and Chinese was 4.9%, 3.9%, 2.9%, 
2.1%, 0.4% and 2.2% in 2001, respectively. Wandsworth has a relatively high 
level of deprivation. According to the 2000 Index of Multiple Deprivation 
Wandsworth is ranked at 148 of all local authorities and in 2007 it was ranked 
128 (rank is out of 357 local authorities in England, the higher the rank the more 
deprived the area). 
 
The CONDUIT quality improvement programme: 
The Wandsworth Primary Care Trust initiated a programme to establish a 
comprehensive disease register in September 2000. The Cutting Out Needless 
Deaths Using Information Technology (CONDUIT) programme was initially 
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piloted in Battersea, Wandsworth South and Putney localities in 63 practices 
covering a registered population of 382,188 and targeted individuals with  
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Figure 3 London Boroughs 
Source: www.ons.gov.uk 
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hypertension and ischemic heart disease.  In 2003, due to changes in the 
practices computers, the practices in Putney locality were dropped from 
CONDUIT 2 and from subsequent CONDUIT collections. CONDUIT 2 involved 
34 practices and included patients with hypertension, ischemic heart disease 
and diabetes. CONDUIT 3 involved 32 practices in 2005 and included patients 
with hypertension, ischemic heart disease, diabetes and asthma.  
The output from this programme resulted in a standardised method of 
identifying patients with cardiovascular disease and diabetes, and facilitated the 
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establishment of accurate chronic disease registers. In addition, the findings of 
the CONDUIT programme have been published in leading international journals. 
My work builds on the early CONDUIT efforts and involved analysis of data from 
practices that participated in this programme. Practices that participated in the 
study serve a more ethnically diverse and deprived population than Putney. 
 
The study area covered 32 practices. Of these 29 practices agreed to take part 
in this study. The practices had a median list size of 7,451 patients. Ten 
practices had more than 10,000 patients; ten practices had between 5,000 and 
9,000 patients and nine practices had less than 4,000 patients.  
 
Identification of diabetes cases: 
The method used to identify patients in Wandsworth was piloted in 2002 (265). 
The study concluded it is essential to search beyond diagnostic Read codes, 
such as C10, and include diabetes management codes from computerised 
medical records. The inclusion criteria used in my study are: 
• Diagnostic Read code for diabetes (C10 or sub-codes). 
• Diabetes management Read code (66A). 
• Patient age is more or equal to 18 years. 
Data was collected on all patients, identified in December 2007, retrospectively 
for the years 2000#2007 from computerised patient records at each of the 29 
participating practices by staff of the Wandsworth primary care trust research 
centre. The data subsequently was stored in a secure location at the research 
centre. I was not able to link patient registered in 2007 to previous CONDUIT 
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because the ethics committee did not approve the extraction of a unique patient 
identifier.  
 
5.1.2 Study variables !
The process and outcome indicators collected were according to the indicators 
used in the QOF (Box 4). The main outcome variables were HbA1c, total 
cholesterol, and blood pressure levels based on patients’ last recorded 
measurement in each year. Further, I constructed three outcome variables 
corresponding to the control targets used in QOF: HbA1c"7.5%, 
cholesterol"5.0 mmol/l, and blood pressure "145/85 mm Hg. 
 
Process indicators included were recording of HbA1c, cholesterol, and blood 
pressure, visual examination of feet, retinal screening, recording of peripheral 
pulses or ability to feel vibration, recording of serum creatinine, recording of BMI, 
and recording of micro-albuminuria. 
 
 
Box 4 List of indicators used in QOF 
• The percentage of patients with diabetes whose notes record BMI the 
previous 15 months. 
• The percentage of patients with diabetes whose notes record of 
HbA1c or equivalent in the previous 15 months. 
• The percentage of patients with diabetes whose notes record of retinal 
screening in the previous 15 months. 
• The percentage of patients with diabetes whose notes record of the 
presence or absence of peripheral pulses in the previous 15 months. 
• The percentage of patients with diabetes whose notes record of 
neuropathy testing in the previous 15 months. 
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• The percentage of patients with diabetes whose notes record of blood 
pressure in the previous 15 months. 
• The percentage of patients with diabetes in whom the last blood 
pressure is 145/85 or less. 
• The percentage of patients with diabetes who have a record of micro-
albuminuria testing in the previous 15 months. 
• The percentage of patients with diabetes who have a record of 
estimated glomerular filtration rate (eGFR) or serum creatinine testing 
in the previous 15 months. 
• The percentage of patients with diabetes who have a record of total 
cholesterol in the previous 15 months. 
• The percentage of patients with diabetes whose last measured total 
cholesterol within previous 15 months is 5.0 mmol/l or less. 
• The percentage of patients with diabetes whose last measured HbA1c 
within previous 15 months is 7.5 mmol/l or less. 
• The percentage of patients with diabetes whose notes record smoking 
status in the previous 15 months. 
• The percentage of patients with diabetes whose notes contain a 
record that smoking cessation advice has been offered within the 
previous 15 months. 
 
My main predictor variable was ethnicity. In the UK, ethnicity recording has 
historically been low. In October 2000, the UK government required the 
recording of ethnic group in patient records (mainly in NHS trusts) in similar 
fashion to the ethnic categories used in the 2001 census (266). Recently, two 
main incentives were introduced to improve ethnicity coding nationally: the QOF 
and the Directly Enhanced Services. Despite this, ethnicity coding in primary 
care remains low in general practice for meaningful use in health services 
research and epidemiological research (267). For example, practices 
participating in the national diabetes audit in 2004-05 had only 17% of their 
registered patients with ethnicity coding and slightly improved in the following 
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year to 36% (268). Similarly, in 2006/7 the level of ethnicity coding in 530 
practices contributing to the QRESEARCH database was 10.2% (269). 
The Wandsworth Primary Care Trust implemented a financial scheme in 2002 to 
improve the level of ethnicity coding for patients with chronic conditions through 
the use of templates with limited list of ethnicity codes. Information on ethnic 
background is collected from the patient during consultation or upon registration 
and is entered in the patients’ electronic record using the 2001 census 
classification. Due to the small numbers in some of the ethnic groups, I had to 
group them into one. For example, I combined Indian, Pakistanis and 
Bangladeshis into one south Asian group (See appendix 3 for breakdown of the 
main ethnicity groups and cross sectional analysis). Additional patient level 
information collected includes age, sex, BMI, and SES. I used practice postcode 
to assign a SES score to each patient using the index of multiple deprivation as I 
could not use patient post code (270) because the ethnical committee did not 
agree for this information to be extracted. The index is used to measure area 
level SES in the UK and is composed of several dimensions including income, 
employment, health and disability, education skills and training, barriers to 
housing and services, living environment, and crime. 
To adjust for the severity of diabetes, I further collected information on the 
duration of diabetes and the number of comorbid medical conditions, Duration 
of diabetes was calculated in years using the date of diagnosis entered in the 
electronic medical record. Comorbid conditions included hypertension, stroke, 
atrial fibrillation, heart failure, coronary heart disease (CHD), asthma, chronic 
obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and 
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depression. I chose these as they are most commonly observed and commonly 
managed in primary care.  
Further, I collected data on whether a patient was prescribed any oral 
hypoglycemic agent (Sulfonylurease, Metformin, Glitazone), Insulin, any 
antihypertensive medication (Angiotension-converting enzyme, Beta blocker, 
Calcium channel blocker, Diuretics), and any lipid lowering medication. 
 
5.1.3 Analysis !
Interrupted time series analysis: 
I estimated unadjusted annual mean values and 95% confidence interval for 
HbA1c, cholesterol, and systolic and diastolic blood pressure for each ethnic 
group and for all the population. These variables were approximately normally 
distributed. For binary outcomes, I present annual percentage achievement with 
95% confidence interval for each ethnic group and for all the population. 
The QOF was implemented nationally, meaning using a gold standard method, 
similar to a control trial, is not an option. Further, limiting my analysis to a pre-
post study design may over-estimate the impact of QOF as quality of care was 
improving before the introduction of QOF. To estimate changes in risk factor 
control associated with QOF while controlling for secular trend, I fitted a 
segmented regression model of the time series for all the population and 
individually in the three ethnic groups for each of the outcome variables (271, 
272). In addition, to accommodate the multilevel nature of the data (multiple 
measurements per patients, and patients clustered within practices), I treated 
patients and practices as random effects in a multilevel model to adjust for the 
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correlation in error term within both individual level and practice level. Ignoring 
such data structure might lead to biased estimate (i.e standard error of model 
coefficients might be underestimated leading to narrower confidence interval) 
(273). The model estimates three main parameters: 
yijt= !0ijt + !1x timeijt + !2x policyijt + !3x years after policyijt + !4 Xijt + Vt + 
Ujt + eijt 
 
 !1 estimates the change in the outcome associated with each year before QOF 
was introduced in April 2004 where time is a continuous variable ranging from 1 
to 8 to represent time in years, !2 estimates the immediate change associated 
with QOF where policy is coded as zero before the intervention and coded as 1 
for the years after the intervention, and !3 estimates the change in the outcome 
associated with each year after QOF had been introduced where years after 
policy is a continuous variable representing the number of years after the 
intervention and coded as zero for the years before the intervention. !4 are 
estimates of covariates adjusted for in the model, these include age, gender, 
duration of diabetes, number of co-morbid medical conditions, and SES. Vt  and 
Ujt are the variances of the intercept for practice level and patient level and eijt is 
the residual error.  For the continuous variables (HbA1c, cholesterol, and systolic 
and diastolic blood pressure) I use a linear regression model (using the xtmixed 
syntax) and present change in mean values with 95% confidence interval. For 
the binary outcome, I used a logistic regression (using the xtmelogit syntax) and 
present the change in odds ratios with 95% confidence interval.  
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For the key indicators (HbA1c, cholesterol, systolic, and diastolic blood 
pressure) I present the models unadjusted in Appendix 5. 
 
As part of my sensitivity analysis I ran the models on patients with complete 
records over the study period to investigate whether change in the case mix in 
the post-QOF years had an effect on my original estimates. Further, I tested for 
attrition bias using Heckman selection model (274). Details of the sensitivity 
analysis are in Appendix 4. 
Further, I estimated the overall trend for each indicator using a simpler linear 
model ( y = $0 + $1 x time), where y is the percentage of patients achievement in 
a given indicator in each year; time is a chronological index of the eight year 
extracted ranging from 1 (2000) to 8 (2007). 
Cross sectional analysis: 
For each binary indicator, e.g. HbA1c measured, I used a logistic regression 
with ethnicity as a dummy variable and the White group as the reference group 
to examine if inequalities present at the start of study were addressed at the end 
of the study period. I fitted the model for each indicator separately for the year 
2000 and for the year 2007. All analyses were adjusted for age, gender, duration 
of diabetes, number of comorbidities, SES, and practice level clustering.  
 
I performed all analysis using the statistical software Stata version 10. 
 
Ethical approval: 
The study was approved by the Wandsworth Local Research Ethics Committee. 
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5.2 Results !
I identified 7,542 patients with diabetes registered with practices in 2007. I 
excluded 108 with implausible or missing values. The mean age of patients was 
59.1 years and 49.6% were female. Overall, 90.0% of patients had their ethnicity 
coded. White patients comprised 42.7% of the sample, 24.3% were Black, and 
22.2% were South Asian (Table 8).  
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Table 8 Sample characteristics 
 2000  2001  2002  2003  2004  2005  2006  2007  
  Numbers % Numbers % Numbers % Numbers % Numbers % Numbers % Numbers % Numbers % 
Male 1,448 52.6 1,760 52.6 2,047 52.4 2,300 51.7 2,623 51.5 2,947 51.3 3,284 50.8 3,749 50.4 Gender 
  Female 1,303 47.4 1,589 47.4 1,861 47.6 2,147 48.3 2,465 48.5 2,802 48.7 3,183 49.2 3,685 49.6 
18-44 507 18.4 591 17.6 668 17.1 763 17.2 843 16.7 966 16.8 1,126 17.4 1,329 17.9 
45-54 510 18.5 605 18.1 688 17.6 741 16.7 845 16.6 928 16.1 1,025 15.8 1,151 15.5 
55-64 832 30.2 976 29.1 1,094 28.0 1,172 26.4 1,303 25.6 1,410 24.5 1,514 23.4 1,645 22.1 
65-74 665 24.2 846 25.3 997 25.5 1,207 27.1 1,355 26.6 1,525 26.5 1,691 26.1 1,945 26.2 
Age group 
>=75 237 8.6 331 9.9 461 11.8 564 12.7 742 14.6 920 16.0 1,111 17.2 1,364 18.3 
White 1,104 40.1 1,354 44.5 1,614 45.5 1,847 45.7 2,139 42.0 2,410 46.5 2,751 47.1 3,181 42.7 
Black 682 24.8 836 27.5 963 27.1 1,103 27.3 1,255 24.7 1,416 27.3 1,584 27.1 1,811 24.3 
South 
Asian 697 25.3 832 27.4 948 26.7 1,066 26.3 1,198 23.6 1,321 25.5 1,465 25.1 1,653 22.2 
Other 12 0.4 17 0.6 19 0.5 26 0.6 35 0.69 32 0.6 35 0.6 45 0.6 
Ethnicity 
 
Missing 256 9.3 310 9.2 364 9.3 405 9.1 461 9.06 570 9.9 632 9.7 739 9.9 
0 691 25.1 863 25.8 1,038 26.6 1,202 27.0 1,434 28.2 1,679 29.2 1,952 30.2 2,368 31.8 
1 985 35.8 1,229 36.7 1,437 36.8 1,649 37.1 1,886 37.1 2,146 37.3 2,399 37.1 2,727 36.7 Comorbidity 
!2 1,075 39.1 1,257 37.5 1,433 36.6 1,596 35.9 1,768 34.7 1,924 33.5 2,116 32.7 2,339 31.5 
Total  2,751   3,349   3,908   4,447   5,088  5,749   6,467   7,434   
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5.2.1 Process measures 
 
HbA1c recording: 
Recording of HbA1c increased substantially during the study period from 33.2% 
(95% CI: 31.5!35.0) in 2000 to 79.8% (95% CI: 78.9!80.8) in 2007 at an 
average rate of 6.9%, p<0.01. HbA1c recording increased from 33.9%, 37.8%, 
and 24.1% in 2000 to 78.4%, 84.3%, and 81.6% for white, black, and South 
Asian patients in 2007, respectively (Figure 4 and table 9). 
In the pre-QOF period, the proportion of people having their HbA1c recorded 
increased annually (AOR: 1.81; 95% CI: 1.74!1.89, p<0.01). The introduction of 
QOF was associated with an additional immediate improvement in the 
proportion of people having their HbA1c recorded (AOR: 1.73; 95% CI: 
1.49!2.02, p<0.01). In the post-QOF years, annual improvements in the 
proportion of people to have HbA1c recorded were significantly lower than that 
during the pre-QOF period (AOR: 0.63; 95% CI: 0.58!0.67, p<0.01). These 
findings were similar for the three ethnic groups (Table 10).  
Inequalities were not abolished in 2000 for south Asian patients (AOR: 0.83; 
95% CI: 0.63!1.09). However, at the end of the study period south Asian and 
black patients were more likely to have their HbA1c measured when compared 
to white group (AOR: 1.42; 95% CI: 1.26!1.80 and AOR: 1.54; 95% CI: 
1.30!1.81, respectively). 
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Figure 4 Annual percentages of patients with HbA1c recorded
! "$!
!
Table 9 Percentage of patients with HbA1c measured 
 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 33.9 (31.1-36.7) 48.6 (46.0-51.3) 60.7 (58.3-63.1) 60.9 (58.6-63.1) 72.1 (70.2-74.0) 76.8 (75.1-78.4) 79.7 (78.2-81.2) 78.4 (77.0-79.9) 
Black 37.8 (34.1-41.4) 46.1 (42.7-49.5) 60.0 (56.9-63.1) 65.0 (62.1-67.8) 76.6 (74.3-78.9) 81.8 (79.8-83.8) 84.3 (82.5-86.1) 84.3 (82.6-86.0) 
South Asian 24.1 (20.9-27.2) 33.2 (30.0-36.5) 46.9 (43.7-50.1) 54.2 (51.2-57.2) 71.5 (68.9-74.0) 76.9 (74.7-79.2) 79.4 (77.3-81.5) 81.6 (79.8-83.5) 
ALL 33.2 (31.5-35.0) 44.8 (43.1-46.5) 57.3 (55.7-58.8) 62.1 (60.7-63.6) 72.5 (71.3-73.7) 77.9 (76.8-78.9) 80.0 (79.1-81.0) 79.8 (78.9-80.8) 
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Table 10 Interrupted time series for HbA1c measured 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 
 HbA1c, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.81 (1.74-1.89)** 1.78 (1.67-1.90)** 1.84 (1.70-2.00)** 1.90 (1.76-2.06)** 
Level change with QOF 1.73 (1.49-2.02)** 1.51 (1.18-1.92)** 1.85 (1.34-2.56)** 1.89 (1.40-2.57)** 
Post-QOF trend 0.63 (0.58-0.67)** 0.63 (0.57-0.70)** 0.63 (0.55-0.73)** 0.64 (0.56-0.73)** 
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Cholesterol recording: 
Cholesterol recording increased at an average rate of 7.5%, p<0.01 between 
2000 and 2007. Recording increased from 30.7% (95% CI: 28.9!32.4) in 2000 
to 80.6% (95% CI: 79.7!81.5) in 2007. Cholesterol recording increased from 
32.1%, 36.9%, and 21.8% in 2000 to 78.5%, 84.4%, and 83.9% for white, 
black, and South Asian patients in 2007, respectively (Figure 5 and table 11). 
In the pre-QOF period, the proportion of people having their cholesterol 
recorded increased on annual basis (AOR: 1.82; 95% CI: 1.75!1.90, p<0.01). 
The introduction of QOF was associated with an additional immediate 
improvement in the proportion of people having their cholesterol recorded (AOR: 
1.74; 95% CI: 1.50!2.02, p<0.01). In the post-QOF years the proportion of 
people having their cholesterol recorded was significantly lower than that during 
the pre-QOF period (AOR: 0.63; 95% CI: 0.59!0.68, p<0.01). These findings 
were similar for black and south Asian patients. However, QOF introduction had 
no additional immediate improvements in the proportion of white patients having 
their cholesterol recorded (AOR: 1.16; 95% CI: 0.92!1.48, p>0.05) (Table 12). 
The South Asian group was less likely to have cholesterol measured when 
compared to the white group in 2000 (AOR: 0.74; 95% CI: 0.56-0.98). By the 
end of the study period South Asian were more likely to have a cholesterol 
measurement when compared to the white group (AOR: 1.55; 95% CI: 1.28-
1.87). Similarly, black patients were more likely to have cholesterol measured 
when compared to white patients (AOR: 1.40; 95% CI: 1.18-1.66).  
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Figure 5 Annual percentages of patients with cholesterol measured
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Table 11 Percentage of patients with cholesterol measured 
 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 32.1 (29.3-34.9) 43.9 (41.2-46.5) 58.0 (55.6-60.4) 63.5 (61.3-65.7) 73.3 (71.5-75.2) 76.2 (74.5-77.9) 79.8 (78.3-81.3) 78.5 (77.1-79.9) 
Black 36.9 (33.3-40.5) 43.8 (40.5-47.2) 55.2 (52.0-58.3) 63.5 (60.7-66.3) 76.2 (73.8-78.6) 81.5 (79.5-83.5) 83.9 (82.0-85.7) 84.4 (82.7-86.1) 
South Asian 21.8 (18.7-24.8) 32.0 (28.9-35.2) 41.7 (38.6-44.9) 50.0 (46.9-53.0) 73.0 (70.5-75.5) 77.8 (75.5-80.0) 81.2 (79.2-83.2) 83.9 (82.1-85.7) 
ALL 30.7 (28.9-32.4) 41.8 (40.1-43.5) 52.2 (50.6-53.8) 59.5 (58.1-61.0) 72.9 (71.7-74.1) 77.2 (76.1-78.3) 80.4 (79.4-81.3) 80.6 (79.7-81.5) 
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Table 12 Interrupted time series for cholesterol measured 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Cholesterol, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.82 (1.75-1.90)** 1.94 (1.82-2.07)** 1.72 (1.59-1.86)** 1.55 (1.45-1.66)** 
Level change with QOF 1.74 (1.50-2.02)** 1.16 (0.92-1.48) 2.07 (1.51-2.83)** 1.87 (1.44-2.43)** 
Post-QOF trend 0.63 (0.59-068)** 0.58 (0.52-0.64)** 0.67 (0.59-0.77)** 0.79 (0.70-0.89)** 
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Blood pressure recording: 
The recording of blood pressure increased from 55.3% (95% CI: 55.3!57.2) in 
2000 to 90.1% (95% CI: 89.4!90.8) in 2007 at an average rate of 5.6%, p<0.01. 
Blood pressure recording increased from 52.1%, 61.7%, and 49.6% in 2000 to 
90.8%, 92.2%, and 89.5% for white, black, and South Asian patients in 2007, 
respectively (Figure 6 and table 13). 
In the pre-QOF period, the proportion of people having their blood pressure 
recorded increased annually (AOR: 1.35; 95% CI: 1.31!1.39, p<0.01). The 
introduction of QOF was associated with an additional immediate improvement 
in the proportion of people having their blood pressure recorded (AOR: 1.38; 
95% CI: 1.19!1.59, p<0.01). In the post-QOF years, annual improvements in 
the proportion of people having their blood pressure measured was significantly 
lower than that during pre-QOF period (AOR: 0.92; 95% CI: 0.87!0.98, p<0.01). 
These findings were similar for black and south Asian patients. However, QOF 
introduction was not associated with additional improvement in the proportion of 
white patients having their blood pressure measured (AOR: 1.21; 95%: 
0.91!1.61, p>0.05) (Table 14). 
The south Asian group was less likely to have blood pressure measured when 
compared to the white group in 2000 (AOR: 0.78; 95% CI: 0.61!0.99). By the 
end of the study period no inequalities were evident for South Asian or black 
groups when compared to the white group (AOR: 1.16; 95% CI: 0.90!1.48 and 
AOR: 1.25; 95% CI: 0.99!1.58, respectively). 
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Figure 6 Annual percentages of patients with blood pressure recorded
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Table 13 Percentage of patients with blood pressure measured 
Values in brackets are 95% Confidence Interval 
 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 52.1 (49.2-55.1) 58.2 (55.6-60.9) 67.8 (65.5-70.1) 74.4 (72.4-76.4) 81.2 (79.5-82.9) 85.3 (83.9-86.8) 88.9 (87.7-90.0) 90.8 (89.8-91.8) 
Black 61.7 (58.0-65.3) 63.2 (60.0-66.5) 72.5 (69.7-75.4) 77.5 (75.0-79.9) 85.9 (84.0-87.8) 89.3 (87.7-90.9) 91.0 (89.6-92.5) 92.2 (90.9-93.4) 
South Asian 49.6 (45.9-53.3) 50.2 (46.8-53.6) 61.6 (58.5-64.7) 66.3 (63.4-69.1) 80.5 (78.3-82.7) 84.6 (82.6-86.5) 87.9 (86.2-89.5) 89.5 (88.1-91.0) 
ALL 55.3 (53.5-57.2) 58.7 (57.0-60.4) 67.0 (65.5-68.5) 72.4 (71.1-73.7) 81.8 (80.7-82.8) 85.5 (84.6-86.5) 88.2 (87.4-89.0) 90.1 (89.4-90.8) 
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Table 14 Interrupted time series for blood pressure measurement 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Blood pressure, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.35 (1.31-1.39)** 1.82 (1.70-!1.96)** 1.60 (1.46-1.76)** 1.25 (1.40-1.66)** 
Level change with QOF 1.38 (1.19-1.59)** 1.21 (0!.91-1.61) 2.13 (1.43-3.18)** 2.61 (1.83-3.73)** 
Post-QOF trend 0.92 (0.87-0.98)** 0.81 (0.72-0.92)** 0.80 (0.67-0.96)** 0.90 (0.77-1.05) 
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BMI recording: 
The recording of BMI increased from 39.2% (95% CI: 37.4!41.4) in 2000 to 
76.5% (95% CI: 75.6!77.5) in 2007 at an average rate of 6.1%, p<0.01. BMI 
recording increased from 38.3%, 46.7%, and 36.4% in 2000 to 77.3%, 78.9%, 
and 78.1% for white, black, and South Asian patients in 2007, respectively 
(Figure 7 and table 15). 
In the pre-QOF period, the proportion of people having their BMI recorded 
increased annually (AOR: 1.54; 95% CI: 1.48!1.60, p<0.01). The introduction of 
QOF was associated with an additional improvement in the proportion of people 
having their BMI recorded (AOR: 1.88; 95% CI: 1.62!1.18, p<0.01). In the post-
QOF years, annual improvements in the proportion of people having their BMI 
recorded were significantly lower than that during the pre-QOF years (AOR: 
0.70; 95% CI: 0.66!0.75, p<0.01). These findings were similar for black and 
South Asian patients (Table 16). 
No inequalities were evident between ethnic groups in 2000. However, at the 
end of the study period black patients were more likely to have their BMI 
measured when compared to white group (AOR: 1.22; 95% CI: 1.04!1.43). 
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Figure 7 Annual percentages of patients with BMI measured
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Table 15 Percentage of patients with BMI measured 
Values in brackets are 95% Confidence Interval 
 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 38.3 (35.4-41.1) 43.9 (41.2-46.5) 55.7 (53.2-58.1) 62.3 (60.1-64.5) 72.1 (70.2-74.0) 74.4 (72.6-76.1) 79.4 (77.9-81.0) 77.3 (75.9-78.2) 
Black 46.7 (43.0-50.5) 51.0 (47.6-54.4) 59.5 (56.3-62.6) 64.7 (61.9-67.5) 77.3 (75.0-79.6) 79.0 (76.9-81.2) 84.9 (83.1-86.6) 78.9 (77.0-80.7) 
South Asian 36.4 (32.8-40.0) 38.2 (34.9-41.5) 49.5 (46.3-52.7) 55.0 (52.0-58.0) 71.1 (68.5-73.6) 76.6 (74.4-78.9) 80.1 (78.0-82.1) 78.1 (76.1-80.0) 
ALL 39.2 (37.4-41.1) 43.4 (41.7-45.1) 53.7 (52.1-55.2) 59.2 (57.8-60.6) 71.5 (70.3-72.8) 74.0 (72.9-75.1) 79.5 (78.5-80.5) 76.5 (75.6-77.5) 
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Table 16 Interrupted time series for BMI measurement 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 BMI measured, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.54 (1.48-1.60)** 1.66 (1.56-1.77)** 1.46 (1.35-1.57)** 1.49 (1.38-1.61)** 
Level change with QOF 1.88 (1.62-2.18)** 1.39 (1.10-1.74)** 2.37 (1.75-3.20)** 2.96 (2.19-3.99)** 
Post-QOF trend 0.70 (0.66-0.75)** 0.66 (0.59-0.72)** 0.66 (0.58-0.75)** 0.70 (0.61-0.80)** 
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Retinal screening: 
The percentage of patients having retinal screening increased from 4.9% (95% 
CI: 4.1!5.7) in 2000 to 56.6% (95% CI: 55.5!57.8) in 2007 at an average rate of 
9.0%, p<0.01. Patients who had their retinal screening increased from 2.2%, 
5.1%, and 8.3% in 2000 to 58.0%, 58.7%, and 58.6% for white, black, and 
South Asian patients in 2007, respectively (Figure 8 and table 17). 
In the pre-QOF period the proportion of people having their retinal screening 
recorded increased annually (AOR: 3.43; 95% CI: 3.23!3.63, p<0.01). The 
introduction of QOF was not associated with additional immediate improvement 
in the proportion of people having their retinal screening recorded (AOR: 1.06; 
95% CI: 0.92!1.23, p>0.05). In the post-QOF years, annual improvements in 
the proportion of people having their retinal screening were significantly lower 
than that during the pre-QOF years (AOR: 0.27; 95% CI: 0.25!0.29, p<0.01). 
These findings were similar for white, black and south Asian patients (Table 18). 
No inequalities were evident for black and south Asian patients when compared 
with white patients in 2000 or 2007. 
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Figure 8 Annual percentages of patients with retinal screening
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Table 17 Percentage of patients with retinal screening 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 2.71 (1.75-3.67) 9.67 (8.09-11.2) 21.5 (19.5-23.5) 43.2 (40.9-45.4) 56.5 (54.4-58.6) 62.2 (60.3-64.1) 62.0 (60.2-63.8) 58.0 (56.3-59.7) 
Black 5.13 (3.47-6.79) 7.89 (6.06-9.72) 20.6 (18.1-23.2) 44.1 (41.2-47.0) 54.1 (51.4-56.9) 61.3 (58.8-63.9) 63.8 (61.4-66.1) 58.7 (56.4-61.0) 
South Asian 8.32 (6.26-10.3) 7.33 (5.55-9.10) 17.1 (14.7-19.6) 40.3 (37.3-43.2) 48.6 (45.8-51.4) 58.5 (55.9-61.2) 59.8 (57.3-62.3) 58.3 (55.9-60.6) 
ALL 4.87 (4.06-5.67) 8.36 (7.42-9.29) 19.3 (18.1-20.5) 41.6 (40.2-43.1) 52.8 (51.4-54.2) 60.0 (58.8-61.3) 60.6 (59.4-61.8) 56.6 (55.5-57.8) 
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Table 18 Interrupted time series for retinal screening 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 
 Retinal screening, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 3.43 (3.23-3.63)** 3.76 (3.42-4.13)** 3.39 (3.02-3.79)** 2.99 (2.67-3.34)** 
Level change with QOF 1.06 (0.92-1.23) 0.96 (0.77-1.21) 0.92 (0.69-1.22) 1.21 (0.89-1.63) 
Post-QOF trend 0.27 (0.25-0.29)** 0.24 (0.21-0.27)** 0.27 (0.24-0.32)** 0.34 (0.30-040)** 
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Smoking status: 
The percentage of patients having their smoking status recorded increased from 
30.3% (95% CI: 28.5!32.0) in 2000 to 76.4% (95% CI: 75.5!77.4) in 2007 at an 
average rate of 5.7%, p<0.01. Patients who had their smoking status recorded 
increased from 30.0%, 36.3%, and 26.1% in 2000 to 79.1%, 78.4%, and 
76.2% for white, black, and South Asian patients in 2007, respectively (Figure 9 
and table 19). 
In the pre-QOF period the proportion of people having their smoking status 
recorded increased annually (AOR: 1.58; 95% CI: 1.52!1.64, p<0.01). The 
introduction of QOF was associated an additional improvements in the 
proportion of people having their smoking status recorded (AOR: 3.25; 95% CI: 
2.77!3.81, p<0.01). In the post-QOF years, annual improvements in the 
proportion of people having their smoking status recorded were significantly 
lower than that during the pre-QOF years (AOR: 0.65; 95% CI: 0.61!0.69, 
p<0.01). These findings were similar for white, black and South Asian patients 
(Table 20). 
No inequalities were evident for black and South Asian patients when compared 
with white patients in 2000 or 2007. 
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Figure 9 Annual percentages of patients with smoking status recorded
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Table 19 Percentage of patients having their smoking status recorded 
Values in brackets are 95% Confidence Interval 
 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 30.0 (27.3-32.7) 39.2 (36.6-41.8) 49.7 (47.3-52.1) 60.8 (58.5-63.0) 75.1 (73.2-76.9) 75.3 (73.6-77.1) 79.2 (77.7-80.7) 79.1 (77.7-80.6) 
Black 36.3 (32.7-39.9) 40.0 (36.7-43.4) 46.8 (43.6-49.9) 58.9 (56.0-61.8) 80.3 (78.1-82.5) 77.6 (77.5-79.8) 81.8 (79.9-83.7) 78.4 (76.5-80.3) 
South Asian 26.1 (22.8-29.3) 34.8 (31.6-38.1) 41.4 (38.3-44.5) 48.0 (45.0-51.0) 75.2 (72.7-77.6) 77.5 (75.3-79.8) 79.1 (77.0-81.2) 76.2 (74.2-78.3) 
ALL 30.3 (28.5-32.0) 37.4 (35.8-39.0) 45.6 (44.1-47.2) 55.5 (54.1-57.0) 74.9 (73.7-76.1) 74.9 (73.8-76.1) 78.5 (77.5-79.5) 76.4 (75.5-77.4) 
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Table 20 Interrupted time series for smoking status 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Smoking status, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.58 (1.52-1.64)** 1.76 (1.65-1.86)** 1.48 (1.38-1.58)** 1.47 (1.37-1.58)** 
Level change with QOF 3.25 (2.77-3.81)** 2.07 (1.61-2.66)** 3.57 (2.58-4.93)** 6.17 (4.42-8.62)** 
Post-QOF trend 0.65 (0.61-0.69)** 0.64 (0.58-0.70)** 0.68 (0.60-0.77)** 0.64 (0.56-0.72)** 
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Smoking advice: 
The percentage of patients having their smoking status recorded increased from 
2.25% (95% CI: 1.69!2.28) in 2000 to 42.6% (95% CI: 41.5!43.7) in 2007 at an 
average rate of 5.0%, p<0.01. Patients who had a smoking advice offered 
increased from 2.08%, 2.78%, and 2.58% in 2000 to 48.0%, 41.5%, and 
38.5% for white, black, and South Asian patients in 2007, respectively (Figure 
10 and table 21). 
In the pre-QOF period the proportion of people having a smoking advice offered 
increased annually (AOR: 2.26; 95% CI: 2.12!2.42, p<0.01). The introduction of 
QOF was associated with an additional immediate improvement in the 
proportion of people having a smoking advice offered to them (AOR: 1.49; 95% 
CI: 1.26!1.76, p<0.01). In the post-QOF years, annual improvements in the 
proportion of people being offered a smoking advice was less significantly lower 
than that during the pre-QOF years (AOR: 0.60; 95% CI: 0.55!0.65, p<0.01). 
These findings were similar for white, black and South Asian patients (Table 22). 
By the end of the study period black and south Asian were less likely to be 
offered a smoking advice when compared to white (AOR: 0.70; 95% CI: 
0.61!0.81 and AOR: 0.71; 95% CI: 0.61!0.84, respectively).  
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Figure 10 Annual percentages of patients having a smoking advice offered 
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Table 21 Percentages of patients having smoking advice 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 2.08 (1.23-2.92) 7.90 (6.46-9.34) 18.4 (16.5-20.3) 23.1 (21.2-25.0) 45.0 (42.9-47.1) 41.2 (39.3-43.2) 45.2 (43.4-47.1) 48.0 (46.2-49.7) 
Black 2.78 (1.54-4.02) 6.33 (4.68-7.99) 12.2 (10.1-14.3) 17.5 (15.3-19.8) 38.4 (35.7-41.1) 31.2 (28.7-33.6) 35.2 (32.8-37.5) 41.5 (39.2-43.7) 
South Asian 2.58 (1.40-3.76) 4.80 (3.35-6.26) 9.70 (7.81-11.5) 11.9 (9.96-13.8) 25.1 (22.6-27.5) 23.7 (21.4-26.0) 25.3 (23.0-27.5) 38.5 (36.2-40.9) 
ALL 2.25 (1.69-2.28) 6.53 (5.70-7.37) 14.0 (13.0-15.1) 18.0 (16.9-19.2) 37.1 (35.8-38.4) 33.2 (31.9-34.4) 36.5 (35.3-37.7) 42.6 (41.5-43.7) 
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Table 22 Interrupted time series for smoking advice 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 
 
 
 Smoking advice, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 2.26 (2.12-2.42)** 2.46 (2.24-2.71)** 2.21 (1.94-2.52)** 1.89 (1.63-2.18)** 
Level change with QOF 1.49 (1.26-1.76)** 2.02 (1.58-2.58)** 1.35 (0.97-1.88) 0.78 (0.53-1.15) 
Post-QOF trend 0.60 (0.55-0.65)** 0.49 (0.44-0.55)** 0.63 (0.54-0.74)** 0.93 (0.78-1.11)** 
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Peripheral pulse screening: 
The percentage of patients having their peripheral pulses examined increased 
from 12.2% (95% CI: 11.0!13.4) in 2000 to 68.6% (95% CI: 67.5!69.6) in 2007 
at an average rate of 9.0%, p<0.01. Patients who had their peripheral pulse 
exam recorded increased from 15.5%, 13.3%, and 5.8% in 2000 to 67.3%, 
73.8%, and 71.3% for white, black, and South Asian patients in 2007, 
respectively (Figure 11 and table 23). 
In the pre-QOF period the proportion of people having their peripheral pulse 
exam recorded increased annually (AOR: 2.26; 95% CI: 2.16!2.36, p<0.01). 
The introduction of QOF was associated with an additional immediate 
improvement in the proportion of people having their peripheral pulse exam 
recorded (AOR: 1.79; 95% CI: 1.56!2.07, p<0.01). In the post-QOF years, 
annual improvements in the proportion of people having their peripheral pulse 
exam recorded were significantly lower than that during the pre-QOF (AOR: 
0.46; 95% CI: 0.43!0.49, p<0.01). These findings were similar for white, black 
and South Asian patients (Table 24). 
Inequalities were not abolished in 2000 for South Asian patients (AOR: 0.69; 
95% CI: 0.44!1.08). However, at the end of the study period black and South 
Asian patients were more likely to have their peripheral pulse examined when 
compared to white group (AOR: 1.29; 95% CI: 1.12!1.49 and AOR: 1.20; 95% 
CI: 1.03!1.41, respectively). 
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Figure 11 Annual percentages of patients with peripheral pulse screened
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Table 23 Percentages of patients with peripheral pulse screening 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 15.5 (13.4-17.7) 20.6 (18.5-22.8) 36.3 (33.9-38.6) 45.9 (43.6-48.1) 58.8 (56.7-60.9) 66.2 (64.3-68.1) 69.6 (67.8-71.3) 67.3 (65.7-68.9) 
Black 13.3 (10.7-15.9) 20.2 (17.4-22.9) 37.0 (34.0-40.1) 49.5 (46.6-52.5) 66.2 (63.5-68.8) 74.2 (71.9-76.5) 75.4 (73.3-77.5) 73.8 (71.8-75.8) 
South Asian 5.88 (4.13-7.63) 19.3 (16.6-22.0) 33.2 (30.2-36.2) 41.4 (38.5-44.4) 59.1 (56.3-61.9) 69.7 (67.3-72.2) 73.9 (71.6-76.1) 71.3 (69.1-73.5) 
ALL 12.2 (11.0-13.4) 19.7 (18.4-21.1) 34.6 (33.1-36.1) 44.4 (42.9-45.8) 59.3 (57.9-60.6) 67.8 (66.6-69.0) 70.7 (69.6-71.8) 68.6 (67.5-69.6) 
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Table 24 Interrupted time series for peripheral pulse screening 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Peripheral pulse screening, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 2.26 (2.16-2.36)** 2.13 (1.99-2.28)** 2.40 (2.19-2.62)** 2.42 (2.21-2.66)** 
Level change with QOF 1.79 (1.56-2.07)** 1.62 (1.30-2.01)** 1.84 (1.38-2.44)** 1.94 (1.45-2.60)** 
Post-QOF trend 0.46 (0.43-0.49)** 0.49 (0.45-0.55)** 0.42 (0.37-0.47)** 0.43 (0.38-0.49)** 
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Serum creatinine: 
The percentage of patients having their serum creatinine measured increased 
from 24.4% (95% CI: 22.8!26.0) in 2000 to 81.6% (95% CI: 80.7!82.5) in 2007 
at an average rate of 8.4%, p<0.01. Patients who had their serum creatinine 
recorded increased from 27.7%, 28.7%, and 15.4% in 2000 to 80.4%, 86.1%, 
and 84.2% for white, black, and South Asian patients in 2007, respectively 
(Figure 12 and table 25). 
In the pre-QOF period the proportion of people having their serum creatinine 
recorded increased annually (AOR: 2.13; 95% CI: 2.04!2.23, p<0.01). The 
introduction of QOF was associated with an additional immediate improvement 
in the proportion of people having their serum creatinine recorded (AOR: 1.39; 
95% CI: 1.20!1.63, p<0.01). In the post-QOF years, annual improvements in 
the proportion of people having their serum creatinine recorded were 
significantly lower than that during pre-QOF years (AOR: 0.56; 95% CI: 
0.52!0.60, p<0.01). These findings were similar for black and South Asian 
patients. However, QOF did not have any positive effect on the proportion of 
white patients having their serum creatinine recorded (AOR: 0.92; 95% CI: 
0.72!1.17) (Table 26). 
No inequalities were evident between ethnic groups in 2000. However, at the 
end of the study period black and South Asian patients were more likely to have 
their creatinine measured when compared to white group (AOR: 1.44; 95% CI: 
1.20!1.72 and AOR: 1.47; 95% CI: 1.21!1.78, respectively). 
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Figure 12 Annual percentages of patients with serum creatinine measured
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Table 25 Percentage of patients with serum creatinine measured 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 27.7 (25.0-30.3) 41.7 (39.0-44.3) 56.2 (53.8-58.6) 64.3 (62.1-66.5) 74.5 (72.7-76.4) 76.6 (74.9-78.3) 80.0 (78.5-81.5) 80.4 (79.0-81.8) 
Black 28.7 (25.3-32.1) 40.4 (37.0-43.7) 55.6 (52.5-58.8) 63.5 (60.7-66.3) 78.8 (76.6-81.1) 83.1 (81.2-85.1) 84.7 (83.0-86.5) 86.1 (84.5-87.7) 
South Asian 15.4 (12.8-18.1) 28.7 (25.6-31.8) 42.1 (39.0-45.3) 50.1 (47.1-53.1) 73.6 (71.1-76.1) 77.5 (75.3-79.8) 81.2 (79.2-83.2) 84.2 (82.4-85.9) 
ALL 24.4 (22.8-26.0) 37.3 (35.6-38.9) 51.3 (49.7-52.8) 59.4 (58.0-60.8) 74.2 (73.0-75.4) 77.6 (76.5-78.7) 80.6 (79.6-81.5) 81.6 (80.7-82.5) 
! "#&!
!
Table 26 Interrupted time series for serum creatinine 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 Serum creatinine, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 2.13 (2.04-2.23)** 2.20 (2.05-2.35)** 2.10 (1.93-2.28)** 2.14 (1.96-2.33)** 
Level change with QOF 1.39 (1.20-1.63)** 0.92 (0.72-1.17) 1.75 (1.27-2.42)** 1.89 (1.39-2.57)** 
Post-QOF trend 0.56 (0.52-0.60)** 0.54 (0.49-0.61)** 0.56 (0.48-0.64)** 0.62 (0.54-0.71)** 
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Urine micro-albuminuria: 
The percentage of patients having their micro-albuminuria measured increased 
from 0.65% (95% CI: 0.38!0.95) in 2000 to 44.9% (95% CI: 43.8!46.1) in 2007 
at an average rate of 8.6%, p<0.01. Patients who had their micro-albuminuria 
recorded increased from 0.36%, 1.31%, and 0.28% in 2000 to 43.4%, 51.8%, 
and 45.4% for white, black, and South Asian patients in 2007, respectively 
(Figure 13 and table 27). 
In the pre-QOF period the proportion of people having their micro-albuminuria 
recorded increased annually (AOR: 4.46; 95% CI: 3.80!5.24, p<0.01). The 
introduction of QOF was associated with an additional immediate improvement 
in the proportion of people having their micro-albuminuria recorded (AOR: 3.92; 
95% CI: 3.05!5.02, p<0.01). In the post-QOF years, annual improvements in 
the proportion of people having their micro-albuminuria recorded were less 
significantly lower than that during the pre-QOF years (AOR: 0.20; 95% CI: 
0.17!0.24, p<0.01). These findings were similar for white, black and south Asian 
patients (Table 28). 
At the end of the study period black patients were more likely to have micro-
albuminuria recorded when compared to the white group (AOR: 1.37; 95% CI: 
1.20!1.55) and South Asian had similar care to the white group (AOR: 1.14; 
95% CI: 0.99!1.31). No inequalities were evident in 2000. 
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Figure 13 Annual percentages of patients with urine micro-albuminuria measured
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Table 27 Percentage of patients with urine micro-albuminuria measured 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 0.36 (0.01-0.71) 0.59 (0.18-0.99) 1.54 (0.94-2.15) 11.4 (10.0-12.9) 36.0 (34.0-38.1) 46.0 (44.0-48.0) 48.7 (46.9-50.6) 43.4 (41.6-45.1) 
Black 1.31 (0.46-2.17) 0.95 (0.29-1.61) 1.14 (0.46-1.18) 11.3 (9.45-13.2) 40.5 (37.8-43.2) 54.7 (52.1-57.3) 54.9 (52.4-57.3) 51.8 (49.5-54.1) 
South Asian 0.28 (-0.11-0.68) 0.48 (0.00-0.95) 0.52 (0.00-0.98) 4.97 (3.66-6.27) 35.8 (33.1-38.6) 49.4 (46.7-52.1) 50.8 (48.2-53.4) 45.4 (43.0-47.8) 
ALL 0.65 (0.35-0.95) 0.65 (0.38-0.93) 1.15 (0.81-1.48) 9.57 (8.71-10.4) 35.8 (34.5-37.1) 47.7 (46.4-49.0) 49.8 (48.6-51.0) 44.9 (43.8-46.1) 
! "#%!
!
Table 28 Interrupted time series for urine micro-albuminuria 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 Urine micro, OR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 4.46 (3.80-5.24)** 5.90 (4.50-7.73)** 3.63 (2.80-4.72)** 3.99 (2.61-6.10)** 
Level change with QOF 3.92 (3.05-5.02)** 2.14 (1.45-3.16)** 5.32 (3.42-8.29)** 9.27 (4.86-17.6)** 
Post-QOF trend 0.20 (0.17-0.24)** 0.15 (0.12-0.20)** 0.25 (0.19-0.33)** 0.22 (0.14-0.35)** 
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Foot screening: 
The percentage of patients having their feet examined increased from 4.68% 
(95% CI: 3.89!5.47) in 2000 to 59.9% (95% CI: 58.8!61.0) in 2007 at an 
average rate of 8.6%, p<0.01. Patients who had their feet examined recorded 
increased from 2.62%, 4.54%, and 7.74% in 2000 to 62.1%, 63.8%, and 
60.3% for white, black, and South Asian patients in 2007, respectively (Figure 
14 and table 29). 
In the pre-QOF period the proportion of people having their foot screening 
recorded increased annually (AOR: 2.64; 95% CI: 2.52!2.78, p<0.01). The 
introduction of QOF was associated with an additional immediate improvement 
in the proportion of people having their foot exam recorded (AOR: 1.32; 95% CI: 
1.15!1.53, p<0.01). In the post-QOF years, annual improvements in the 
proportion of people having their foot exam were significantly lower than that 
during the pre-QOF years (AOR: 0.35; 95% CI: 0.33!0.38, p<0.01). These 
findings were similar for white, black and South Asian patients (Table 30). 
No inequalities were evident between ethnic groups in 2000. However, at the 
end of the study period black and South Asian patients were more likely to have 
their foot examined when compared to white group (AOR: 1.31; 95% CI: 
1.08!1.59 and AOR: 1.46; 95% CI: 1.18!1.82, respectively). 
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Figure 14 Annual percentages of patients with foot screening
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Table 29 Percentage of patients with foot screening 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 2.62 (1.68-3.57) 16.9 (14.9-18.9) 36.1 (33.7-38.4) 42.9 (40.6-45.1) 54.0 (51.9-56.1) 61.1 (59.2-63.1) 64.4 (62.6-66.2) 62.1 (60.4-63.8) 
Black 4.54 (2.97-6.11) 15.3 (12.8-17.7) 33.7 (30.7-36.7) 44.9 (42.0-47.9) 62.2 (59.5-64.9) 68.5 (66.0-70.9) 70.8 (68.6-73.1) 63.8 (61.6-66.0) 
South Asian 7.74 (5.75-9.73) 19.4 (16.7-22.1) 31.5 (28.5-34.5) 39.2 (36.2-42.1) 56.8 (54.0-59.6) 66.4 (63.9-69.0) 69.2 (66.8-71.5) 60.3 (57.9-62.6) 
ALL 4.68 (3.89-5.47) 16.7 (15.5-18.0) 32.9 (31.5-34.4) 40.9 (39.5-42.4) 54.9 (53.6-56.3) 62.1 (60.8-63.3) 64.9 (63.7-66.0) 59.9 (58.8-61.0) 
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Table 30 Interrupted time series for foot screening 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Foot screen prescribed, OR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 2.64 (2.52-2.78)** 2.89 (2.67-3.13)** 2.86 (2.59-3.15)** 2.15 (1.97-2.36)** 
Level change with QOF 1.32 (1.15-1.53)** 0.83 (0.67-1.04) 1.47 (1.11-1.95)** 2.74 (2.06-3.65)** 
Post-QOF trend 0.35 (0.33-0.38)** 0.36 (0.32-0.40)** 0.30 (0.26-0.34)** 0.38 (0.33-0.43)** 
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5.2.2 Intermediate outcomes measures 
 
HbA1c control: 
The percentage of patients’ achieving the HbA1c target of !7.5%, increased 
from 41.0% (95% CI: 37.7"44.2) in 2000 to 58.2% (56.9"59.5) in 2007, at an 
average rate of 2.7%, p<0.01. Patients who had their HbA1c controlled 
increased from 44.8%, 41.8%, and 34.5% in 2000 to 59.1%, 57.4%, and 
54.5% in 2007 for white, black and south Asian in 2007, respectively (Figure 15 
and table 31). 
In the pre-QOF period the proportion of people having their HbA1c controlled 
increased annually (AOR: 1.31; 95% CI: 1.23"1.39, p<0.01). The introduction of 
QOF was not associated with an additional immediate improvement in the 
proportion of people having their HbA1c controlled (AOR: 1.00; 95% CI: 
0.83"1.21, p>0.05). In the post-QOF years, annual improvement in the 
proportion of people having HbA1c controlled was significantly lower than that 
during the pre-QOF years (AOR: 0.76; 95% CI: 0.70"0.83, p<0.01). These 
findings were similar for white, black and South Asian patients (Table 32). 
A trend of significant reductions in mean HbA1c was evident in all three ethnic 
groups before QOF introduction (p<0.01). There was no significant step change 
in HbA1c levels associated with the initial introduction of QOF in white and black 
patients and HbA1c levels increased significantly relative to the pre-QOF trend in 
South Asian patients (0.18%; 95% CI: 0.02"0.34). There was a significant 
sustained annual increase in mean HbA1c in each ethnic group (P<0.01) in the 
post-QOF period relative to the pre-QOF trend (Table 33 and 34). 
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In 2000 south Asian patients were less likely to achieve the QOF target of !7.5% 
when compared to white patients (AOR: 0.66; 95%: 0.60"0.96) and the black 
group had an AOR of 0.82; 95% CI: 0.56"1.19. These inequalities were not 
corrected for in 2007. Black patient and south Asian were less likely to achieve 
the QOF target !7.5% when compare to white patients (AOR: 0.82; 95% CI: 
0.71"0.94 and AOR: 0.72; 95% CI: 0.61"0.85). 
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Figure 15 Annual percentages of patients with HbA1c !7.5%
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Table 31 Percentage of patients with HbA1c !7.5% 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 44.8 (39.7-49.8) 45.8 (42.0-49.6) 57.3 (53.2-60.4) 59.2 (56.4-62.1) 62.2 (59.8-64.6) 61.9 (59.6-64.1) 66.0 (64.0-68.0) 59.1 (62.9-62.9) 
Black 41.8 (35.8-47.9) 45.5 (40.6-50.5) 51.9 (47.8-55.9) 50.7 (47.0-54.4) 51.9 (48.8-55.1) 57.3 (54.5-60.2) 60.5 (57.9-63.1) 57.4 (54.9-59.9) 
South Asian 34.5 (27.2-41.7) 36.1 (30.4-41.7) 44.7 (40.0-49.3) 45.6 (41.6-49.7) 52.2 (48.9-55.6) 50.5 (47.4-53.6) 58.4 (55.5-61.2) 54.5 (51.8-57.1) 
ALL 41.0 (37.8-44.2) 43.5 (40.9-46.0) 52.8 (50.7-54.9) 53.2 (51.3-55.1) 56.5 (54.9-58.1) 57.7 (56.2-59.1) 62.4 (61.0-63.7) 58.2 (56.9-59.5) 
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Table 32 Interrupted time series for controlled HbA1c 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 HbA1c <=7.5%, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.31 (1.23-1.39)** 1.41 (1.28-1.55)** 1.20 (1.07-1.35)** 1.21 (1.05-1.40)** 
Level change with QOF 1.00 (0.83-1.21) 0.89 (0.66-1.2) 1.19 (0.84-1.69) 1.05 (0.70-1.58) 
Post-QOF trend 0.76 (0.70-083)** 0.65 (0.57-0.75)** 0.84 (0.72-0.98)* 0.93 (0.78-1.12) 
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Table 33 Annual mean value of HbA1c 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 8.1 (7.9-8.3) 8.0 (7.9-8.2) 7.6 (7.5-7.7) 7.5 (7.4-7.6) 7.5 (7.4-7.6) 7.4 (7.4-7.5) 7.3 (7.2-7.4) 7.5 (7.4-7.5) 
Black 8.5 (8.2-8.8) 8.2 (8.0-8.4) 7.9 (7.7-8.0) 8.0 (7.8-8.1) 7.9 (7.8-8.0) 7.7 (7.6-7.8) 7.6 (7.5-7.7) 7.8 (7.7-7.9) 
South Asian 8.6 (8.3-8.9) 8.3 (8.1-8.5) 8.0 (7.8-8.2) 7.9 (7.8-8.1) 7.9 (7.8-8.0) 7.9 (7.8-8.0) 7.7 (7.6-7.8) 7.8 (7.7-7.8) 
ALL 8.3 (8.2-8.5) 8.2 (8.1-8.3) 7.8 (7.7-7.8) 7.8 (7.7-7.8) 7.7 (7.6-7.8) 7.7 (7.6-7.7) 7.5 (7.4-7.5) 7.7 (7.6-7.7) 
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Table 34 Interrupted time series analysis for HbA1c levels 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 HbA1c, %, (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.21 (-0.23, -0.18)** -0.20 (-0.24, -0.17)** -0.21 (-0.27, -0.15)** -0.20 (-0.26, -0.15)** 
Level change with QOF 0.04 (-0.04, 0.12) 0.07 (-0.04, 0.18) -0.12 (-0.29, 0.04) 0.18 (0.02, 0.34)* 
Post-QOF trend 0.19 (0.15, 0.22)** 0.21 (0.16, 0.26)** 0.21 (0.14, 0.29)** 0.11 (0.04, 0.18)** 
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Cholesterol control: 
The percentage of patients’ achieving the cholesterol target of !5.0 mmol/l, 
increased from 46.8% (95% CI: 43.5"50.2) in 2000 to 77.5% (95% CI: 
76.4"78.5) in 2007, at an average rate of 4.8%, p<0.01. Patients who had their 
cholesterol controlled increased from 42.2%, 44.8%, and 59.2% in 2000 to 
76.9%, 76.4%, and 80.4% in 2007 for white, black and south Asian, 
respectively (Figure 16 and table 35). 
In the pre-QOF period the proportion of people having their cholesterol 
controlled increased annually (AOR: 1.41; 95% CI: 1.33"1.51, p<0.01). The 
introduction of QOF was associated with an additional immediate improvement 
in the proportion of people having their cholesterol controlled (AOR: 1.42; 95% 
CI: 1.17"1.72, p<0.01). This was true for white (AOR: 1.69; 95% CI: 1.26"2.26) 
but not for black or South Asian patients. In the post-QOF years, annual 
improvements in the proportion of people having their cholesterol controlled 
were significantly lower than that during the pre-QOF years (AOR: 0.96; 95% CI: 
0.88"1.85, p<0.01). These findings were similar for white, black and South 
Asian patients (Table 36). 
A trend of significant reductions in mean total cholesterol was evident in all three 
ethnic groups before QOF introduction (p<0.01). The introduction of QOF was 
associated with significant additional reductions in cholesterol levels in white and 
black patients but not in South Asian patients (-0.07 mmol/l; 95% CI: - 
0.20"0.04).  There was no significant sustained annual reduction in cholesterol 
levels in black and South Asian patients in the post-QOF period relative to the 
pre-QOF trend. White patients experienced a significant increase in mean 
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cholesterol trend in the post-QOF period relative to the pre-QOF trend (0.04 
mmol/l; 95% CI: 0.01"0.08) (Table 37 and 38). 
 
In 2000, South Asian patients were more likely to achieve the QOF target of !5.0 
mmol/l when compared to white patients (AOR: 2.03; 95%: 1.36"3.01) and the 
black group had an AOR: 1.18 (95% CI: 0.85"1.65).  However in 2007 this 
picture did not change. South Asian patients were more likely to achieve the 
QOF target !5.0 mmol/l when compare to white patients (AOR: 1.36; 95% CI: 
1.11"1.66) and black patients had an AOR: 1.14 (95% CI: 0.95"1.37). 
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Figure 16 Annual percentages of patients with cholesterol !5.0 mmol/l
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Table 35 Percentage of patients with cholesterol !5.0 mmol/l 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 42.2 (37.0-47.4) 46.3 (42.3-50.4) 50.4 (47.2-53.6) 57.6 (54.8-60.4) 67.3 (65.0-69.7) 70.6 (68.5-72.7) 77.2 (75.5-79.0) 76.9 (75.2-78.5) 
Black 44.8 (38.6-51.0) 54.7 (49.6-59.8) 54.6 (50.4-58.9) 62.3 (58.7-65.9) 66.6 (63.6-69.6) 72.3 (69.7-74.9) 76.5 (74.2-78.8) 76.4 (74.3-78.5) 
South Asian 59.2 (51.3-67.1) 53.1 (47.1-59.2) 61.1 (56.2-65.9) 62.8 (58.7-66.9) 70.7 (67.7-73.7) 72.8 (70.1-75.5) 79.0 (76.7-81.4) 80.4 (78.3-82.4) 
ALL 46.8 (43.5-50.2) 50.9 (48.2-53.6) 53.8 (51.6-55.9) 60.0 (58.1-61.8) 67.4 (65.9-68.9) 71.2 (69.9-72.6) 77.2 (76.1-78.3) 77.5 (76.4-78.5) 
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Table 36 Interrupted time series for controlled cholesterol 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Cholesterol <=5.0 mmol/l, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.41 (1.33-1.51)** 1.47 (1.34-1.62)** 1.46 (1.30-1.65)** 1.37 (1.18-1.58)** 
Level change with QOF 1.42 (1.17-1.72)** 1.69 (1.26-2.26)** 1.28 (0.88-1.85) 1.14 (0.75-1.75) 
Post-QOF trend 0.96 (0.88-1.05) 0.92 (0.80-1.05) 0.85 (0.72-1.01) 1.08 (0.89-1.31) 
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Table 37 Annual mean value of cholesterol (mmol/l) 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 5.2 (5.1-5.3) 5.2 (5.1-5.3) 5.0 (5.0-5.1) 4.9 (4.8-4.9) 4.6 (4.6-4.7) 4.6 (4.5-4.6) 4.4 (4.3-4.4) 4.4 (4.3-4.4) 
Black 5.1 (5.0-5.3) 4.9 (4.8-5.0) 4.9 (4.9-5.0) 4.8 (4.7-5.0) 4.6 (4.5-4.7) 4.6 (4.5-4.6) 4.4 (4.3-4.5) 4.4 (4.3-4.5) 
South Asian 5.0 (4.8-5.2) 4.9 (4.8-5.0) 4.8 (4.7-4.9) 4.7 (4.6-4.8) 4.4 (4.3-4.5) 4.4 (4.4-4.5) 4.2 (4.2-4.3) 4.2 (4.2-4.3) 
ALL 5.1 (5.1-5.2) 5.0 (5.0-5.1) 5.0 (4.9-5.0) 4.9 (4.8-4.9) 4.6 (4.5-4.6) 4.5 (4.5-4.6) 4.4 (4.3-4.4) 4.4 (4.3-4.4) 
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Table 38 Interrupted time series for controlled cholesterol levels 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 !
 Cholesterol, mmol/l (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.13 (-0.15, -0.11)** -0.15, (-0.17, -0.12)** -0.11 (-0.14, -0.08)** -0.13 (-0.17, -0.08)** 
Level change with QOF -0.12 (-0.18, -0.06)** -0.13 (-0.21, -0.05)** -0.10 (-0.20, -0.01)* -0.07 (-0.20, 0.04) 
Post-QOF trend 0.03 (0.01, 0.05)* 0.04 (0.01, 0.08)* 0.03 (-0.01, 0.07) 0.02 (-0.03, 0.07) 
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Blood pressure control: 
The percentage of patients’ achieving the blood pressure target of !145/85 mm 
Hg, increased from 65.7% (95% CI: 63.7"68.1) in 2000 to 83.0% (95% CI: 
82.1"83.9) in 2007, at an average rate of 2.7%, p<0.01. Patients who had their 
blood pressure controlled increased from 63.3%, 61.5%, and 72.5% in 2000 to 
83.2%, 80.7%, and 84.8% in 2007 for white, black and south Asian, 
respectively (Figure 17 and table 39). 
In the pre-QOF period the proportion of people having their blood pressure 
controlled increased annually (AOR: 1.05; 95% CI: 1.00"1.10, p<0.05), however 
this was not true for black and South Asian patients. The introduction of QOF 
was associated with an additional immediate improvement in the proportion of 
people having their blood pressure controlled (AOR: 1.40; 95% CI: 1.19"1.65, 
p<0.01) but black patients did not enjoy such benefits (AOR: 1.28; 95% CI: 
0.94"1.75). In the post-QOF years, annual improvements in the proportion of 
people having their blood pressure controlled were significantly more likely to 
achieve the blood pressure target when compared with the pre-QOF years 
(AOR: 1.18; 95% CI: 1.10"1.27, p<0.01) (Table 40). 
A trend of a significant reduction in mean systolic blood pressure was evident in 
white patients (-0.50 mm Hg; 95% CI: -0.93 to -0.08, p<0.01) but not in black 
(0.31 mm Hg; 95% CI: -0.20"0.83) or South Asian patients (0.42 mm Hg; 95% 
CI: -0.16"1.01) before QOF introduction. The introduction of QOF was 
associated with initial accelerated reductions in systolic blood pressure control in 
white (-2.12 mm Hg; 95% CI: -3.48 to -0.77, p<0.01) and black (-2.32 mm Hg; 
95% CI: -4.03 to -0.61, p<0.01) patients but not in South Asian patients (-1.08 
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mm Hg; 95% CI: -2.97"0.08). There was a significant sustained annual 
decrease in mean systolic blood pressure in black (-1.68 mm Hg; 95% CI: -2.41 
to -0.95) and South Asian patients (-1.79 mm Hg; 95% CI: -2.60 to -0.98), but 
not in White patients, in the post-QOF period relative to the pre-QOF trend 
(Table 41 and 43). 
A trend of significant reductions in mean diastolic blood pressure was evident in 
all three ethnic groups before QOF (p<0.01). The introduction of QOF was 
associated with an accelerated reduction in systolic blood pressure levels in 
white patients (-1.01 mm Hg; 95% CI: -1.79 to -0.24) but not in black or South 
Asian patients. There was no significant sustained annual reduction in mean 
diastolic blood pressure in any group in the post-QOF period relative to the pre-
QOF trend (Table 42 and 44). 
In 2000 no inequalities were evident for black and south Asian patients (AOR: 
0.89; 95% CI: 0.67"1.19 and 1.37; 95% CI: 0.96"1.95, respectively). However, 
at the end of the study period black patients were less likely to achieve the QOF 
target (AOR: 0.84%; 95% CI: 0.73"0.97) when compared to white patients. 
South Asian patients were more likely to achieve the QOF target when 
compared to white patients (AOR: 1.25; 95% CI: 1.07"1.46). 
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Figure 17 Annual percentages of patients with blood pressure !145/85 mm Hg
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Table 39 Percentage of patients with blood pressure !145/85 mm Hg 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 63.3 (59.4-67.3) 64.6 (61.2-67.9) 66.3 (63.5-69.1) 70.6 (68.2-73.0) 73.6 (71.5-75.7) 78.6 (76.8-80.3) 83.1 (81.6-84.6) 83.2 (81.8-84.6) 
Black 61.5 (56.8-66.1) 62.0 (57.8-66.1) 61.8 (58.1-65.4) 63.5 (60.2-66.7) 71.5 (68.8-74.2) 71.8 (69.3-74.3) 78.4 (76.3-80.5) 80.7 (78.8-82.6) 
South Asian 72.5 (67.8-77.2) 75.1 (70.9-79.2) 72.6 (68.9-76.2) 71.4 (68.0-74.7) 77.6 (74.9-80.2) 80.5 (78.1-82.8) 84.1 (82.1-86.1) 84.8 (83.0-86.7) 
ALL 65.7 (63.3-68.1) 66.7 (64.6-68.9) 67.1 (65.3-68.9) 69.1 (67.5-70.7) 74.1 (72.8-75.5) 77.3 (76.1-78.5) 82.2 (81.2-83.2) 83.0 (82.1-83.9) 
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Table 40 Interrupted time series of controlled blood pressure 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Blood pressure <=145/85, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.05 (1.00-1.10)* 1.14 (1.06-1.23)** 1.02 (0.93-1.12) 0.93 (0.84-1.04) 
Level change with QOF 1.40 (1.19-1.65)** 1.37 (1.06-1.77)* 1.28 (0.94-1.75) 1.68 (1.17-2.41)** 
Post-QOF trend 1.18 (1.10-1.27)** 1.04 (0.93-1.16) 1.32 (1.16-1.52)** 1.29 (1.10-1.51)** 
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Table 41 Annual mean value of systolic blood pressure 
 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 
140.5 (139.0-
142.1) 
139.8 (138.4-
141.1) 
140.3 (139.2-
141.4) 
138.3 (137.3-
139.3) 
136.7 (135.9-
137.5) 
135.1 (134.3-
135.8) 
133.3 (132.6-
134.0) 
132.9 (132.3-
133.5) 
Black 
141.1 (139.3-
142.8) 
141.4 (139.7-
143.0) 
142.7 (141.3-
144.1) 
141.4 (140.0-
142.7) 
138.3 (137.2-
139.3) 
138.2 (137.2-
139.2) 
135.8 (134.9-
136.6) 
135.0 (134.2-
135.8) 
South Asian 
135.6 (133.5-
137.6) 
135.8 (134.0-
137.6) 
137.4 (135.9-
139.0) 
136.3 (134.9-
137.6) 
135.2 (134.0-
136.4) 
134.2 (133.2-
135.2) 
132.2 (131.2-
133.1) 
131.0 (130.1-
131.9) 
ALL 
139.3 (138.3-
140.2) 
139.1 (138.3-
140.0) 
139.9 (139.2-
140.7) 
138.5 (137.9-
139.2) 
136.7 (136.2-
137.2) 
135.6 (135.2-
136.1) 
133.6 (133.2-
134.0) 
132.9 (132.5-
133.3) 
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Table 42 Annual mean value of diastolic blood pressure 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 80.2 (79.4-81.0) 79.9 (79.2-80.6) 79.2 (78.6-79.7) 78.6 (78.0-79.1) 77.6 (77.1-78.1) 76.9 (76.5-77.3) 75.8 (75.4-76.2) 76.0 (75.6-76.4) 
Black 82.6 (81.7-83.6) 81.8 (81.0-82.7) 81.7 (81.0-82.5) 80.4 (79.7-81.1) 79.2 (78.6-79.8) 79.1 (78.6-79.7) 78.0 (77.5-78.5) 77.7 (77.2-78.2) 
South Asian 81.4 (80.3-82.4) 80.3 (79.3-81.2) 78.6 (77.8-79.5) 78.5 (77.6-79.3) 77.4 (76.6-78.0) 76.6 (76.0-77.2) 76.1 (75.6-76.6) 75.6 (75.0-76.1) 
ALL 81.2 (80.7-81.7) 80.7 (80.2-81.2) 79.7 (79.4-80.1) 79.1 (78.8-79.5) 78.1 (77.8-78.4) 77.5 (77.2-77.8) 76.6 (76.3-76.8) 76.5 (76.3-76.8) 
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Table 43 Interrupted time series for systolic blood pressure levels 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 
 Systol ic blood pressure, mm Hg (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.03 (-0.31, 0.25) -0.50 (-0.93, -0.08)* 0.31 (-0.20, 0.83) 0.42 (-0.16, 1.01) 
Level change with QOF -1.95 (-2.87, -1.02)** -2.12 (-3.48, -0.77)** -2.32 (-4.03, -0.61)** -1.08 (-2.97, 0.08) 
Post-QOF trend -1.04 (-1.42, -0.64)** -0.21 (-0.80, 0.37) -1.68 (-2.41, -0.95)** -1.79 (-2.60, -0.98)** 
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Table 44 Interrupted time series for diastolic blood pressure levels 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Diastol ic blood pressure, mm Hg (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.84 (-1.00, -0.67)** -0.69 (-0.93, -0.44)** -0.84 (-1.14, -0.54)** -1.06 (-1.41, -0.72)** 
Level change with QOF -0.51 (-1.05, 0.01) -1.01 (-1.79, -0.24)* -0.33 (-1.32, 0.65) 0.20 (-0.90, 1.30) 
Post-QOF trend 0.19 (-0.03, 0.41) 0.10 (-0.23, 0.43) 0.12 (-0.30, 0.54) 0.40 (-0.07, 0.87) 
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Achievement of all of three intermediate outcome targets: 
The percentage of patients’ achieving all the three intermediate outcome 
indicators, increased from 1.4% (95% CI: 0.9!1.8) in 2000 to 15.6% (14.8!16.4) 
in 2007, at an average rate of 2.8%, p<0.01. Patients who achieved the target 
for the three intermediate outcomes increased from 1.2%, 1.6%, and 0.8% in 
2000 to 17.5%, 15.6%, and 15.6% in 2007 for white, black and South Asian, 
respectively (Figure 18 and table 45). 
In the pre-QOF period, the proportion of people having all the three intermediate 
outcomes controlled increased annually (AOR: 1.80; 95% CI: 1.64!1.97, 
p<0.01). The introduction of QOF was not associated with an additional 
immediate improvement in the proportion of people having all the three 
intermediate outcome indicators controlled (AOR: 1.17; 95% CI: 0.93!1.46). In 
the post-QOF years, patients were less likely to achieve all the three intermediate 
outcome indicators when compared with the pre-QOF years (AOR: 0.63; 95% 
CI: 0.56!0.70, p<0.01) (Table 46). This was true for white and black but not 
South Asian patients (AOR: 0.80; 95% CI: 0.64!1.00). 
There were no inequalities evident in 2000 in the achievement of all three 
intermediate outcome targets; however, in 2007 South Asian patients were less 
likely to have all three intermediate outcome targets controlled when compared 
to the white group (AOR: 0.79; 95% CI: 0.65!0.95). 
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Figure 18 Annual percentages of patents that achieved all the three intermediate outcomes 
! "#$!
!
Table 45 Annual percentages of patients achieving all three intermediate outcomes 
Values in brackets are 95% Confidence Interval !!
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 1.2 (0.6!1.9) 2.5 (1.7!3.4) 6.1 (4.9!7.3) 8.9 (7.6!10.2) 12.3 (10.9!13.7) 14.8 (13.4!16.3) 20.3 (18.8!21.8) 17.5 (16.2!18.8) 
Black 1.6 (0.6!2.5) 3.3 (2.1!4.5) 3.3 (2.1!4.4) 7.1 (5.6!8.6) 7.8 (6.3!9.3) 12.5 (10.7!14.2) 15.3 (13.5!17.1) 14.6 (13.0!16.3) 
South Asian 0.8 (0.1!1.5) 2.8 (1.7!4.0) 4.7 (3.3!6.1) 4.9 (3.6!6.2) 10.9 (9.1!12.7) 10.4 (8.7!12.1) 18.0 (16.0–19.9) 15.6 (13.8!17.3) 
ALL 1.4 (0.9!1.8) 2.7 (2.1!3.3) 4.7 (4.0!5.3) 7.2 (6.5!8.0) 10.5 (9.6!11.3) 12.8 (11.9!13.6) 17.9 (16.9!18.8) 15.6 (14.8!16.4) 
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Table 46 Interrupted time series for the achievement of all three intermediate outcomes 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 Al l  three intermediate outcomes, OR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.80 (1.64!1.97)** 2.02 (1.76!2.33)** 1.70 (1.42!2.04)** 1.57 (1.30!1.90)** 
Level change with QOF 1.17 (0.93!1.46) 0.95 (0.68!1.31) 1.25 (0.79!1.97) 1.41 (0.86!2.29) 
Post-QOF trend 0.63 (0.56!0.70)** 0.55 (0.47!0.65)** 0.65 (0.53!0.81)** 0.80 (0.64!1.00) 
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5.2.3 Prescribing data 
 
Oral Hypoglycemic Agents (OHAs): 
The percentage of patients’ prescribed OHAs increased from 30.1% (95% CI: 
28.4!31.8) in 2000 to 58.9% (95% CI: 57.8!60.0) in 2007, at an average rate of 
4.6%, p<0.01. Patients who had OHAs prescribed increased from 26.8%, 
37.5%, and 29.2% in 2000 to 52.3%, 65.8%, and 67.5% in 2007 for white, 
black and South Asian, respectively (Figure 19 and table 47).  
In the pre-QOF period, the proportion of people having OHAs prescribed in their 
record increased annually (AOR: 1.76; 95% CI: 1.67!1.86, p<0.01). The 
introduction of QOF was associated with an immediate additional improvement 
in the proportion of people having OHAs prescribed (AOR: 1.42; 95% CI: 
1.18!1.70, p<0.01) but South Asian patients did not enjoy similar shift (AOR: 
1.23; 95% CI: 0.86!1.76). In the post-QOF years, annual improvements in the 
proportion of patients being prescribed OHAs were significantly lower than the 
pre-QOF years (AOR: 0.74; 95% CI: 0.68!0.80, p<0.01) (Table 48). 
Black patients were more likely to be prescribed OHAs in 2000 (AOR: 1.60; 95% 
CI: 1.29!1.98) when compared to white group and the south Asian group had 
similar prescribing rates (AOR: 1.06; 95% CI: 0.84!1.35). However, in 2007 
black and South Asian groups were more likely to be prescribed OHAs (AOR: 
1.71; 95% CI: 1.51!1.94 and AOR: 1.83; 95% CI: 1.59!2.09, respectively), 
when compared to the white group. 
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Figure 19 Annual percentage of patients prescribed OHAs
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Table 47 Percentage of patients prescribed OHAs 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 26.8 (24.1-29.4) 32.2 (29.7-34.7) 35.5 (33.1-37.8) 40.0 (37.7-42.2) 44.9 (42.8-47.0) 49.2 (47.2-51.2) 51.5 (49.7-53.4) 52.3 (50.6-54.1) 
Black 37.5 (33.8-41.1) 42.9 (39.5-46.4) 46.7 (43.5-49.8) 49.5 (46.5-52.4) 56.0 (53.2-58.7) 60.5 (57.9-63.0) 64.5 (62.1-66.8) 65.8 (63.6-68.0) 
South Asian 29.2 (25.8-32.6) 38.3 (35.0-41.6) 41.7 (38.6-44.9) 46.8 (43.8-49.8) 52.2 (49.4-55.0) 59.8 (57.2-62.5) 64.0 (61.5-66.4) 67.5 (65.3-69.8) 
ALL 30.1 (28.4-31.8) 36.7 (35.1-38.4) 39.7 (38.2-41.3) 43.8 (42.3-45.3) 49.3 (48.0-50.7) 54.3 (53.0-55.6) 57.4 (56.2-58.6) 58.9 (57.8-60.0) 
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Table 48 Interrupted time series for prescribed OHAs 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 OHA prescribed, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 1.76 (1.67-1.86)** 1.81 (1.65-1.98)** 1.61 (1.45-1.78)** 1.94 (1.75-2.16)** 
Level change with QOF 1.42 (1.18-1.70)** 1.38 (1.03-1.85)* 1.54 (1.08-2.19)* 1.23 (0.86-1.76) 
Post-QOF trend 0.74 (0.68-080)** 0.67 (0.59-0.77)** 0.87 (0.74-1.01) 0.77 (0.66-0.90)** 
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Insulin: 
The percentage of patients’ prescribed Insulin increased from 15.4% (95% CI: 
14.0!16.7) in 2000 to 19.9% (95% CI: 19.0!20.8) in 2007, at an average rate of 
0.5%, p<0.01. Patients who had Insulin prescribed increased from 18.7%, 
16.1%, and 10.3% in 2000 to 22.5%, 22.1%, and 16.2% in 2007 for white, 
black and South Asian, respectively (Figure 20 and table 49). 
In the pre-QOF period the proportion of people having Insulin prescribed in their 
record increased annually (AOR: 2.40; 95% CI: 2.16!2.67, p<0.01). The 
introduction of QOF was not associated with an additional immediate 
improvement in the proportion of people having Insulin prescribed (AOR: 0.83; 
95% CI: 0.58!1.19). In the post-QOF years, annual improvements in the 
proportion of patients having an insulin prescription was significantly lower than 
that during pre-QOF years (AOR: 1.10; 95% CI: 0.93!1.20) except for white 
patients (AOR: 1.67; 95% CI: 1.28!2.17) (Table 50). 
South Asian patients were less likely to be prescribed insulin in 2000 (AOR: 
0.47; 95% CI: 0.34!0.65) when compared to the white group. These inequalities 
were not abolished at the end of the study period (AOR: 0.70; 95% CI: 
0.59!0.83). Black patients had a similar rate of insulin prescribing in 2000 and 
2007, when compared to the white group (AOR: 0.80; 95% CI: 0.61!1.05 and 
AOR: 0.87; 95% CI: 0.75!1.01).
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Figure 20 Annual percentage of patients prescribed insulin
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Table 49 Percentage of patients prescribed insulin 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 18.7 (16.4-21.0) 18.9 (16.8-21.0) 17.9 (16.0-19.8) 17.9 (16.2-19.7) 18.1 (16.5-19.8) 18.8 (17.2-20.4) 20.1 (18.6-21.6) 22.5 (21.0-23.9) 
Black 16.1 (13.3-18.8) 16.8 (14.3-19.4) 16.8 (14.4-19.1) 18.2 (15.9-20.5) 18.3 (16.1-20.4) 18.9 (16.9-21.0) 19.7 (17.7-21.7) 20.1 (18.3-22.0) 
South Asian 10.3 (8.0-12.5) 11.7 (9.5-13.9) 11.9 (9.8-13.9) 13.1 (11.1-15.1) 14.4 (12.4-16.4) 15.5 (13.5-17.4) 15.8 (13.9-17.7) 16.2 (14.4-17.9) 
ALL 15.4 (14.0-16.7) 16.3 (15.0-17.5) 15.8 (14.7-17.0) 16.7 (15.6-17.8) 17.1 (16.1-18.2) 17.5 (16.5-18.5) 18.5 (17.6-19.5) 19.9 (19.0-20.8) 
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Table 50 Interrupted time series for prescribed insulin 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Insul in prescribed, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 2.40 (2.16-2.67)** 2.38 (2.02-2.80)** 2.77 (2.23-3.45)** 2.15 (1.68-2.73)** 
Level change with QOF 0.83 (0.58-1.19) 0.64 (0.36-1.14) 1.28 (0.62-2.66) 1.45 (0.70-3.01) 
Post-QOF trend 1.10 (0.93-1.30) 1.67 (1.28-2.17)** 0.70 (0.51-0.98)* 0.80 (0.58-1.10) 
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Antihypertensive medications:  
The percentage of patients’ prescribed antihypertensive medication (AHT) 
increased from 43.5% (95% CI: 41.6!45.3) in 2000 to 68.8% (95% CI: 
67.7!69.8) in 2007, at an average rate of 4.1%, p<0.01. Patients who had AHT 
medication prescribed to them increased from 44.5%, 51.3%, and 36.1% in 
2000 to 69.3%, 73.5%, and 70.2% in 2007 for white, black and South Asian, 
respectively (Figure 21 and table 51).  
In the pre-QOF period the proportion of people having antihypertensive 
medications prescribed in their record increased annually (AOR: 2.40; 95% CI: 
2.25!2.60, p<0.01). The introduction of QOF was not associated with an 
additional immediate improvement in the proportion of people having any AHT 
medication prescription (AOR: 1.26; 95% CI: 0.98!1.61). In the post-QOF years, 
annual improvements in the proportion of people having any AHT medication 
prescribed was significantly lower than that during the pre-QOF (AOR: 0.98; 
95% CI: 0.98!1.10), this was true for white, black and South Asian patients 
(Table 52). 
South Asian patients were less likely to be prescribed AHT medication in 2000 
(AOR: 0.61; 95% CI: 0.49 !0.76) when compared to the white group. However, 
these inequalities were abolished at the end of the study period (AOR: 1.00; 
95% CI: 0.87!1.16). Black patients were more likely to be prescribed AHT 
medication in 2000 and 2007, when compared to the white group (AOR: 1.25; 
95% CI: 1.03!1.53 and AOR: 1.24; 95% CI: 1.08!1.42, respectively).
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Figure 21 Annual percentages of patients prescribed AHT medications 
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Table 51 Percentage of patients prescribed AHT medications 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 44.5 (41.6-47.5) 48.1 (45.4-50.8) 51.4 (48.9-53.8) 56.9 (54.6-59.1) 61.6 (59.5-63.6) 65.3 (63.4-67.2) 67.1 (65.3-68.8) 69.3 (67.7-70.9) 
Black 51.3 (47.5-55.0) 55.9 (52.6-59.3) 59.2 (56.1-62.4) 61.6 (58.7-64.5) 66.9 (64.3-69.5) 69.4 (67.0-71.8) 72.3 (70.1-74.5) 73.5 (71.5-75.5) 
South Asian 36.1 (32.5-39.7) 43.8 (40.4-47.2) 48.8 (45.6-52.0) 51.5 (48.4-54.5) 56.6 (53.8-59.4) 62.6 (59.9-65.2) 67.5 (65.1-69.9) 70.2 (68.0-72.5) 
ALL 43.5 (41.6-45.3) 48.4 (46.7-50.1) 52.0 (50.4-53.5) 55.7 (54.2-57.1) 60.3 (58.9-61.6) 64.1 (62.9-65.3) 67.1 (66.0-68.3) 68.8 (67.7-69.8) 
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Table 52 Interrupted time series for prescribed AHT medications 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 AHT prescribed, AOR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 2.40 (2.25-2.60)** 2.59 (2.29-2.93)** 2.32 (2.01-2.68)** 2.46 (2.12-2.85)** 
Level change with QOF 1.26 (0.98-1.61) 1.30 (0.86-1.97) 1.28 (0.76-2.15) 1.13 (0.72-1.80) 
Post-QOF trend 0.98 (0.88-1.10) 0.96 (0.79-1.17) 1.07 (0.85-1.36) 1.00 (0.81-1.24) 
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Lipid-lowering medications: 
The percentage of patients’ prescribed any lipid-lowering agent increased from 
15.3% (95% CI: 14.0!16.7) in 2000 to 67.4% (95% CI: 66.4!68.5) in 2007, at 
an average rate of 8.0%, p<0.01. Patients who had lipid-lowering medication 
prescribed increased from 18.1%, 11.2%, and 16.2% in 2000 to 68.6%, 66.7%, 
and 71.3% in 2007 for white, black and South Asian, respectively (Figure 22 and 
table 53).  
In the pre-QOF period the proportion of people having lipid-lowering 
medications prescribed in their record increased annually (AOR: 3.93; 95% CI: 
3.59!4.31, p<0.01). The introduction of QOF was not associated with an 
additional immediate improvement in the proportion of people having any lipid-
lowering medication prescribed (AOR: 2.32; 95% CI: 1.84!2.92). In the post-
QOF years, annual improvements in the proportion of people having any lipid-
lowering medication prescribed was significantly lower than that during pre-QOF 
years (AOR: 0.66; 95% CI: 0.59!0.74, p<0.01), this was true for white, black 
and South Asian patients (Table 54).  
Black patients were less likely to be prescribed a lipid lowering medication in 
2000 (AOR: 0.56; 95% CI: 0.42 !0.75) when compared to the white group. 
However, these inequalities were attenuated at the end of the study period but 
not abolished (AOR: 0.96; 95% CI: 0.84!1.10). Relative to white patients, south 
Asian patients had similar prescribing record of lipid lowering medication in 2000 
(AOR: 0.82; 95%: 0.62!1.09) that were abolished in 2007 but did not reach 
significant levels (AOR: 1.12; 95% CI: 0.97!1.30).
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Figure 22 Annual percentages of patients prescribed any lipid lowering medication 
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Table 53 Percentage of patients prescribed any lipid lowering medications 
Values in brackets are 95% Confidence Interval 
 
Ethnicity 2000 2001 2002 2003 2004 2005 2006 2007 
White 18.1 (15.8-20.3) 23.6 (21.3-25.8) 31.3 (29.0-33.6) 40.0 (37.7-42.2) 50.9 (48.7-53.0) 60.2 (58.2-62.2) 66.3 (64.5-68.1) 68.8 (67.2-70.4) 
Black 11.2 (8.9-13.6) 14.8 (12.4-17.2) 22.3 (19.6-24.9) 30.0 (27.3-32.7) 42.0 (39.3-44.8) 53.8 (51.2-56.4) 62.1 (59.7-64.5) 66.7 (59.7-64.5) 
South Asian 16.2 (13.4-18.9) 22.1 (19.2-24.9) 30.2 (27.3-33.2) 37.4 (34.5-40.3) 50.9 (48.0-53.7) 61.4 (58.8-64.0) 68.1 (65.7-70.5) 71.3 (69.2-73.5) 
ALL 15.3 (14.0-16.7) 20.8 (19.4-22.1) 27.9 (26.5-29.3) 35.9 (34.5-37.3) 47.6 (46.3-49.0) 57.5 (56.2-58.8) 64.3 (63.2-65.5) 67.4 (66.4-68.5) 
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Table 54 Interrupted time series for any lipid lowering prescribed 
Note: Values are adjusted for age, sex, SES, duration of diabetes, and number of comorbidities, and clustering. 
*p<0.05, **p<0.01 
 
 Lipid lowering prescribed, OR (95% CI) 
 ALL White Black South Asian 
Pre-QOF 3.93 (3.59-4.31)** 4.46 (3.79-5.26)** 4.23 (3.50-5.12)** 3.39 (2.89-3.99)** 
Level change with QOF 2.32 (1.84-2.92)** 2.04 (1.40-2.98)** 2.15 (1.36-3.38)** 2.87 (1.84-4.49)** 
Post-QOF trend 0.66 (0.59-0.74)** 0.61 (0.51-0.74)** 0.67 (0.54-0.84)** 0.71 (058-0.88) 
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6.0 Impact of pay for performance on diabetes intermediate 
outcomes in ethnic minority patients with and without 
comorbid medical conditions: cross sectional study 
 
A key objective of my study is to assess the impact of the quality and outcome 
framework on ethnic minority patients with and without comorbid medical 
conditions. Because of the sample size, I had to limit my analysis to 2007, 
however acknowledging the limitation of this in the discussion section of my 
thesis. 
 
6.1 Data analysis 
 
I divided comorbid conditions into cardiovascular conditions with concordant 
management goals (hypertension, heart failure, stroke, atrial fibrillation, CHD, 
CKD) and other conditions with discordant management goals (COPD, asthma, 
depression) and calculated the number of comorbidities for each patient.  
I calculated mean HbA1c, systolic and diastolic blood pressure and total 
cholesterol and the percentage of patients achieving the quality and outcome 
framework intermediate outcome target (HbA1c!7.5%, blood pressure !145/85 
mm Hg, cholesterol !5.2 mmol/l) by ethnic group and comorbidity status. 
Regression analyses were undertaken to examine associations between 
ethnicity, number of comorbidities and each of the outcome measures while 
controlling for age, sex, duration of illness, BMI and neighbourhood SES score. 
To adjust for clustering of patients within practices, I fitted a random effects 
model for all the regression analysis. I included an interaction terms in each 
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model to examine whether association between comorbidity and the outcome 
measures varied between ethnic groups. 
 
6.2 Results !
Overall 52.2% had hypertension, 14.3% had depression, 12.9% had CHD, 
12.1% had COPD, 10.4% had asthma, 6.4% had experienced a stroke, 4.6% 
had CKD, 3.4% had atrial fibrillation, and 2.7% had heart failure. Men comprised 
a larger proportion of patients than women to have concordant comorbid 
medical conditions (60.1% vs. 57.8%), but this was reversed in discordant 
comorbid medical conditions (7.1% vs. 11.3%). Black patients were more likely 
to have at least one concordant comorbid condition than white or south Asian 
patients (65.5% vs. 59.4% vs. 57.6%). White patients were more likely to have 
at least one discordant comorbid condition compared to South Asian or black 
patients (11.0% vs. 7.7% vs. 6.0%). 
Table 55 Sample characteristics (2007) 
 White Black South Asian 
N 3,181 1,811 1,653 
Age: median (IQR) 64 (50-72) 64 (51-72) 60 (51-69) 
Female: % 47.4 54.1 46.5 
BMI: median (IQR) 29.2 (25.6-33.7) 29.1 (26.1-33.1) 27.0 (24.3-30.4) 
Diabetes duration: median (IQR) 5 (2-8) 5 (2-9) 6 (2-9) 
Comorbidity: n (%)    
No of comorbidity 940 (29.6)  518 (28.6) 574 (34.7)  
1 concordant condition   1,271 (40.0)  914 (50.5)  647 (39.2)  
"2 concordant condition 617 (19.4)  271 (15.0)  304 (18.4)  
"1 discordant condition 351 (11.0)      108 (6.0) 127 (7.7) 
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HbA1c management: 
Black and south Asian patients were significantly less likely than white patients 
to achieve the HbA1c target of !7.5% (AOR, 0.82; 95% CI 0.71-0.94 and AOR, 
0.72; 95% CI 0.61-0.85, respectively) (Tables 56 and 59). Compared to white 
patients, mean HbA1c was significantly higher among black (0.3%, p<0.01) and 
south Asian patients (0.2%, p<0.01) (Table 60). 
Patients with concordant comorbid conditions had significantly lower mean 
HbA1c and were significantly more likely to achieve the HbA1c target compared 
to those without (AOR, 1.20; 95% CI 1.03-1.39 for patients with 1 concordant 
comorbid condition). Patients with discordant conditions had similar HbA1c 
control as those without co-morbidity (AOR, 1.18; 95% CI 0.93-1.49). No 
significant interaction between ethnicity and comorbidity was found. 
 
Table 56 HbA1c control by ethnicity and number of comorbidities 
 No comorbidity 1 concordant 
condition 
"2 concordant 
conditions 
"1 discordant 
conditions 
HbA1c, Mean (SE), %     
White 7.8 (0.07) 7.4 (0.04) 7.3 (0.06) 7.7 (0.12) 
Black 8.3 (0.11) 7.7 (0.06) 7.5 (0.09) 7.6 (0.18) 
South Asian 7.9 (0.08) 7.7 (0.06) 7.6 (0.07) 8.1 (0.18) 
HbA1c!7.5%     
White 37.5 49.5 52.5 41.6 
Black 33.8 40.5 45.8 48.1 
South Asian 34.8 36.0 35.6 31.0 
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Blood pressure: 
Black patients were significantly less likely to achieve the blood pressure 
treatment target (AOR, 0.84; 95% CI: 0.73-0.97) than white patients. However, 
South Asian patients were more likely to reach the management target for blood 
pressure control (AOR, 1.25; 95% CI: 1.07-1.46) (Table 57 and 59). 
Patients with concordant comorbid conditions were significantly less likely to 
achieve the blood pressure target compared to patients without any comorbidity 
(AOR, 0.62; 95% CI: 0.53-0.71 for patients with 1 concordant comorbid 
condition). Patients with discordant conditions had similar blood pressure 
control to those without any comorbidity (AOR, 1.19; 95% CI: 0.96-1.48) (Table 
57 and 59). 
When white patients with no comorbidities were the reference group, mean 
systolic blood pressure was higher in white patients with one concordant 
comorbidity (4.6 mm Hg, p<0.01) but similar in those with two or more 
concordant comorbidities. Relative to white patients without comorbidity, mean 
systolic blood pressure was similar among black patients without comorbidity 
but was significantly higher among black patients with 1 (5.9 mm Hg, p<0.01) 
and >2  concordant comorbid conditions (6.2 mm Hg, p < 0.01). Relative to 
white patients without comorbidity, mean systolic blood pressure was 
significantly lower among south Asian patients without comorbidity but was 
similar among south Asian patients with concordant comorbid conditions. No 
interaction effect was found for achievement of blood pressure target or diastolic 
blood pressure (p>0.05) (Table 60). 
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Table 57 Blood pressure control by ethnicity and number of comorbidities 
 No 
comorbidity 
1 concordant 
condition 
"2 concordant 
conditions 
"1 discordant 
conditions 
Systolic, mean (SE),mm Hg     
White 128.3 (0.5) 136.4 (0.4) 134.4 (0.7) 127.3 (0.9) 
Black 129.8 (0.7) 137.4 (0.5) 138.6 (1.1) 126.5 (1.4) 
South Asian 126.9 (0.7) 133.9 (0.7) 133.6 (1.1) 125.5 (1.5) 
Diastolic, mean (SE),mm Hg     
White 76.7 (0.3) 76.7 (0.3) 73.4 (0.4) 76.4 (0.5) 
Black 77.8 (0.4) 78.4 (0.3) 75.6 (0.7) 76.5 (0.9) 
South Asian 76.2 (0.4) 76.7 (0.4) 72.4 (0.6) 74.6 (0.8) 
BP!145/85 mmHg, %     
White 45.9 30.4 36.8 49.2 
Black 44.6 26.5 33.0 48.9 
South Asian 53.0 40.7 42.6 56.5 
 
Cholesterol: 
South Asian patients had significantly lower mean cholesterol levels and were 
significantly more likely to achieve the cholesterol treatment target than white 
patients (AOR, 1.36; 95% CI 1.11-1.66). No significant difference was found 
between black and white patients in achievement of cholesterol target (Table 58, 
59 and 60). 
Patients with concordant comorbid conditions had significantly lower mean 
cholesterol levels and were significantly more likely to achieve the cholesterol 
target compared to patients without comorbidity  (AOR, 1.40; 95% CI 1.17-1.68 
for patients with 1 concordant comorbid condition). Patients with discordant 
conditions had similar achievements in cholesterol target compared to those 
without comorbidities (AOR, 1.01; 95% CI 0.77-1.32). No significant interaction 
was found between ethnicity and comorbidities (Table 58, 59 and 60). 
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Table 58 Cholesterol control by ethnicity and number of comorbidities 
 No 
comorbidity 
1 concordant 
condition 
"2 concordant 
conditions 
"1 discordant 
conditions 
Cholesterol, mean (SE), 
mmol/L 
    
White 4.6 (0.04) 4.4 (0.03) 4.1 (0.04) 4.5 (0.06) 
Black 4.5 (0.05) 4.4 (0.03) 4.2 (0.06) 4.6 (0.11) 
South Asian 4.5 (0.06) 4.1 (0.03) 3.9 (0.06) 4.6 (0.11) 
Cholesterol!5.0 mmol/L, %     
White 75.9 82.2 87.9 77.1 
Black 77.4 83.5 86.5 76.9 
South Asian 79.0 87.3 90.7 75.0 
 
! "#)!
 
Table 59 Odds of achieving intermediate outcome targets by ethnicity and 
number of comorbidities 
Measure HbA1c !7.5 Cholesterol!5.0  BP!145/85 All targets 
Ethnic group: AOR (95% CI) AOR (95% CI) AOR (95% CI) AOR (95% CI) 
White (ref) 1.00  1.00  1.00  1.00  
Black 0.82 (0.71-0.94) 1.14 (0.95-1.37) 0.84 (0.73-0.97) 0.79 (0.65"0.95) 
South Asian 0.72 (0.61-0.85) 1.36 (1.11-1.66) 1.25 (1.07-1.46) 1.07 (0.85-1.33) 
Number of comorbidites:     
No comorbidity (ref) 1.00  1.00  1.00  1.00  
1 concordant condition 1.20 (1.03-1.39) 1.40 (1.17-1.68) 0.62 (0.53-0.71) 0.97 (0.79-1.20) 
"2 concordant condition 1.28 (1.06-1.55) 1.81 (1.40-2.33) 0.78 (0.65-0.94) 1.24 (0.96-1.60) 
"1 discordant condition 1.18 (0.93-1.49) 1.01 (0.77-1.32) 1.19 (0.96-1.48) 1.25 (0.92-1.70) 
ref = reference group; BP = blood pressure 
Note: Values are adjusted for age, sex, diabetes duration, BMI, socioeconomic status and practice level 
clustering. 
Note: All interactions between ethnicity and comorbidity were not significant (p>0.05) 
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Table 60 Mean differences in intermediate outcomes by ethnicity and number 
of comorbidites 
Measure Systolic† Diastolic‡ Cholesterol‡ HbA1c‡ 
Ethnic group (comorbidity) Mean difference    
  White (0)  0     
  White (1 concordant)  4.6 (3.0,6.1)**    
  White ("2 concordant)  1.5 (-0.3,3.3)    
  White ("1 discordant) -1.4 (-3.5,0.8)    
  Black (0)  0.9 (-0.9,2.9)    
  Black (1 concordant)  5.9 (4.3,7.6)**    
  Black ("2 concordant)  6.2 (3.8,8.5)**    
  Black ("1 discordant) -3.1 (-6.7,0.3)    
  SA (0) -2.3 (-4.2,-0.3)*    
  SA (1 concordant)  2.6 (-0.5,5.3)    
  SA ("2 concordant)  1.4 (-0.8,3.6)    
  SA ("1 discordant) -4.2 (-7.5,-0.9)*    
Ethnic group:     
  White (ref)  0 0 0 
  Black  1.3 (0.7,1.9)** -0.04 (-0.1,0.02) 0.3 (0.1,0.4)** 
  South Asian  -0.5 (-1.2,0.2) -0.2 (-0.2,-0.1)** 0.2 (0.04,0.3)** 
Number of comorbidites:     
  No comorbidity (ref)  0 0 0 
  1 concordant condition  1.5 (0.9,2.1)** -0.1 (-0.2,-0.1)** -0.2 (-0.3,-0.1)** 
  "2 concordant condition  -0.1 (-0.9,0.6) -0.3 (-0.4,-0.2)** -0.2 (-0.4,-0.1)** 
  "1 discordant condition  -1.0 (-2.0,-0.6)* -0.01 (-0.1,0.01) -0.1 (-0.3,0.1) 
ref = reference group 
Note: Values are adjusted for age, sex, diabetes duration, BMI, socioeconomic status and practice level 
clustering. 
†Interaction between ethnicity and comorbidity significant (p=0.03). 
‡ Interaction between ethnicity and comorbidity not significant (p>0.05). 
*P<0.05, **P<0.01 !
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7.0 Discussion !
7.1 Main findings 
The quality of diabetes care, as measured by the QOF indicators, has improved 
substantially throughout the study period; however, QOF had a different impact 
on process and intermediate outcomes. The introduction of QOF was 
associated with an accelerated improvement in the recording of nearly all of the 
process indicators but annual improvements in the proportion of patients having 
a recording in some of the process indicators were significantly lower than that 
during the pre-QOF years. However, inequalities that were present before QOF 
in some of the process indicators have largely disappeared at the end of the 
study period. For example, South Asian patients were less likely to have a blood 
pressure recording, when compared to white patients, before QOF introduction 
but at the end of the study period these differences had disappeared. One 
exception is the smoking advice indicator where black and South Asian patients 
were less likely to have a smoking advice compared to the white group at the 
end of the study period. 
There was a trend of increasing prescribing of OHAs, insulin, AHT medications, 
and lipid lowering agents in the years before QOF. The introduction of QOF was 
not associated with additional increases in the level of prescribing. Inequalities in 
the prescribing levels of insulin seen before QOF remained present at the end of 
the study period. 
My analysis indicates an underlying trend of general improvements in HbA1c, 
cholesterol and blood pressure control predating QOF. The introduction of QOF 
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was associated with initial accelerated improvements in systolic blood pressure 
in white and black patients but this was only sustained in black patients. Initial 
improvements in diastolic blood pressure in white patients and in cholesterol in 
black and white patients were not sustained in the post-QOF period. There was 
no beneficial impact of QOF on HbA1c in any ethnic group. Existing inequalities 
in risk factor control remained largely intact at the end of the study period. 
Further, the QOF had no significant impact on the achievement of a composite 
of all the three outcome indicators. At the end of the study period, South Asian 
patients were less likely to achieve a composite of all the three outcome 
indicators when compared to the white group, a situation that was not evident 
before QOF. 
Findings from the cross sectional study suggest that patients with concordant 
comorbid conditions are more likely to reach the treatment targets for HbA1c 
and cholesterol, but less likely to reach the blood pressure target, compared to 
patients with no comorbidity. Ethnic inequalities in blood pressure management 
were more pronounced among patients with cardiovascular comorbidities. For 
instance, black patients with one, two or more concordant medical conditions 
had higher systolic blood pressure when compared to white patients without 
comorbidity. People with discordant conditions, such as asthma and 
depression, were not better managed than those without comorbidity. 
7.2 Previous research 
The improvements I found in diabetes care before the introduction of QOF is 
similar to findings published elsewhere (133). Few studies have examined the 
impact of pay for performance on health care inequalities especially on ethnic 
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inequalities. A recent systematic review in the United States found one study 
that assessed the impact of public reporting of Coronary Artery Bypass Graft 
(CABG) on ethnic inequalities but no studies relevant to the impact of pay for 
performance were found (232). The study found that the release of CABG report 
card widened the white versus black differences by 2.3 percentage points and 
2.5 percentage points in white versus Hispanic differences in receiving CABG. In 
the comparison group no significant differences were found between white, 
black and Hispanic patients in CABG use (275). Findings from my systematic 
review suggest that the impact of pay for performance on inequalities in chronic 
disease management is limited. I found only one study that used an interrupted 
time series design to estimate the effect of QOF on ethnic inequalities, which 
found initial widening in inequalities in HbA1c and blood management control 
(234). However, process indicators and cholesterol outcome were not examined 
in this study. Furthermore, only one measurement point was examined after 
QOF. My work examines the longer-term impact of QOF on diabetes care 
management using a segmented time-series methodology. I found that QOF 
had no significant effect on HbA1c levels; these actually reversed slightly during 
the post-QOF years, which is in keeping with previous findings. For example, 
Vamos et al, found that the annual increase seen in HbA1c before QOF reversed 
to a decline of 0.2% in the year after QOF (42, 276).  
Campbell et al (203), found significant additional improvements in the level of 
performance for diabetes care associated with the introduction of QOF; 
however, it is difficult to compare it with my findings as they performed their 
analysis using a summary indicator and not on individual indicators. 
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Furthermore, their analysis used practice level data and did not adjust for various 
patient level covariates. Calvert et al., found a small improvement in HbA1c 
target level of !7.5% and no improvement was evident for a target level of 
!10%. However, the authors did not use a segmented time series analysis (204). 
Serumaga et al (277), did not find any significant impact of QOF among 
hypertensive patients in the UK. Furthermore, the authors did not find significant 
decline in blood pressure control over time (from 2000 to 2007). This is in 
contrast to findings from national (278) and international studies (129).  
The decrease in the proportion of patients meeting the targets seen in the post-
QOF years can be attributable to ceiling effect or the lack of financial incentives. 
Practices that reached a certain threshold may not be inclined to take on 
additional work (279). This conclusion has also been reached by others (203). 
 
Few studies have examined the interaction between ethnicity and comorbidity in 
inequalities in diabetes care and to my knowledge no study has previously been 
undertaken in the UK. My finding that patients with comorbidity were less likely 
to have a controlled blood pressure is consistent with a previous study in the UK 
(42). This finding was unanticipated given that blood pressure control is 
incentivised for four of the six cardiovascular conditions examined in this study 
(stroke, CHD, hypertension, CKD) in the QOF. This finding may be partly 
explained by the much poorer blood pressure control among black patients with 
comorbidity. This suggests that there is an important additional inequality in care 
between ethnic groups with cardiovascular comorbidity that has not been 
addressed by the QOF.  
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Patients with discordant comorbid conditions did not have better care than 
patients without comorbidity; this finding suggest that more frequent contact 
with health services by itself does not improve the management of diabetes 
unless these conditions have concordant treatment goals. Data from the United 
States suggests that the number of patients’ encounters with health care 
providers did not have an effect on the achievement of hypertension treatment 
goals with discordant or concordant conditions (280). I was not able to adjust for 
the number of patient visits in my cross sectional analysis. 
Previous work in Wandsworth found that the presence of cardiovascular 
comorbidity was associated with better blood pressure control among white 
hypertensive patient when compared to white patients without comorbidity. 
However, similar association was not evident in black patients with 
cardiovascular comorbidities (239). In Italy, patients with low level of comorbidity 
benefited more from glycaemic control compared to those with high level of 
comorbidity (51).  
My study is in keeping with other studies that have evaluated ethnic inequalities 
in diabetes care in the UK. For example, a previous analysis in the Wandsworth 
area, found poor HbA1c control in south Asian and black patients compared to 
white (258) and analysis of the HSE found poor glycaemic control in Pakistani 
patients but not in the Indian group or the black group, this findings might be 
explained by the sample size of the study (136).  
Ethnic inequalities in diabetes care are a persistent feature in developed 
countries. Analysis of the National Health and Nutrition Examination Survey 
(NHANES) in the United States found that non-Hispanic black patients with 
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diabetes were less likely to have a controlled glycaemic levels (AOR: 0.57; 95% 
CI: 0.39"0.84, p<0.05) when compared to non-Hispanic Whites (281). Similarly, 
over a period of eight years (from 1999"2006) black patients had lower rate of 
glycaemic control (-16.5%, p<0.001) when compared to white patients (282). A 
longitudinal study of blood pressure control from 1996 to 2006 in the Veterans 
Affairs Health System in the United States found non-Hispanic black and 
Hispanic patients to be more likely to have a poor control of blood pressure 
when compared to white patients (AOR: 1.5; 95% CI: 1.3"1.7 and AOR: 1.5; 
95% CI: 1.4"1.9, respectively) (283). A systematic review conducted in the 
United States found higher levels of HbA1c of 0.5% in Hispanic patients than 
non-Hispanic whites (284). In Norway, South Asian patients were less likely to 
have a controlled HbA1c compared to Norwegian patients (AOR: 0.6; 95% CI: 
05"0.9) (285). 
There were significant increases in the levels of prescribing. However, QOF 
generally had no significant impact on the proportion of patients prescribed 
medication for secondary prevention; the only exception to this was for lipid 
lowering medication. The variations I found in prescribing are consistent with 
previous findings in the UK. For example, analysis from 26 practices in Brent, 
North London, found that South Asian patients were less likely to be prescribed 
insulin in 1997 and 2006 when compared to the white group (286). Similarly, 
previous work in Wandsworth found that South Asian patients were less likely to 
be prescribed insulin in 2005 (233). This may be explained by a host of barriers, 
such as providers’ reluctance to tackle patients’ barriers to initiate insulin therapy 
(e.g. sense of loss of control and personal failure) (287). 
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7.3 Strengths and limitations !
My study has a number of strengths and limitations. The QOF was implemented 
nationally, which meant I did not have control over the intervention and as such I 
could not use a gold standard method such as a randomised controlled trial to 
evaluate its impact. Nevertheless, the interrupted time series employed is a 
robust quasi-experimental method that can withstand many biases and is 
superior to pre-post study designs that do not take underlying trends into 
account (288). Further, as QOF was the only major quality improvement initiative 
introduced in primary care during 2004, it is reasonable to attribute any 
additional improvements in diabetes management seen to this policy.  
My study is based on retrospective data from patients registered with practices 
in 2007, which means that I did not have information on patients that died or 
changed their practice during the study period. However, my sensitivity 
analyses, accounting for attrition bias, yielded results substantiating the 
robustness of findings from my main analysis.   
I was not able to assess the interaction between ethnicity and comorbidity using 
an interrupted time series method. The inequalities findings between patients 
with comorbid conditions are limited by the cross sectional design of the study 
and as such I am limited in my conclusions. Due to small numbers in some of 
the ethnic groups, I had to combine patients into three main groups (for 
example, I combined patients from Indian, Pakistani and Bangladesh ethnic 
background into south Asian group). I accept that this might mask differences in 
diabetes management (289). I was not able to distinguish between patients with 
type-1 and type-2 diabetes.  
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29 out of 32 practices participated in this study; hence my findings present a 
comprehensive snapshot of the care delivered in this ethnically diverse location. 
However, my findings were derived from one primary care organisation in the 
UK, which may not translate to other areas in the UK. Further, the UK health 
system is different in the way it is financed, organised and governed compared 
to the more market based health systems such as that in the United States. 
Hence, my findings may not be applicable to other systems, particularly those 
that do not offer universal health coverage. Nonetheless, my findings suggest 
that minority groups with diabetes may not be receiving optimal care even in a 
health system that offers universal coverage. 
Improvements seen in process indicators may be due to improvements in 
recording and not necessarily improvement in care provided. The differences I 
found in the intermediate indicators may be attributable to variations in 
recording. However, this is likely to be minimised because data for cholesterol 
and HbA1c are downloaded electronically to the patient’s electronic record from 
the local hospital laboratory. I used practice postcode to assign deprivation 
score to each patient, patients attending the same practice may be from 
different socioeconomic background. However, practice derived deprivation 
score are generally accepted as a reasonable proxy measure for patient 
deprivation (290). 
7.4 Policy implications 
The rising epidemic of diabetes presents a major challenge to the NHS in the 
coming years. This challenge underlines the importance of ongoing efforts to 
improve the quality of diabetes management in primary care, especially given 
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that diabetes is a major contributor to inequalities in mortality (291).  The 
introduction of QOF appears to have accelerated improvements in diabetes 
management for the quality indicators included in the QOF, particularly, in the 
process aspect of quality. Nonetheless, not all groups appear to have benefited 
equally from this policy, people from certain ethnic minority groups, and many 
people with diabetes are still not meeting established treatment targets. For 
example, only half of the patients in this study achieved HbA1c!7.5%. 
The use of QOF to improve the management of diabetes and reduce variations 
in care further will be a challenge. Greater emphasis on outcome measures 
might be more appropriate since process measures have been largely met. This 
is visible in the retirement of the recording of HbA1c, cholesterol and blood 
pressure indictors in the 2011-12 revision of QOF. However, retirement of such 
indicators does not mean it should not be monitored. Experience from the 
United States shows that rate in the level of screening for diabetic retinopathy 
decreased by 3% per year after removing the financial incentive attached to it 
(292). Similarly, financial incentives linked to a diabetes clinical decision support 
system improved HbA1c control, however use of the system lowered when the 
incentives were discontinued (293). An increase in the threshold for achievement 
of existing targets may be more appropriate, as it may lead to greater overall net 
benefits to patients, especially that practices are offered exception reporting. 
The presence of exception reporting and threshold target may limit the public 
health impact of QOF (294). This has also been recently suggested by the 
Marmot review (230), which proposed setting higher thresholds to provoke 
active case finding of patients with undiagnosed or untreated disease. 
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Inclusion of an inequality-reducing element in pay for performance schemes may 
be warranted. Strategies, among others, include rewarding improvement as well 
as absolute achievements, inclusion of disease areas and quality indicators that 
are more important in minority patients or directly rewarding reductions in 
inequalities. For example, the Massachusetts Medicaid programme has recently 
developed a pay for performance programme aimed at reducing inequalities in 
the quality of hospital care between ethnic groups (295). However, evaluation of 
the programme demonstrated the complexity of designing a pay for 
performance scheme directed at reducing inequalities. For example, lack of 
sufficient numbers of patients may present difficulties to payers in identifying 
high performers. In addition, it demonstrated the importance of choosing 
measures that are relevant to inequalities reduction (296). However, It is 
important to note that ignoring the context that people are in and focusing on 
health services alone cannot solve inequalities. 
 
As discussed earlier, ethnicity-coding levels are low in the UK. It is essential to 
identify people from ethnic minorities to evaluate service use by such patients 
and investigate differences between patients. Further, spoken language and 
communication can influence many aspects of care. For example, a qualitative 
study in England found that providers face uncertainty when dealing with 
ethnically diverse population, which may lead to reluctance in providing care 
(297). Having a financial incentive can help in improving the levels of ethnicity 
coding and recording of first language. For example, the QOF+ scheme offers 
financial rewards to practices in Hammersmith and Fulham in London to reach 
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ethnicity levels between 60% to 90% (298).  
The current diagnostic case definition for diabetes used in QOF should be 
revisited as some patients might be overlooked, for example patients with a 
diabetic treatment Read code. Further, the impact of exception reporting on 
diabetes management requires further and ongoing evaluation. The framework 
does not capture other aspects of diabetes management. Patients’ 
communication, engagement and empowerment are not adequately incentivised 
by QOF and evidence suggests that QOF had no positive effect on 
improvements in physicians-communications (203).  This is one of the quality 
measures where the UK compares less favourably to other nations (299). 
Additionally, meeting these challenges will require better coordination between 
primary and secondary care with investment in both sectors. This requires 
improvements in providing patients with continued, personal and coordinated 
care, elements that may need to be reflected in QOF in the future. Furthermore, 
the amount of money attached to QOF may need to be reconsidered. For 
instance, such resources could be used to go beyond simply monitoring 
intermediate outcome target but to develop new innovative performance 
measures indicators, such as to measure the support of shared decision-making 
(300), or indicators that measures response to poor intermediate outcome (301, 
302). Such innovations in performance measurement could focus the attention 
of providers to patient’s most likely benefit from appropriate treatment.  
The national implementation of QOF limits the ability to conduct cost-
effectiveness studies, however, the involvement of NICE in reviewing and 
developing indicators for QOF could help in the selection of cost effective 
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indicators. Under the new process there will be a chance to pilot new indicators 
to test their validity and monitor any unintended consequences although the six-
month piloting period may not be sufficient to evaluate the effect of new 
indicators (303). 
The QMAS may need to be modified to include patient level variables such as 
age, sex, and ethnicity. Not only to allow for the continuous equity audit of 
health care but also to monitor any potential indicators based on personalised 
risk quality measures in the future. 
Longer-term follow up of the impact of QOF is essential to assess whether some 
of the persisting inequalities in diabetes management that have been identified 
are reduced over time. Indicators used in pay for performance schemes, such 
as QOF, are mostly driven from trials that exclude patients with comorbidity. 
Research on the impact of QOF on such patients is limited. 
The research presented in this thesis, and other work carried out in the 
Department of Primary Care & Public Health at Imperial College London, helped 
in the planning of the QOF+ programme in NHS Hammersmith & Fulham. The 
QOF+ programme offers additional incentives for achieving quality targets and 
for recording of ethnicity status in primary care. An evaluation to assess the 
impact of the programme on quality of care and intermediate health outcomes is 
currently underway. 
 
7.5 Future research 
The introduction of QOF in the UK has attracted international interest; however 
many unanswered question remains in regards to the QOF and to pay for 
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performance in general. First, we know little about which incentive structure may 
be better suited to reducing health care inequity. For example, whether 
rewarding absolute achievement is more effective than rewarding improvements 
in care in tackling inequalities is unclear. Two, understanding which practice 
characteristics explain the variations between practices is essential. Some 
practice characteristic has been examined in the QOF context such as practice 
size. The use of multi-level modeling can assist in exploring these factors. Third, 
QOF was used to complement capitation payment in primary care. 
Understanding how effective pay for performance within other payment methods 
(e.g. fee for service) compared to capitation is essential and whether any 
unintended consequences may surface. Fourth, even though exception-
reporting rates have been low and there was no evidence of gaming, 
nevertheless, long term monitoring on patients whom are exception reported is 
important since ethnic minorities and patient with comorbidities are more likely 
to be exception reported and might be at risk of receiving less attention relative 
to those not exception reported. Fifth, there is an interest in designing local 
incentive schemes. For example, the NHS review in 2008 encouraged devolving 
part of QOF budget to local primary care organizations to design locally led 
incentive schemes (304). Evaluating such schemes in terms of their effectiveness 
and if they can be used to tackle inequalities is needed. Evidence from the 
Massachusetts scheme discussed earlier demonstrates how the use of financial 
incentives to tackle inequalities needs careful design. Sixth, my work was 
confined to quantitative analysis. However, recent qualitative work by the Kings 
fund to review the impact of QOF on inequalities found that few practices 
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thought they had a role in reducing health inequalities and there was no 
evidence of proactive case finding (305). In addition, qualitative research on the 
effect of QOF, or any pay for performance scheme, on the culture of primary 
care is warranted as such schemes may lead to a financially driven model of 
primary care or the fragmentation of general practice (306). 
7.6 Conclusion 
My findings suggest that universal quality improvement schemes, such as QOF, 
have not addressed important inequalities in diabetes management over time, 
i.e. are not consistent with the inverse equity hypothesis. They provide support 
for the view that targeted interventions at the level of the patient that focuses on 
the interaction between the patient and the provider may be needed to meet the 
needs of minorities with poor risk factor control. Targets that are driven by 
guidelines and embedded in public reporting or in pay for performance schemes 
may present a challenge to providers caring for patients from a specific ethnic 
background, or patients presenting with comorbid conditions. Designers of pay 
for performance should weigh the effect of such schemes on ethnic minorities 
and patients suffering from complex conditions and consider incorporating 
targeted incentives to address the persistence of such disparities. Local efforts 
in the UK to reduce inequalities by using financial incentives to improve care in 
minority groups and monitor progress through better recording of ethnicity and 
first language may represent a promising step forward. 
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Appendix 2 Summary of systematic review studies !
A. Studies without pre-intervention data 
 
First Author, 
Year 
(reference) 
Study Design 
Target population 
Data level 
 
Disease/indicator 
Disparity 
dimension 
Key analysis and findings 
Study 
quality* 
Ashworth, M., 
2007 (241) 
Serial cross sectional study 
for 2004-5 & 2005-06 after 
QOF introduction. 
n=8264 GP practices in 
England.  
Practice level data. 
 
Multiple indicators for 10 
clinical conditions 
Socioeconomic 
 
Multivariate regression. 
 
The first year difference in total QOF scores between most and 
least deprived practices was 64.5 points (95% CI = 57.6 to 
71.3), in the second year this difference decreased to 30.4 
(95% CI = 26.4 to 34.4). 
 
Practices located in the highest deprivation quintile were less 
likely to achieve a threshold of 1040 QOF points (OR: 0.47). 
 
2+ 
Ashworth, M., 
2008 (242) 
 
Serial cross sectional study 
for 2004-05 & 2005-06 & 
2006-07 after QOF 
introduction. 
n=8192 GP practices in 
England. 
Practice level data. 
 
Blood pressure monitoring & 
control for five chronic 
conditions 
Socioeconomic 
 
Multivariate analysis of differences of proportion of patient with 
up to date blood pressure monitoring in the least and most 
deprived areas.  
 
By the third year deprivation had a weak positive effect on 
blood pressure monitoring (p<0.001). 
 
2+ 
! "#%!
Ashworth, M., 
2006 (243) 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=8480 GP practices in 
England. 
Practice level data. 
 
Multiple indicators for 10 
clinical conditions 
Socioeconomic 
 
Multivariate analysis of QOF scores, deprivation and various 
confounders.  
 
Social deprivation was inversely related to total QOF scores (P 
< 0.001). 
 
1+ 
Ashworth, M., 
2007 (244) 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=8430 GP practices in 
England 
Practice level data. 
. 
Statin prescribing 
Age, gender, 
ethnicity and 
Socioeconomic 
 
Multivariate analysis of statin prescribing and nine predictor 
variables using forward stepwise selection. 
 
Higher volume of statin prescribing was associated with 
deprivation (p<0.001). 
 
Practices with a higher proportion of patients aged >75 years 
prescribed less statins (p<0.001). 
 
Practices with Proportion of patients from an Afro-Caribbean or 
south Asians ethnic group prescribed less statins (p<0.001). 
 
1+ 
Baker, D., 
2003 (245) 
Serial cross sectional study 
from 1991 to 1999 after 
the 1990 GP contract. 
n=60 District Health 
Authority. 
Practice Level data. 
 
Cervical screening Socioeconomic 
 
Ratio of the mean value of target achievement for the deprived 
group to the affluent group was calculated. 
 
t test to test for the significance of differences between the two 
groups. 
Disparity ratio decreased over the nine years from 0.46 in 1991 
to 0.77 in 1999. 
 
Mean rate of change for the affluent group was 1.27% per year 
and 4.04% for the deprived group (t=6.1, p<0.001). 
 
2+ 
! "#"!
Doran, T., 
2006 (246) 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=8105 GP practices in 
England. 
Practice level data. 
 
Multiple indicators for 10 
clinical conditions 
Socioeconomic 
 
Multiple linear regressions for the association of area, patient 
and practice with overall reported achievements. 
 
Practices with high proportion of population living in income 
deprived household had lower achievements (p<0.01). 
 
1+ 
Doran, T., 
2008 (247) 
Serial cross sectional study 
for 2004-05 & 2005-06 & 
2006-07 after QOF. 
N=7637 GP practices in 
England. 
Practice level data. 
 
48 clinical activity indicators 
covering 11 chronic 
conditions 
Socioeconomic 
 
Logistic regression to calculate the odds of a practice from 
each deprivation quintile being in the top and bottom 
performing 5% of practices in regards to achievements. 
 
Multiple linear regressions to analyze the association of practice 
level characteristics with practice achievements, exclusion of 
patients and changes in outcome. 
 
The gap between deprived and affluent areas in mean 
achievement narrowed from 4% in the first year to 0.8% in the 
third year. Deprivation was no longer associated with 
achievements (p=0.062). 
 
2+ 
Gulliford, M., 
2007 (197) 
 
Serial cross sectional 
survey for 2004-05 after 
QOF introduction. 
N=8484 GP practices in 
England, n=26 GP 
practices south London 
Practice level data. 
 
Three intermediate outcome 
indicators for Diabetes 
Socioeconomic 
 
Multivariate regression to analyze the association of HbA1c 
target with practice and population characteristic. 
 
Practice in located in highest deprivation tertile had lower 
proportion of patients achieving HbA1C target (57.1%) 
compared to practices located in the lowest deprivation tertile 
(60.2%) p<0.001. 
 
1+ 
! "##!
Mclean, G., 
2006 (248) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=1024 GP practices in 
Scotland 
Practice level data. 
 
33 clinical indicators for 
CHD, Stroke, Hypertension, 
Diabetes and COPD 
Socioeconomic 
Linear regression analysis to estimate the trend across 
deprivation for paid and delivered quality. 
 
For 17 out of 33 indicators delivered quality falls with increased 
deprivation (p<0.05).  
 
 
1+ 
Millett, C., 
2007 (203) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=8970 GP practices in 
England & Scotland 
Practice level data. 
 
17 process & intermediate 
indicators for Diabetes 
Socioeconomic 
Comparison of achievement between practices in affluent and 
deprived areas. 
 
In general, practices in deprived areas performed worse than 
practices in affluent areas. 
1+ 
Saxena S., 
2007 (249) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=8970 GP practices in 
England & Scotland 
Practice level data. 
 
26 indicators for CHD, 
Hypertension and Stroke 
Socioeconomic 
Comparison of achievement between practices in affluent and 
deprived areas using Kruskal–Wallis test. 
 
Affluent practices had better achievements in some of the QOF 
scores (p<0.0001). 
1+ 
Sigfrid, L., 
2006 (250) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=49 GP practices in 
Brighton and Hove, 
England. 
Practice level data. 
 
Exception reporting and 
achievement for 15 indicators 
for Diabetes 
Socioeconomic 
Spearman’s correlation coefficients to calculate the correlation 
between exception reporting, achievements and deprivation. 
 
Correlation between exception reporting and deprivation for 10 
indicators but no correlation seen for achievements indicators 
(p<0.05). 
1+ 
! "#&!
Strong, M., 
2006 (251) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. 
n=38 GP practices in 
South Yorkshire, England 
Practice level data 
 
11 process and outcome 
indicators for CHD 
Socioeconomic 
Spearman rank correlation coefficients for achievements 
against deprivation. 
 
Only one indicator showed positive association with deprivation: 
recording of smoking status (r=0.34, p=0.04).  
1+ 
Sutton, M., 
2006 (252) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. n=60 GP 
practices in Scotland. 
Practice level data. 
 
Multiple indicators for 10 
clinical conditions  
Socioeconomic 
Multivariate analysis using forward stepwise selection. 
 
Deprivation was positively associated with achievements 
(P=0.038.). 
1+ 
Wright, J., 
2006 (253) 
 
Cross sectional survey for 
2004-05 after QOF 
introduction. N=8569 GP 
practices in England. 
Practice level data. 
 
Overall quality points 
achieved 
Socioeconomic 
Multivariate regression of overall QOF points in relation to 
deprivation. 
 
Negative association between deprivation and achievements 
(p<0.001). 
1+ 
Gray, J., 2007 
(256) 
 
Cross sectional survey for 
2005-06  
n=32 GP practices in south 
west London, England. 
Patient level data 
 
13 process and outcome 
indicators for Diabetes 
Ethnicity 
 
Adjusted odds ratio and 95% CI interval were calculated for 
each ethnic group and compared to a reference group. 
 
Black and south Asians were less likely to achieve all three 
intermediate outcomes AOR: 0.76 (95% CI 0.67–0.87) for the 
black group and AOR: 0.76 (95% CI 0.59–0.98) for the south 
Asians group. 
 
1+ 
! "#'!
Karve, A., 2008 
(259) 
Cross sectional survey for 
2006-07 Medicare P4P   
n=3449 Hospitals in USA. 
Hospital level data. 
 
AMI, CAP & HF/process 
measures 
Ethnicity  
 
Multiple logistic regression to calculate adjusted odds ratio of 
ranking in accordance to performance of hospitals treating 
>20% African American relative to hospital treating <20% 
African American. 
 
Hospital with >20% African American were more likely to be 
ranked in the lowest quintile of performance. AOR for AMI and 
CAP were 1.8 (95% CI 1.4-2.4) and 2.3 (95% CI 1.8-2.9) 
respectively.  
 
For HF hospitals with>20% African American were as likely as 
hospital with >20% African American to be ranked in the 
highest or lowest quintile. 
 
1+ 
Jha, A., 2010 
(260) 
Cross sectional study for 
baseline year (2003) and 
three years after P4P in 
2006-07 
n=251 P4P hospital 
compared with n=3017 as 
control 
AMI, CHF & 
Pneumonia/process 
measures 
SES 
 
Measure the association between the disproportionate-share 
index (a marker for caring for poor people) and change in 
performance while controlling for various hospital 
characteristics. 
 
In the P4P group higher disproportionate-share index was 
associated with improved performance for AMI (0.6%, 95% CI 
0.2-1.1), pneumonia (1.2%, 95% CI: 0.5-1.8), but not CHF 
(0.3%, 95% CI: !0.3-1.0). 
 
In the control group higher disproportionate-share index was 
associated with improved performance only for pneumonia 
(0.3%, 95% CI: 0.1-0.5). 
 
Interaction term was used to determine if the association 
between the index and change in performance varied between 
the two groups. It was negative and significant for AMI (-0.6, 
p=0.045) and pneumonia (-0.9, p=0.009) but not for CHF (-0.2, 
p=0.65). 
 
3+ 
! "#(!
B. Studies with pre-intervention data 
 
McGovern, M., 
2008 (254) 
Serial cross sectional study 
before (March 2004) & after 
(March 2005). 
n=310 GP practices in 
Scotland. 
58406 patients included 
before QOF. 
75495 patients included 
after QOF. 
Patient level data. 
 
11 process and outcome 
indicators for CHD 
Age, gender and 
socioeconomic 
 
Chi-square test for the difference between groups. 
Multiple logistic regressions to determine odds ratio and 95% 
CI for the achievements of quality indicators with relation to 
age, gender and deprivation. 
 
Overall increase in recording of all indicators (p<0.05). 
 
Post QOF, women were less likely than men to be recorded in 
9 indicators. Older patient were less likely than the young to 
have a recording in 7 indicators and the most deprived patients 
were less likely to be recorded in 4 indicators. 
 
2+ 
Millett, C., 
2007 (198) 
Longitudinal survey before 
(June-October 2003) & 
after (November 2005-
January 2006). 
n=32 GP practices in south 
west London, England. 
4284 patients included 
before & after QOF. 
Patient Level Data. 
 
Recording of smoking status 
and smoking cessation 
advice for Diabetes 
Age, gender, 
ethnicity and 
socioeconomic 
 
McNemar test to test for the differences between the two 
measurement points. 
Multiple logistic regression specifying for the clustering of 
patients within practices to analyze the association of the 
achievements with age, sex, ethnic background and deprivation 
group. 
 
Increase of the proportion of patient offered the advice from 
48% to 83.5% (p<0.001), the variation in the provision of 
smoking advice was attenuated in 2005. 
 
Smoking prevalence decreased from 20% to 16.2% (p<0.001), 
these reductions were largely equitable between the different 
groups. 
 
 
2+ 
! "#)!
Simpson, C., 
2006 (255) 
 
Serial cross sectional study 
before (March 2004) & after 
(March 2005). 
n=310 GP practices in 
Scotland. 
21901 patients included 
before QOF. 
32401 patients included in 
after QOF. 
Patient level data. 
 
 
10 process and outcome 
indicators for Stroke 
Age, gender, and 
socioeconomic 
Chi-square test for the difference between groups. 
Multivariate logistic regressions to determine odds ratio and 
95% CI for the achievements of quality indicators with relation 
to age, gender and deprivations. 
 
Increases were larger for affluent and older patient. Women 
were less likely than men to have a smoking status recorded 
(AOR: 0.87; 95% CI 0.81-0.95) or receive antiplatelet or 
anticoagulant therapy (AOR: 0.93; 95% CI 0.86-0.99). 
 
2+ 
Millett, C., 
2007 (231) 
 
Longitudinal survey before 
(June-October 2003) & 
after (November 2005-
January 2006). 
n=32 GP practices in south 
west London England. 
4284 patients included 
before & after. 
Patient Level Data. 
 
3 treatment targets for 
diabetes 
Ethnicity 
 
 
McNemar test to test for the differences between the two 
measurement points. 
Multivariate logistic regressions specifying for the clustering of 
patients within practices to analyze the association of the 
achievements with ethnicity. 
 
More patients reached the treatment target in 2005 than 2003 
(p=0.005 for HbA1c, p<0.001 for blood pressure and 
cholesterol targets). 
 
Black Caribbean group were less likely than the white group to 
reach HbA1c target (AOR: 0.75; 95% CI: 0.57-0.97) or the 
blood pressure target (AOR: 0.65; 95% CI 0.53-0.81). 
 
2+ 
! "#*!
Millett, C., 
2008 (258) 
 
Serial cross sectional study 
before (June-October 
2003) & after (November 
2005-January 2006). 
n=32 GP practices in south 
west London England. 
2891 patients included 
before QOF. 
3101 patients included 
after QOF. 
Patient Level Data. 
 
 
8 process of care and 
intermediate outcome for 
CHD 
Ethnicity 
 
Multivariate logistic regressions to analyze the association of the 
achievements with ethnicity. 
Improvements in blood pressure control target were better in 
the black group compared to the white (54.8% vs. 58.3%). 
 
Variations in blood pressure recording between south Asians 
and white groups seen before the contract were attenuated 
after QOF (96.9% south Asians vs. 97.3% white in 2005). 
 
2+ 
Millett, C., 
2009 (232) 
 
Longitudinal survey 
between 2000 and 2005. 
n=16 GP practices in south 
west London. 
1968 patients included 
HbA1c, systolic and diastolic 
levels for diabetes 
Ethnicity 
 
Multilevel model were used to assess the effect of QOF. White 
Introduction of QOF was associated with improvement in 
systolic and diastolic blood pressure (-5.3 & -4.4) compared to 
black group (-2.3 & -1.8) but no significant reductions were 
evident for the south Asian group. 
 
HbA1c levels decreased in the white group by 0.3% but no 
benefit were seen for the black & south Asian group. 
 
2+ 
! "#+!
Hamilton, F, 
2010 (257) 
Longitudinal survey 
between 1997 and 2005. 
n=422 GP practices in UK. 
154,945 patients included 
Patient Level Data 
6 process & intermediate 
control targets for diabetes 
Age, sex, and 
socioeconomic 
 
GEE models to predict post-QOF using underling trends from 
1997 to 2003. t-test was used to compare actual target 
achievements with predicted ones. 
 
All groups did not benefit in terms of HbA1c control.  
 
Younger patients (18-44 years) benefited less from QOF in 
terms of blood pressure and cholesterol targets and existing 
inequalities in 1997 were not addressed specially for blood 
pressure control. 
 
Females benefited more from QOF in terms of blood pressure 
and cholesterol but existing inequalities in 1997 were not 
addressed for blood pressure and cholesterol control. 
 
Patients attending practices in deprived or affluent areas 
benefited similarly from QOF.  
   
2+ 
AMI: Acute Myocardial Infarction, AOR: Adjusted Odds Ratio, OR: Odds Ratio, CAP: Community Acquired Pneumonia, CHD: Chronic Heart Disease, CI: Confidence Interval, COPD: Chronic Obstructive 
Pulmonary Disease, GP: General Practitioner, HF: Heart Failure, P4P: Pay for Performance, QOF: Quality and Outcome Framework, SES: Socioeconomic status 
Note: Studies were graded on a scale from 1+ (poor) to 4+ (excellent). 
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Appendix 3 Analysis with expanded ethnicity !
Appendix table 1: Sample characteristics in 2007 with expanded ethnicity 
Ethnicity Number % 
Age: Median 
(IQR), years 
Female: % 
BMI: 
median 
(IQR) 
Diabetes 
duration: 
median (IQR) 
British 2,464 33.2 63 (50-74) 47.1 29 (26-34) 5 (2-8) 
Irish 157 2.1 68 (60-75) 42.7 29 (26-33) 5 (2-8) White 
Other 534 7.2 63 (45-73) 49.9 29 (26-33) 4 (1-8) 
African 649 8.7 56 (46-65) 45.4 28 (25-32) 4 (1-7) 
Caribbean 1,062 14.3 68 (57-74) 59.6 29 (26-33) 6 (2-10) Black 
Other 100 1.3 66 (51-74) 52.7 29 (27-33) 5 (2-9) 
Indian 723 9.7 63 (52-71) 46.7 27 (24-30) 6 (2-10) 
Pakistani 467 6.3 58 (49-68) 44.7 28 (25-31) 5 (2-9) 
Bangladeshi 99 1.3 59 (49-68) 41.4 26 (23-28) 5 (1-10) 
South Asian 
Other 364 4.8 59 (51-67) 50.3 27 (24-30) 5 (2-7) !!
Appendix table 2: Inequalities in HbA1c management in 2007 
HbA1c controlled OHA prescribed Insulin prescribed 
Ethnicity % Measured  
% AOR % AOR % AOR 
British 79.1 60.0 1.0 51.3 1.0 23.7 1.0 
Irish 83.4 71.0 1.54 (1.02-2.32) 57.3 1.22 (0.87-1.72) 19.1 0.78 (0.49-1.25) White 
Other 75.3 63.1 1.15 (0.91-1.45) 56.3 1.31 (1.07-1.60) 18.3 0.62 (0.47-0.82) 
African 82.4 54.8 0.94 (0.76-1.17) 62.6 1.58 (1.30-1.93) 18.8 0.71 (0.55-0.92) 
Caribbean 86.3 59.4 0.93 (0.78-1.11) 67.6 1.83 (1.55-2.16) 20.8 0.87 (0.71-1.07) Black 
Other 79.1 52.8 0.78 (0.47-1.29) 71.4 2.25 (1.38-3.65) 24.2 1.05 (0.61-1.83) 
Indian 82.6 55.3 0.88 (0.71-1.09) 69.6 2.31 (1.89-2.83) 14.7 0.43 (0.33-0.57) 
Pakistani 81.2 49.1 0.76 (0.59-0.97) 68.1 2.36 (1.87-3.00) 18.4 0.64 (0.48-0.87) 
Bangladeshi 87.9 65.5 1.66 (1.02-2.70) 64.6 1.88 (1.20-2.94) 16.2 0.47 (0.25-0.87) 
South Asian 
Other 82.0 56.0 0.92 (0.70-1.21) 65.7 1.90 (1.47-2.46) 17.2 0.67 (0.48-0.94) 
AOR; adjusted odss ratio; adjusted for age, gender, diabetes duration, BMI, comorbidity, and practice level deprivation 
OHA; oral hypoglycemic agents 
Controlled: HbA1c levels !7.5% 
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Appendix table 3: Inequalities in Cholesterol management in 2007 
 
Cholesterol controlled  Lipid lowering prescribed  
Ethnicity % Measured  
% AOR % AOR 
British 79.2 80.9 1.0 69.4 1.0 
Irish 83.4 87.0 1.40 (0.82-2.38) 79.6 1.16 (0.75-1.79) White 
Other 75.9 81.7 1.04 (0.79-1.38) 64.7 0.94 (0.74-1.19) 
African 83.8 81.1 1.23 (0.95-1.60) 63.8 0.93 (0.74-1.16) 
Caribbean 85.7 82.6 1.12 (0.90-1.39) 68.4 0.76 (0.64-0.92) Black 
Other 79.1 83.3 1.50 (0.75-2.98) 73.6 1.41 (0.81-2.44) 
Indian 85.5 84.5 1.36 (1.04-1.79) 71.1 0.92 (0.74-1.16) 
Pakistani 82.0 85.6 1.61 (1.02-1.52) 70.2 1.14 (0.87-1.49) 
Bangladeshi 86.9 89.5 2.10 (1.02-4.28) 80.8 2.09 (1.15-3.77) 
South Asian 
Other 85.5 81.0 1.09 (0.78-1.52) 73.3 1.20 (0.89-1.62) 
AOR; adjusted odss ratio; adjusted for age, gender, diabetes duration, BMI, comorbidity, and practice level deprivation 
Controlled: Cholesterol !5.0 mmol/l 
 
 
Appendix table 4: Inequalities in blood pressure management in 2007 
 
Blood pressure controlled >=2 antihypertensive prescribed 
Ethnicity % Measured  
% AOR % AOR 
British 91.8 75.3 1.0 45.4 1.0 
Irish 92.4 73.8 0.82 (0.55-1.22) 49.7 1.22 (0.87-1.72) White 
Other 87.6 78.1 1.10 (0.86-1.41) 42 1.31 (1.07-1.60) 
African 90.6 69.4 0.69 (0.55-0.78) 42.7 1.58 (1.30-1.93) 
Caribbean 94.2 72.9 0.85 (0.70-1.02) 58.8 1.83 (1.55-2.16) Black 
Other 85.7 70.5 0.78 (0.46-1.32) 52.7 2.25 (1.38-3.65) 
Indian 91.3 76.8 1.04 (0.82-1.32) 48.1 2.31 (1.89-2.83) 
Pakistani 87.2 76.9 1.10 (0.83-1.45) 38.8 2.36 (1.87-3.00) 
Bangladeshi 91.9 89 2.02 (1.02-3.99) 41.4 1.88 (1.20-2.94) 
South Asian 
Other 90.7 79.2 1.1 (0.85-1.60) 43.3 1.90 (1.47-2.46) 
 
AOR; adjusted odss ratio; adjusted for age, gender, diabetes duration, BMI, comorbidity, and practice level deprivation 
Controlled: blood pressure levels !145/85 mm Hg !
! "#"!
Appendix 4 Sensitivity analysis !
The dataset consists of the historical records (2000-2007) of patients registered 
with practices in 2007. Some patients might not have complete records 
throughout each year and I did not capture information on patients with diabetes 
conditions registered with practices during the study period who moved away or 
died before 2007. If there were systematic differences between the type of 
individuals who have complete records and those who do not, analysis would 
suffer and inferences about the effect of the policy may be inaccurate. 
For example, HbA1c missing values ranged from 56% to 19%, cholesterol 
ranged from 59% to 18%, systolic and diastolic blood pressure ranged from 
42% to 9.1% for 2000 and 2007, respectively.   
To test if these missing values had any effect on my estimates I used Heckman 
sample selection model. The Heckman selection model consists of two parts. 
The first is the outcome equation  yijt = Xijt B + uijt1. The second is a selection 
equation is used to predict whether or not somebody responds Zijt = Wijt r + uijt2. 
The dependent variable is observed if Z>0. Where y are the outcome measure, X 
are the covariates in the outcome equation, W are the covariates in the selection 
equation. In these equations, rho (") is the correlation between two error terms, 
i.e. corr(uijt1, uijt2)=". I did not use any exclusion restriction to estimate the model; 
therefore the same regressors were used in both equations. 
I used the Likelihood-ratio (LR) test as a test of H0: " = 0. Under the H0 there is 
no selection problem. Selection bias would not be a problem if the estimated 
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correlation coefficient, rho ("), is not statistically significant and LR test does not 
reject independence of the two error terms. 
My findings from the Heckman model indicate that attrition bias was not an 
issue except for systolic and diastolic blood pressure. However, the magnitudes 
of the coefficient are still consistent with the original findings. 
Appendix table 5: Results of the sensitivity analysis 
 Systolic  Diastolic 
 Heckman 
Coefficient 
Selection 
Coefficient 
Heckman 
Coefficient 
Selection 
Coefficient 
Baseline trend -0.320 0.208** -1.044** 0.208** 
Level change  -2.133** 0.192** -0.640** 0.192** 
Trend change  -0.838** -0.0493** 0.331* -0.0503** 
rho (standard error)  -0.220 (0.033)  -0.261 (0.036) 
P value for LR test   0.001  0.001 
*Indicates significance at the 5% level and ** at the 1% level 
 
The change in patient mix might introduce bias in my estimates (i.e more 
patients were included in later years compared to earlier years). To assess if this 
is introduces bias I repeated the analysis on patients who were followed in all 
years (i.e same patient in every year). The results are similar to my initial findings 
and my conclusion is the same (Appendix table 6). 
Appendix table 6: Interrupted time series analysis on patients with a 
measurement in every year 
 Hba1c, % (n= 
1775) 
Systolic BP, mm 
Hg (n=1950) 
Systolic BP, mm 
Hg (n=1950) 
Cholesterol, 
mmol/l (n=1600) 
Pre-QOF -0.17 (-0.20, -
0.14) -0.16 (-0.47, 0.14) -1.0 (-1.2, -0.87) 
-0.16 (-0.18, -
0.13) 
QOF introduction  
0.11 (0.01, 0.22) -1.6 (-2.8, -5.1) -0.42 (-1.1, 0.23) 
-0.14 (-0.22, -
0.07) 
Post-QOF 0.16 (0.11, 0.20) -1.3 (-1.6, -0.62) 0.83 (-0.20, 0.37) 0.06 (0.02, 0.09) 
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Appendix 5 Model output unadjusted 
For the intermediate indicators, I repeated the analysis without any adjustment. 
The findings were similar. For example, the impact of QOF on HbA1c was 0.04 
(-0.04, 0.12) for the adjusted model and 0.05 (-0.02, 0.13) for the unadjusted 
model. One exception to this was the impact of QOF on diastolic blood 
pressure, which was -0.51 (-1.05, 0.01) in the adjusted model compared to -
0.63 (-1.14, -1.11) in the unadjusted model. However, the result for each of the 
ethnic groups was similar in the adjusted & unadjusted model. 
 
Appendix table 7: results of the unadjusted interrupted time series for HbA1c 
 HbA1c, % (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.18 (-0.21, -
0.15)** 
-0.18 (-0.21, -
0.14)** 
-0.18 (-0.24, -
0.12)** 
-0.18 (-0.23, -
0.12)** 
QOF  0.05 (-0.02, 0.13) 0.07 (-0.04, 0.18) -0.11 (-0.28, 0.06) 0.17 (0.01, 0.34)* 
Post-QOF  0.19 (0.15, 0.23)** 0.21 (0.16, 0.26)** 0.21 (0.14, 0.29)** 0.11 (0.04, 0.19)** 
*p<0.05, **p<0.01 
 
Appendix table 7: results of the unadjusted interrupted time series for 
Cholesterol 
 Cholesterol, mmol/l (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.14 (-0.15, -
0.11)** 
-0.16 (-0.17, -
0.12)** 
-0.12 (-0.15, -
0.09)** 
-0.14 (-0.18, -
0.10)** 
QOF  -0.11 (-0.17, -
0.06)** 
-0.14 (-0.22, -
0.05)** 
-0.11 (-0.21, -
0.01)* 
-0.08 (-0.20, 0.04) 
Post-QOF  0.03 (0.01, 0.06)* 0.05 (0.01, 0.08)* 0.04 (-0.01, 0.08) 0.02 (-0.03, 0.08) 
*p<0.05, **p<0.01 
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Appendix table 8: results of the unadjusted interrupted time series for Systolic 
blood pressure 
 Systolic blood pressure, mm Hg (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.09 (-0.36, 0.18) -0.56 (-1.08, -
1.30)* 
0.23 (-0.28, 0.74) 0.28 (-0.30, 0.90) 
QOF  -1.90 (-2.80, -
1.10)** 
-2.15 (-3.51, -
0.78)** 
-2.44 (-4.15, -
0.73)** 
-1.09 (-3.00, 0.80) 
Post-QOF  -1.16 (-1.55, -
0.78)** 
-0.40 (-0.99, 0.18) 
-1.75 (-2.48, -
1.02)** 
-1.83 (-2.64, -
1.01)** 
*p<0.05, **p<0.01 
 
Appendix table 9: results of the unadjusted interrupted time series for Diastolic 
blood pressure 
 Diastolic blood pressure, mm Hg (95% CI) 
 ALL White Black South Asian 
Pre-QOF -0.93 (-1.08, -
0.77)** 
-0.79 (-1.03, -
0.55)** 
-0.97 (-1.27, -
0.67)** 
-1.21 (-1.55, -
0.86)** 
QOF  -0.63 (-1.14, -
1.11)* 
-1.07 (-1.85, -
0.30)** 
-0.36 (-1.35, 0.63) 0.16 (-0.94, 1.27) 
Post-QOF  0.27 (0.05, 0.49)* 0.19 (-0.14, 0.52) 0.15 (-0.27, 0.57) 0.46 (-0.06, 0.94) 
*p<0.05, **p<0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! "#$!
Appendix 6 Coefficients of adjustment variables for key intermediate variables 
 
Appendix table 10: Result for HbA1c and cholesterol  !!!!!!!!!!!
  HbA1c, % Cholesterol, mmol/l 
  ALL White Black 
South 
Asian ALL White Black 
South 
Asian 
Baseline trend -0.210*** -0.209*** -0.214*** -0.209*** -0.133*** -0.151*** -0.115*** -0.132*** 
Level change after QOF 0.0421 0.0716 -0.124 0.185** -0.122*** -0.135*** -0.105** -0.0794 
Trend change after QOF 0.191*** 0.213*** 0.218*** 0.115*** 0.0317** 0.0459** 0.0342 0.0170 
Female -0.0654 -0.0555 -0.0400 -0.113 0.269*** 0.349*** 0.201*** 0.200*** 
Age -0.0194*** -0.0183*** -0.0211*** -0.0217*** -0.010*** -0.010*** -0.00199 -0.010*** 
Duration of illness 0.0301*** 0.0308*** 0.0344*** 0.0279*** -0.0116*** -0.011*** -0.013*** -0.0170*** 
IMD Quintile 2 0.125 0.182 0.0695 -0.0277 0.0396 0.0415 0.0628 -0.0829 
IMD Quintile 3 0.172 0.314*** 0.110 -0.137 0.0884 0.0626 0.144** 0.0209 
IMD Quintile 4 0.0430 0.120 -0.131 0.00326 0.0488 0.0410 -0.0200 0.0313 
IMD Quintile 5 0.000125 -0.00685 -0.188 0.374*** 0.0134 0.0904 -0.0942 -0.0119 
One co-morbidity -0.144*** -0.0127 -0.414*** -0.0551 -0.139*** -0.121*** -0.0825 -0.229*** 
Two co-morbidities or more -0.184*** -0.0491 -0.511*** -0.117 -0.205*** -0.209*** -0.186*** -0.209*** 
Black 0.289***    -0.0934***    
Others 0.119    -0.187    
South Asian 0.241***    -0.205***    
Unknown -0.516    0.145    
Constant 9.654*** 9.356*** 10.45*** 10.08*** 5.972*** 6.079*** 5.512*** 6.025*** 
**indicates significance at the 5% level, *** at the 1% level 
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Appendix table 11: Result for HbA1c measured/ HbA1c controlled 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 **indicates significance at the 5% level, *** at the 1% level 
 
  HbA1c Measured, AOR HbA1c Controlled, AOR 
  ALL White Black 
South 
Asian ALL White Black 
South 
Asian 
Baseline trend 1.895*** 1.775*** 1.882*** 1.952*** 1.404*** 1.524*** 1.295*** 1.325*** 
Level change after QOF 1.429*** 1.478*** 1.861*** 1.865*** 1.035 0.911 1.232 1.034 
Trend change after QOF 0.724*** 0.657*** 0.643*** 0.643*** 0.767*** 0.658*** 0.836** 0.927 
Female 0.885** 0.594*** 1.113 0.894 1.151** 1.234** 1.097 1.087 
Age 1.047*** 1.054*** 1.044*** 1.019*** 1.041*** 1.042*** 1.036*** 1.047*** 
Duration of illness 0.990** 1.006 0.992 0.987* 0.919*** 0.915*** 0.923*** 0.921*** 
IMD Quintile 2 1.179 1.048 1.370 1.268 0.871 0.855 0.875 1.113 
IMD Quintile 3 1.230 1.172 1.360 0.945 0.754 0.545*** 0.889 1.371 
IMD Quintile 4 1.042 1.104 1.037 0.994 0.881 0.881 1.073 0.754 
IMD Quintile 5 1.991* 1.699* 2.304** 2.090* 1.005 1.055 1.290 0.557*** 
One co-morbidity 1.629*** 1.610*** 1.668*** 1.977*** 1.172* 1.105 1.516*** 0.992 
Two co-morbidities or more 1.616*** 1.605*** 1.767*** 1.960*** 1.279** 1.086 1.992*** 1.123 
Black 1.359***    0.737***    
Others 1.470    0.794    
South Asian 1.012    0.648***    
Unknown 0.190*    1.452    
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Appendix table 12: Result for cholesterol measured/ cholesterol controlled 
  Cholesterol Measured, AOR Cholesterol Controlled, AOR 
  ALL White Black 
South 
Asian ALL White Black 
South 
Asian 
Baseline trend 1.874*** 1.958*** 1.770*** 1.838*** 1.413*** 1.461*** 1.435*** 1.332*** 
Level change after QOF 1.676*** 1.150 2.094*** 2.453*** 1.449*** 1.686*** 1.252 1.148 
Trend change after QOF 0.659*** 0.605*** 0.685*** 0.732*** 0.957 0.925 0.866* 1.109 
Female 0.762*** 0.609*** 1.032 0.782** 0.520*** 0.422*** 0.588*** 0.662*** 
Age 1.047*** 1.056*** 1.039*** 1.024*** 1.016*** 1.018*** 1.007 1.021*** 
Duration of illness 0.982*** 0.988*** 0.977*** 0.978*** 1.034*** 1.029*** 1.043*** 1.048*** 
IMD Quintile 2 1.390 1.315 1.557 1.587 0.854 0.806 0.812 1.112 
IMD Quintile 3 1.295 1.167 1.389 1.014 0.768* 0.795 0.676 0.906 
IMD Quintile 4 1.114 1.062 1.000 0.899 0.798 0.830 1.033 0.651** 
IMD Quintile 5 2.147** 1.929** 2.322** 1.988* 1.029 0.905 1.276 1.048 
One co-morbidity 1.729*** 1.574*** 1.822*** 1.998*** 1.442*** 1.307** 1.266 1.944*** 
Two co-morbidities or more 1.921*** 1.746*** 2.158*** 2.171*** 1.949*** 2.053*** 1.655*** 1.988*** 
Black 1.357***    1.332***    
Others 1.466    1.523    
South Asian 1.167**    1.556***    
Unknown 0.339    0.755    
**indicates significance at 5% level, *** at the 1% level 
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Appendix table 13: Result for systolic and diastolic blood pressure 
 
  Systolic, mm Hg Diastolic, mm Hg 
  ALL White Black 
South 
Asian ALL White Black 
South 
Asian 
Baseline trend -0.0315 -0.509** 0.316 0.429 -0.843*** -0.692*** -0.847*** -1.067*** 
Level change after QOF -1.950*** -2.127*** -2.325*** -1.081 -0.519* -1.017** -0.334 0.201 
Trend change after QOF -1.040*** -0.215 -1.686*** -1.792*** 0.190 0.102 0.124 0.402 
Female -0.794*** -1.530*** -0.812 0.503 -0.741*** -1.542*** 0.135 -0.460 
Age 0.280*** 0.266*** 0.295*** 0.323*** -0.128*** -0.115*** -0.137*** -0.145*** 
Duration of illness -0.00886 -0.0237 0.0168 -0.0529 -0.178*** -0.162*** -0.208*** -0.194*** 
IMD Quintile 2 -1.862 -2.538 -4.060*** -2.004 -1.531 -1.780 -2.016** -1.423 
IMD Quintile 3 -0.622 -0.578 -2.931*** -0.368 0.155 0.102 -0.122 -0.173 
IMD Quintile 4 -2.656** -2.291 -4.834*** -2.668 -1.365 -1.559 -1.475* -1.291 
IMD Quintile 5 -1.913 -1.671 -4.419*** -2.351 -1.178 -1.352 -1.421 -1.192 
One co-morbidity 5.251*** 4.351*** 6.435*** 5.405*** 2.440*** 1.875*** 3.378*** 2.426*** 
Two co-morbidities or more 4.587*** 3.476*** 6.117*** 4.807*** 1.521*** 0.776** 3.296*** 1.167** 
Black 2.585***    1.858***    
Others -1.801    0.695    
South Asian -1.460***    -0.324    
Unknown 2.923    3.648    
Constant 118.7*** 122.4*** 120.2*** 112.3*** 91.16*** 90.94*** 92.59*** 92.52*** 
**indicates significance at 5% level, ***at 1% level  
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Appendix table 14: Result for blood pressure measured/ blood pressure controlled 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Blood Pressure Measured, AOR Blood pressure Controlled, AOR 
  ALL White Black 
South 
Asian ALL White Black 
South 
Asian 
Baseline trend 1.720*** 1.844*** 1.664*** 1.584*** 1.044* 1.133*** 1.013 0.921 
Level change after QOF 1.707*** 1.207 2.160*** 2.624*** 1.392*** 1.358** 1.251 1.665*** 
Trend change after QOF 0.871*** 0.857** 0.815** 0.908 1.170*** 1.023 1.322*** 1.291*** 
Female 1.019 0.908 1.259* 1.014 1.037 1.088 1.093 0.884 
Age 1.047*** 1.055*** 1.040*** 1.030*** 0.966*** 0.968*** 0.965*** 0.965*** 
Duration of illness 0.974*** 0.982*** 0.970*** 0.969*** 0.999 1.005 0.992 1.002 
IMD Quintile 2 1.010 0.975 0.972 1.474 1.388 1.360 2.136*** 1.439 
IMD Quintile 3 1.305 1.309 1.106 0.989 1.046 1.090 1.342** 0.991 
IMD Quintile 4 0.961 0.954 0.609 1.007 1.324 1.314 1.726*** 1.384 
IMD Quintile 5 1.359 1.378 0.945 1.489 1.309 1.175 1.961*** 1.335 
One co-morbidity 2.514*** 2.346*** 3.210*** 2.141*** 0.431*** 0.521*** 0.385*** 0.359*** 
Two co-morbidities or more 3.063*** 2.850*** 3.698*** 2.915*** 0.444*** 0.534*** 0.393*** 0.382*** 
Black 1.297***    0.720***    
Others 0.726    1.339    
South Asian 0.888    1.169**    
Unknown 0.387    1.176    
**indicates significance at the 5% level, *** at the 1% level 
